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Background: Ageing and high-fat diet (HFD) are both associated with metabolic, cellular, structural, 
and functional remodelling of the heart. There are conflicting reports regarding the vulnerability of the 
ageing heart to cardiac insults including ischaemia and reperfusion (I/R), and similarly, the vulnerability 
of the heart after HFD. Very few studies have been done on the effects of HFD in the ageing heart. In 
this work, we first investigated the effects of ageing on cardiac remodelling and vulnerability to I/R 
compared to adults. We then investigated the effects of HFD in the ageing heart compared to normal 
diet (ND) aged matched controls. We hypothesized that both ageing and HFD increase the vulnerability 
of the heart to I/R injury. 
Methods: C57BL/6 adult (8 weeks) and ageing (80 weeks) male mice were used in this work. Ageing 
mice were fed a standard ND or HFD for a period of 24 weeks. Animal body weights, heart weights, 
and epidydimal fat pads were all measured. Plasma glucose and lipid metabolites were also measured 
using nuclear magnetic resonance (NMR). Hearts were extracted and processed for measuring cardiac 
energy metabolites and amino acids (AA) using high performance liquid chromatography (HPLC). 
Additionally, they were used for protein and phospho-protein quantification using liquid 
chromatography tandem mass spectrometry (LC-MS/MS). Histological examination of cardiac tissue 
included using light microscopy and electron microscopy for ultrastructural examination. Finally, 
vulnerability of the heart to I/R injury was tested using the Langendorff perfusion system.  
Results: Ageing animals had significant increase in body weight, epidydimal fat pads, cardiac 
hypertrophy, with decreased plasma glucose levels. Remodelling of the ageing heart included metabolic 
changes such as changes in cardiac energy metabolites with decreased phosphorylation potential, and a 
decrease in total protein amino acid pool as well as taurine. Additionally, cellular remodelling was 
observed as cardiac protein groups were mainly upregulated during aging including mitochondrial 
proteins, ionic channel proteins, antioxidant enzymes, apoptosis-related proteins, structural (collagen) 
proteins, and lipid and carbohydrate metabolism. Phospho-proteins (ionic transport related proteins, 
cardiac signalling and apoptosis, metabolism and energy production, and structural proteins) were also 
mainly upregulated with ageing. Finally, ageing was associated with structural change including 
increased lipid deposits in the heart and an increase in capillary/myocyte ratio. There was an increase 
in total size and lumen size of coronary arteries with decrease in arterial wall/total artery and lumen size 
ratios, and there were changes in mitochondrial morphometry (mitochondria became smaller in size and 
elongated) but not mitochondrial distribution.  
Feeding aging mice HFD was associated with marked obesity, increased body fat, and significantly 
higher plasma VLDL and LDL, but lower glucose and lactate levels. HFD was also associated with 
atherosclerosis, smaller coronary arteries with smaller lumen sizes, and a higher artery wall/artery size 
and lumen size ratios. Additionally, HFD reduced capillary/myocyte ratio and increased fibrosis in 
ageing hearts. Metabolically, HFD reduced total energy rich phosphates and this was associated with 
altered mitochondrial morphometry as they became larger in size and more rounded, with more densely 
distributed PN and SSL mitochondria. Finally, majority of proteins that changed after HFD in ageing 
were downregulated. These included mitochondrial proteins and carbohydrates metabolism. Proteins 
that increased with HFD included structural (collagen) proteins, apoptotic, and lipid metabolism. 
Antioxidant enzymes and ionic transport related proteins changed in both directions (up and 
downregulation). Phosphorylated proteins were also mainly downregulated with HFD in the ageing 
heart (ionic transport, cardiac signalling and apoptosis, carbohydrate metabolism, transport, structural 
proteins, and enzymes). 
No significant changes were found in the function and vulnerability of the ageing hearts compared to 
their adult controls, nor in the ageing hearts after HFD compared to their ND controls to I/R injury.  
Conclusion: Ageing and HFD (in the ageing heart) are associated with cardiac metabolic, cellular, and 
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1.1 Cardiovascular Diseases  
Cardiovascular diseases (CVD) are the number one cause of death worldwide. In 2016, 17.9 
million people died from CVD, with 85 % of those deaths being from heart attack and stroke 
[World Health Organisation (WHO)]. In the UK, 170,000 people die from CVD each year, 
which accounts for 28 % of deaths yearly [British Heart Foundation (BHF)]. Coronary heart 
disease (CHD) (also known as ischaemic heart disease) is the most common type of CVD and 
is characterised by the gradual build-up of fatty material (plaques) within the coronary arteries 
(atherosclerosis) causing the obstruction of blood flow to the heart and leading to heart attack 
(BHF). 
1.2 Overall View of the Cardiovascular System 
The cardiovascular system (circulatory system) is made up of the heart and the blood vessels. 
The heart contains four chambers, two upper atria, and two lower ventricles. Major blood 
vessels carry the blood from and back to the heart, and branch to smaller vessels and capillaries 
that circulate the whole body. Oxygenated blood is delivered to the left atrium of the heart via 
the pulmonary veins, then passes into the left ventricle through the left atrioventricular valve 
(bicuspid or mitral valve), and then it is pumped from the left ventricle via the aorta to the 
whole body. The aortic valve (semilunar valve) prevents blood from flowing backwards. 
Coronary arteries branch from the aorta to supply the outer cardiac muscle tissue with blood. 
Veins return deoxygenated blood from the body into the right atrium of the heart via the 
superior and inferior venae cava, which then passes through the right atrioventricular valve 
(tricuspid valve) to the right ventricle, and from there it is pumped to the lungs via the 
pulmonary arteries. Regulation of the cardiovascular system is maintained through three 
homeostatic mechanisms; neural, endocrine, and autoregulatory mechanisms [16].  
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The heart consists of three layers, the epicardium (outer lining), the myocardium (the middle 
layer made up of myocytes), and the endocardium (the inner layer). These three layers are 
surrounded by the pericardium that protects the heart. 
Blood vessels also consist of three layers (tunics); outer tunica externa, a middle tunica media, 
and an inner tunica intima. The outer tunica externa is made up of connective tissue (collagen 
and elastic) that help support and facilitate stretching of the vessels. The middle tunica media 
is made up of smooth muscle cells that regulate blood flow by vasodilation or vasoconstriction. 
Finally, the inner tunica intima is made up of endothelial cells. Unlike arteries and veins, 
capillaries only consist of one layer, the tunica intima [17]. 
1.3 Cardiac Metabolism 
There are two main substrates used for energy production in the heart: carbohydrates and fatty 
acids (FAs). In normal conditions, these substrates contribute 30 % and 70 % of the energy for 
the heart from carbohydrates (and a small amount of ketone bodies and amino acids) and FAs, 
respectively. The mitochondria generates 90-95 % of that energy through oxidative 
phosphorylation, while the remaining 5-10 % of energy comes from glycolysis and the 
tricarboxylic acid (TCA) cycle [15, 18]. The majority of cardiac energy (60-70 %) is used for 
contractility, and the remainder (30-40 %) is used for sarcoplasmic reticulum calcium ATPase 
(SERCA) and other ion pumps [19]. The heart is a metabolically flexible organ as the ratio of 
energy from its different substrates shifts under different conditions in accordance with energy 
demands, oxygen availability, and subcellular changes [20]. The energy pool in the heart 
consists of adenosine triphosphate (ATP) and phosphocreatine (PCr); which acts as a 
transporter and buffer system for ATP [21]. A simplified schematic pathway of metabolism in 





1.3.1 Glucose Metabolism 
Glucose is transported into the cytosol of the cell via glucose transporters (GLUTs) such as 
GLUT1; which is the major transporter in foetal hearts, and GLUT4; the dominant transporter 
in adult hearts [22, 23]. Then, glucose is phosphorylated inside the cell into glucose-6-
phosphate (G6P) which is used for glycogen synthesis, the pentose phosphate pathway (PPP), 
or the main glycolytic pathway yielding pyruvate, nicotinamide adenine dinucleotide (NADH), 
and a small amount of ATP [24, 25]. The pyruvate then is either converted into lactate or enters 
the mitochondria to be oxidized into acetyl-CoA by the enzyme pyruvate dehydrogenase 
(PDH). Additionally, it can be carbonylated into oxaloacetate or malate (anaplerotic pathway) 
[5]. The heart stores glucose as glycogen to be used as a substrate for energy production under 
conditions of increased energy demands because glucose is 20-30 % more metabolically 
efficient in producing ATP per mole of oxygen (O2) compared to FAs [26]. 
Figure 1.1: Metabolism and energy production in the heart [15]. More 




Glucose oxidation is mainly regulated by the enzyme PDH, which is inhibited by acetyl-CoA 
and NADH (product inhibition), phosphorylation in the E1 subunit by PDH kinase (PDK) and 
activated by dephosphorylation by PDH phosphatase.  
High circulating FAs are considered an inhibitor of glucose metabolism because they enhance 
the expression of PDK4; the main form of PDK in the heart, via peroxisome proliferator 
activated receptor-α (PPARα), resulting in phosphorylation of PDH and inhibition of the 
oxidation of pyruvate from glycolysis and lactate [27, 28]. The enzyme PDH phosphatase 
activates PDH by dephosphorylation and is increased by calcium (Ca2+) and magnesium 
(Mg2+). This is what happens in β-adrenergic receptor stimulation of the heart, as cytosolic 
Ca2+  transient increases and mitochondrial Ca2+  concentrations rise, leading to the activation 
of PDH phosphatase and increased oxidation of pyruvate [29-31]. Figure 1.2 shows the 
regulation of glucose oxidation in the heart [5]. 
 
Figure 1.2: Regulation of carbohydrate oxidation in the heart [5]. 
Details are mentioned in the text above. 
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1.3.2 Fatty Acid Metabolism 
For FAs to enter the cell they either enter by passive diffusion or they need a transporter protein 
called FA translocase and the membrane FA binding protein [32, 33]. CD36 is the most 
abundant FA translocase in the heart and it regulates the rates of FA uptake in the heart [32, 
34, 35]. In the cytosol, FAs are esterified into fatty acyl-coenzyme A (CoA) which is then either 
esterified into triglycerides by glycerol phosphate acyltransferase or converted into long-chain 
acylcarnitine to enter the mitochondria [36]. This is done by the enzyme carnitine 
palmitoyltransferase I (CPT I), and is an essential regulatory step in the oxidation of FAs [36]. 
In the healthy heart, 70-90 % of fatty acyl-CoA is converted into acylcarnitine, and the 
remaining 30-10 % is esterified into triglycerides [37, 38]. The cardiac triglycerides pool is 
important for energy production during reperfusion of ischaemic hearts [39]. The long chain 
acylcarnitine then enters the mitochondrial matrix by carnitine acyltranslocase and is converted 
back into acyl-CoA by CPT II. Acyl-CoA is then oxidised (β-oxidation) to give acetyl-CoA, 
NADH, and reduced flavin adenine dinucleotide (FADH2) [20].  
CPT I is regulated by malonyl-CoA and other mechanisms that inhibit FA oxidation [40-
42]. Malonyl-CoA is a product of carboxylation of extra-mitochondrial acetyl-CoA by acetyl-
CoA carboxylase (ACC) [43] [44, 45]. ACC is inhibited by phosphorylation by adenosine 5′ 
monophosphate-activated protein kinase (AMPK), which in turn accelerates FA oxidation [46]. 
Malonyl-CaA is converted back into acetyl-CoA and carbon dioxide (CO2) by the enzyme 
malonyl-CoA decarboxylase [47] [48]. Figure 1.3 shows the regulation of FA metabolism in 








1.3.3 Tricarboxylic Acid Cycle (Krebs Cycle) 
Acetyl-CoA from glucose and FA oxidation enters the TCA cycle to generate ATP, CO2, and 
NADH2. The acetyl-CoA joins with oxaloacetate to form citrate via the enzyme citrate 
synthase. The citrate then goes into a series of reactions ending in the formation of oxaloacetate, 
which joins with acetyl-CoA once again starting a new cycle (figure1.4 [11]).  
Intermediates in the TCA cycle are consistently used for other pathways such as amino acid 
and nucleic acid synthesis, and thus they need to be replenished from sources other than acetyl-
CoA (e.g. carboxylation of pyruvate into malate) [49]. This process is called anaplerosis and is 
crucial in the heart as impairment causes cardiac dysfunction and disease [49-51]. One TCA 
cycle yields 3 NADH, 1 FADH2, and only 1 ATP molecule. NADH and FADH2 from the TCA 
cycle then enter the electron transport chain (ETC) located in the inner mitochondrial 
membrane for oxidative phosphorylation generating reactive oxygen species (ROS) mainly 
from complexes I and III [52].  
 
Figure 1.3: Process of fatty acid oxidation in the heart [5]. Details are 





1.3.4 Oxidative Phosphorylation 
The ETC consists of four complexes, complex I (NADH-quinone oxidoreductase), complex II 
(succinate dehydrogenase), complex III (ubiquinol-cytochrome c oxidoreductase), and 
complex IV (cytochrome c oxidase).  
As described in [3], NADH donates two electrons to complex I which uses them to transfer 4 
hydrogen ions (H+) into the inter-membrane space. The two electrons are then transferred to 
complex III via coenzyme Q, which results in 4 more H+ being transferred into the inter-
membrane space from this complex. Cytochrome C carries the two electrons into complex IV. 
In complex IV, the two electrons react with O2 yielding H2O and resulting in two H
+ being 
transferred into the inter-membrane space. So, the total number of protons from NADH 
becomes 10. 
Figure 1.4: Illustration of the TCA (Krebs) cycle [11]. Details are provided 
in the text above. 
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FADH2 enters complex II of the ETC and is then carried by coenzyme Q into complex III 
(resulting in 4 H+ being transferred into the inter-membrane space), and then into complex IV 
via cytochrome C resulting in two more H+  being transferred into the inter-membrane space. 
Making the total number of protons 6 from FADH2.  
ATP synthase then uses this proton gradient to make energy and synthesise ATP from 
adenosine diphosphate (ADP) and inorganic phosphate (Pi). Four protons are used to make one 
molecule of ATP, meaning NADH and FADH2 can generate 2.5 and 1.5 ATP molecules, 
respectively. Figure 1.5 shows a schematic representation of the ETC complexes and the 











1.3.5 Ketone Bodies Metabolism 
Ketone bodies (β-hydroxybutyrate and acetoacetate) are made from FAs in the liver, and in 
normal conditions their contribution to cardiac energy is relatively small. However, in 
situations like starvation or uncontrolled diabetes, levels of ketone bodies in the plasma are 
elevated and they become a major source of energy for the heart [43]. Metabolism of ketone 
Figure 1.5: Representation of the mitochondrial ETC complexes and 






bodies inhibits the oxidation of glucose and lactate, as well as the uptake and oxidation of FAs 
[53-56].  
1.4 Excitation-Contraction Coupling 
1.4.1 Excitation (Action Potential) 
Excitation-contraction (EC) coupling is the process of generating an energy dependant 
electrical signal that leads to the contraction of the heart. Pacemaker cells in the sinoatrial (SA) 
node in the right atrium generate this electrical signal, which then passes through the myocytes 
of the atria via gap junctions and into the ventricles via the atrioventricular (AV) node [57]. 
The action potential in the SA node differs than that in the AV node by having no actual resting 
phase. There are three phases in the SA node action potential. Phase 4 is the spontaneous 
depolarisation phase that triggers the action potential when membrane potential reaches 
between – 40 and – 30 mV. This is followed by phase 0 which is the depolarisation phase. And 
finally, phase 3 which is repolarisation of the membrane, when membrane potential reaches 
about – 60 mV. The depolarisation in the SA node mainly depends on slow Ca2+ currents 
instead of fast Na+ current, which leads to a slower action potential referred to as slow response 
action potential [433].  
The action potential has five phases of depolarisation and repolarisation (phase 0–4). As 
described in [9], phase 4 is called the resting phase, where the myocyte membranes have a 
negative potential of around -90 mV due to the movement of potassium ions (K+) across the 
membrane via the inward rectifying potassium channels. When the electrical signal flows from 
the SA node it leads to rapid depolarisation of the resting membrane (phase 0). Depolarisation 
happens due to the opening of the voltage gated sodium channels and entry of sodium ions 
(Na+) into the myocytes. This is followed by the early repolarisation phase (phase 1), where 
the sodium channels are inactivated and chloride (Cl-) and (K+) are moved out of the cell, 
causing the membrane potential to become positive. Phase 2 of the action potential occurs when 
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the balance between influx of Ca2+, through L-type Ca2+ channels (which open at a potential 
greater than -40 mV), and efflux of (K+), through delayed rectifier potassium channels, 
becomes balanced and the potential plateaus. Finally, when membrane potential drops below -
40 mV, the delayed rectifier potassium channels remain open, and the L-type calcium channels 
close, causing rapid repolarisation (phase 3), until the membrane reaches a potential of -90 mV 
returning to its resting (phase 4) state. This is shown in figure 1.6 below.  
 
1.4.2 Contraction 
There are two types of filaments: thin (actin) filament, and thick (myosin) filament. The actin 
filament is a helix made up of two chains of polymerised actin molecules, and the myosin 
filament consists of a long tail with two heads at one end of the tail [58]. These two filaments 
make up the contraction unit in the heart called the sarcomere. The sarcomere has two bands 
depending on the arrangement of the filaments; the isotropic band (I band) which is made up 
of thin actin filaments, and the anisotropic band (A band) which is made up of both actin and 
myosin filaments. These two bands are contained between Zwischenscheibe lines (Z lines) 
[59]. The thin actin filament has the troponin complex which consists of troponin I (the 
Figure 1.6: Schematic representation of the cardiac action 
potential [9].  
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inhibitor of the actin-myosin interaction), troponin C (the calcium binding site), and troponin 
T (which binds to tropomyosin). 
For the contraction to occur, intracellular Ca2+ needs to bind to the thin actin myofilament 
through troponin C. During phase 3 in the action potential when L-type calcium channels open 
and Ca2+enter the cell, this causes the release of more Ca2+ from the sarcoplasmic reticulum 
(SR); regulated by ryanodine receptor (RyR), increasing the intracellular Ca2+ concentration 
from 0.1 μM to 1 μM in adult cardiomyocytes [6]. This process is known as calcium-induced 
calcium release (CICR). Intracellular Ca2+ then binds to actin causing conformation changes 
that unblock the myosin binding site on the actin molecule [60]. The two filaments bind 
together (The Cross-Bridge Cycle), and this process utilises energy by hydrolysing ATP, 
releasing phosphate, and leading to contraction with the shortening of the I bands and the 
moving of the Z lines closer (the sliding filament theory) [59]. 
 
1.4.3 Relaxation 
During relaxation, a number of proteins lower the concentration of cytosolic Ca2+. 
Calsequestrin is a calcium binding protein in the SR that acts on the RyR when cytosolic Ca2+ 
concentrations are high, and the SR calcium content is low. Calsequestrin inhibits RyR 
stopping the release of more Ca2+ from the SR and allowing the SR to refill [6]. Additionally, 
SERCA regulates the uptake of Ca2+ into the SR to facilitate relaxation [61]. The 
sodium/calcium exchanger (NCX) is the major pathway by which calcium is extruded from the 
cell [62]. When cytosolic Ca2+ concentrations fall, the calcium-troponin C complex dissociates 
allowing relaxation.  
Additional proteins that are involved in the homeostasis of cellular calcium include cyclic 
adenosine monophosphate (cAMP), which activates protein kinase A (PKA). Activated PKA 
phosphorylates phospholamban (PLN) (a protein that inhibits the action of SERCA), which 
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inhibits its activity leading to the activation of SERCA [63]. Figure 1.7 shows the EC coupling 
and regulation of intracellular calcium concentration [6]. 
 
1.5 Ischaemia/Reperfusion Injury 
1.5.1 Overview 
Cessation or reduction of blood flow to the heart (ischaemia) predisposes the myocytes to 
reperfusion injury when blood flow is reintroduced to the heart (reperfusion) [64]. The main 
alterations in I/R causing injury to the heart are generation of ROS, ionic disturbances leading 
to cellular Ca2+ overload, change in cellular pH, inflammation, and the opening of the 
mitochondrial permeability transition pore (mPTP). In ischaemia, the absence of oxygen results 
in the cell switching to anaerobic metabolism, which results in lactate accumulating in the 
myocyte leading to a drop in pH (< 7.0). The decrease in pH and accumulation of protons in 
the cell activates the sodium/hydrogen ion exchanger (Na+/H+ exchanger) which extrudes the 
excess H+ in an attempt to neutralize the pH of the cell, which leads to the efflux of protons in 
Figure 1.7: Excitation-contraction (EC) coupling in the heart and 





exchange for Na+ entering the myocyte. Due to the lack of ATP during ischaemia, the 
sodium/potassium ATPase activity is stopped, which leads to the accumulation of Na+ inside 
the cell. In order to extrude Na+ from the cell, the NCX is activated, and this leads to the 












During reperfusion, oxygen and metabolites are restored for aerobic metabolism, oxidative 
phosphorylation, and ATP production, however, reperfusion is associated with additional 
tissue injury as evident by the fact that intervention during reperfusion have shown to reduce 
infarct size by 50 % [64]. Factors mentioned earlier (oxidative stress, the rapid restoration of 
cellular pH, and the opening of the mPTP) mostly happen during reperfusion.  
Reperfusion injury can trigger reversible injury including arrythmias and cardiac stunning 
(contractile dysfunction), irreversible microvascular obstruction, and lethal myocardial 
reperfusion injury (death of cardiomyocytes that were viable before reperfusion) [13]. 
Microvascular obstruction is characterised by capillary damage and sluggish blood flow that 
hinders the reperfusion of an ischaemic area [65]. This dysfunction in capillaries can be caused 
Figure 1.8: Components of myocardial I/R injury [13]. 
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by a number of reasons such as impairment in vasodilation, compression by swelling myocytes, 
and neutrophil plugging, and it is associated with worsened clinical outcomes such as larger 
MI size, LV remodelling, and lower ejection fraction [66-69].  
1.5.1.1 The Role of pH 
The role of pH in I/R injury has been studied and is called the pH paradox [70]. Manipulations 
to delay the normalisation of cellular pH during reperfusion confirmed its protective role 
against I/R. Reperfusion with an acidic buffer to slow the normalisation of pH in the cell has 
been shown to reduce cell loss in rat hepatocytes [71]. Blocking the Na+/H+ exchanger in an 
attempt to delay cellular pH restoration, helped in reducing loss of myocytes. This effect is 
independent of intracellular Ca2+ concentration, as it did not reduce Ca2+  concentration in the 
cell [70]. Additionally, blocking the NCX  reduced intracellular calcium but not cell death [70]. 
The mechanism proposed here by the author is that during ischaemia there is a release of 
hydrolytic enzymes (phospholipases and proteases) that are activated once pH is normalised 
during early reperfusion. Additionally, the normalisation of pH increases the mitochondrial 
permeability and activates myofibrillar ATPase, which increases the ATP demands in the cell.  
1.5.1.2 The Role of Cellular Calcium Overload 
Intracellular calcium overload starts during ischaemia when the sodium/calcium exchanger is 
activated. This is exacerbated when reperfusion starts because of disruption of plasma 
membrane, damage of SR from ROS, and the re-energisation of the cell [13]. In addition to 
calcium overloading inside the cell, it enters the mitochondria through the calcium uniporter, 
and this induces the opening of the mPTP [72]. 
1.5.1.3 The Role of The Calpain System 
Calpains are Ca2+-dependent nonlysosomal cystein proteases localized in the cytosol of the cell 
when in their inactive form [73]. The calpain family consists of more than 25 calpains or 
calpain-like proteins. Calpains can either be ubiquitous proteins found in almost all cells, or 
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tissue-specific proteins such as calpain 3 found in skeletal muscle. There are two main isoforms 
of calpains, μ-calpain (calpain 1) and m-calpain (calpain 2). The micro/milli-molar indicates 
the Ca2+ concentrations required for the activation of each type [74]. 
Under normal physiological conditions, calpain proteins are found in the cytosol of the cell in 
their inactive form, bound to their inhibitor calpastatin [75]. When intracellular Ca2+ 
concentrations increase, calpains are translocated into the cellular membrane for activation, but 
activation only happens upon reperfusion when pH levels in the cell are normalised [76]. 
Activated calpains in turn activate a number of growth factor receptors, cytoskeletal proteins, 
microtubules associated proteins, and mitochondrial proteins, which all play a role in cellular 
processes such as differentiation and apoptosis [77]. More importantly, because calpains are 
part of the integrated proteolytic system, once activated they target cardiac structural proteins 
that are required for cardiac structural integrity. Both myofibrillar and regulatory proteins of 
the contractile apparatus (important for sarcomere) are affected by calpains activation [78]. 
Additionally, T-tubules junctophilin are also proteolyzed by calpains [79, 80]. The dysfunction 
or loss of organisation of sarcomere and T-tubules are both associated with numerous 
Figure 1.9: Calpain system activation in I/R injury [7]. 
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cardiovascular diseases including I/R injury and heart failure [81-83] figure 1.9 shows the 
activation of calpain proteins [7]. 
1.5.1.4 The Role of Mitochondrial Permeability Transition Pore 
The mPTP was first described in the late 1970s by Haworth and Hunter [84]. Its role in I/R 
injury was first described in 1987 [85]. The mPTP remains closed throughout ischaemia and 
only opens when reperfusion of the heart starts [86]. During ischaemia, the acidosis of the cell 
helps in maintain the mPTP closed, but as reperfusion starts, there is an increase in Ca2+ 
concentration, oxidative stress and rapid normalisation of the cellular pH which all contribute 
to the opening of the mPTP [86-88]. 
The opening of the mPTP causes the influx of water and solutes into the mitochondria leading 
to its swelling. The inner mitochondrial membrane can accommodate for this increase, however 
the outer mitochondrial membrane ruptures releasing the contents of the inter-membrane space, 
which include pro-apoptotic and apoptosis-inducing factors (e.g. cytochrome C) [89]. 
This explains the reported apoptosis in most of the studies investigating ischaemia followed by 
reperfusion rather than in ischaemia on its own [90-92]. 
1.5.1.5 The Role of Oxidative Stress 
ROS are highly reactive molecules that have an unpaired electron in their outer shell. They 
include hydrogen peroxide (H2O2), the superoxide radical anion (O2
•−), and the hydroxyl 
radical (OH•) [93]. Oxidative stress occurs when the generation of ROS is higher than their 
neutralisation by antioxidant defences in the body. ROS lead to DNA oxidation, lipid 
peroxidation, damage to proteins and membranes, ultimately affecting permeability, structure, 
and function [94].  
Reperfusion increases ROS through mitochondrial reenergisation and activation of a number 
of enzymes such as NADPH oxidases (NOX). NOX uses NADPH as the electron donor to 
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reduce O2 and generate O2
•− [95]. Studies have shown that the absence of this enzyme (using 
NOX knock-out mice) reduced reperfusion injury and infarct size by up to 50 % [96].  
Another enzyme activated during reperfusion is xanthine oxidase. This enzyme is present in 
the vascular endothelium and produces ROS (specially O2
•−), which activates neutrophils and  
their adherence to endothelial cells, leading to the production of  more xanthine oxidase and 
thus more superoxide radicals [97]. Additionally, during ischaemia, xanthine dehydrogenase 
can be further converted into xanthine oxidase [98].  
Another enzyme involved in ROS-reperfusion injury is the endothelial nitric oxide (NO) 
synthase (eNOS), which is involved in the regulation of vascular function. With the disruptions 
that occur during I/R, eNOS can become uncoupled and starts producing O2
•− instead of NO 
[99].   
In addition to ROS, reactive nitrogen species (RNS), mainly peroxynitrite anion (ONOO-), 
contribute to reperfusion injury [98]. ONOO- is produced by the reaction between O2•− and 
NO, and its production leads to the uncoupling of eNOS and the other NOS isoform (iNOS), 
increasing the production of O2•−[100]. 
1.5.1.6  The Role of Inflammation 
It is not clear whether inflammation is a result of I/R injury or a contributing factor to the injury. 
Some studies looking at the effects of using anti-inflammatory substances in I/R showed that 
targeting the inflammation reduced I/R injury significantly. A study in felines targeted the 
neutrophil-endothelial cells interaction by administering P-selectin glycoprotein ligand-1 prior 
to reperfusion, which caused a significant reduction in injury caused by I/R [101]. Another 
study using a monoclonal antibody against the intercellular adhesion molecule-1 in endothelial 
cells to prevent the neutrophil-endothelial interaction in rabbits, also showed an improvement 
in I/R outcome and reduction in infarct size [102]. Additionally, another study using inhibition 
of the complement activation in rats showed that targeting C5 complement resulted in a 
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reduction in apoptosis and necrosis, and neutrophil infiltration after I/R [103]. However, other 
trials using the same approaches showed negative results [104, 105]. 
1.6 Ageing and Cardiovascular Disease 
Ageing is considered a risk factor for CVD and heart failure (HF), mainly because of its effects 
on the structural, functional, molecular, and cellular remodelling of the cardiovascular system 
that causes heart dysfunction [8]. Hypertension, CHD, stroke, and heart failure are all forms of 
CVD that are prevalent in the elderly population (> 65 years) and are estimated to increase by 
10 % in the next 20 years [106]. The leading cause of death in Europe and the United States is 
CHD, which associates strongly with ageing [107-109]. 
1.6.1 Cardiovascular Structural and Functional Changes with 
Ageing 
Structurally, some of the most common changes that occur with ageing in the heart include 
hypertrophy. Even though with ageing there is a loss of cardiomyocyte numbers; 45 million 
myocytes are lost in the left ventricle each year, there is an increase in their size as a 
compensatory mechanism and this contributes to the cardiac hypertrophy and increased 
myocardial thickness seen in the ageing heart [110, 111]. In addition, the heart also changes 
from an elliptical to spheroidal shape with an increase in the thickness of the interventricular 
septum (IVS) [112]. Due to increased workload and decreased cardiac reserve capacity in the 
ageing heart, compensatory mechanisms and functional changes occur in the heart and these 
include changes in heart rate, end systolic and diastolic volumes, contractility, and sympathetic 
signalling, which eventually contribute to CVD. Increased left ventricular wall thickness and 
size leads to a decrease in early diastolic cardiac filling, which in turn increases the cardiac 
filling pressure, the prevalence of atrial fibrillations and other arrythmias, and the likelihood of 
HF [12]. Suggested mechanisms for these dysfunctions include alterations in calcium handling, 
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growth factor regulation, and collagen deposition. Figures 1.10 and 1.11 illustrate some of the 
structural and functional changes in the ageing cardiovascular system [8]. 
Figure 1.11: Age-related cardiac and arterial changes in healthy humans [12] 
 




In addition to age-related cardiac changes, ageing also affects the vascular system. Common 
changes include thickening of large arteries, and loss of vascular elasticity [113]. Furthermore, 
the arterial wall media undergoes hypertrophy, accumulation of extracellular matrix, calcium 
deposits, and a decrease in vasodilators release and increase synthesis of vasoconstrictors in 
the vascular endothelium; which contributes to the vascular stiffness [114, 115]. Endothelial 
vasodilation reduction in ageing is thought to be secondary to a reduction in NO bioavailability, 
which is reduced due to a decrease in nitric oxide synthase (eNOS) [116-118]. 
Another common structural change seen with ageing is fibrosis. Collagen content and non-
enzymatic collagen cross-linking increases with ageing, alongside fragmentation of elastic 
fibrils, which contributes further to the stiffening and loss of elasticity in the aged vessels [116]. 
These vascular changes in ageing contribute to hypertension, stroke, and the development of 
atherosclerosis.  
Additional changes that occur with ageing also include the deposition of fat around the 
sinoatrial (SA) node, calcification of the left side of the cardiac skeleton, and a decline in 
number of pacemaker cells. These factors affect the cardiac conduction system and 
contractility, leading to arrhythmias such as atrial fibrillation, paroxysmal supraventricular 
tachycardia, and ventricular arrhythmias [12]. Despite all the changes that happen in the 
cardiovascular system with ageing, left ventricular ejection fraction (LVEF) and resting 
systolic function do not change [119]. 
These changes make the heart more prone to injury and stress, and with the accumulation of 
other conditions associated with ageing such as obesity, dyslipidaemia, and metabolic 
syndrome, the injury threshold of the ageing heart becomes lower [12].  
1.6.2 Cardiac Metabolism in Ageing 
Ageing affects the metabolism of the heart independent of disease. The major shift in 
metabolism with ageing is a decrease in the uptake and oxidation of FAs, with no change in 
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glucose oxidation, despite a decrease in GLUT4 expression in the ageing heart [120, 121]. PDH 
complex is a key enzyme that regulates the competition between mitochondrial glucose and 
FA oxidation. The phosphorylation of this enzyme by PDK in ageing is decreased favouring 
glucose oxidation [122]. Other changes observed in the ageing heart regarding metabolism 
include a decrease in the activity of CPT I and carnitine exchange in old rat hearts [123]. 
Additionally, the suppression of glucose oxidation by FAs was not evident in the ageing heart 
[123]. Furthermore, a reduction in the expression of PPARα; which regulates genes of FA 
metabolic enzymes, and the activity of cytochrome oxidase, citrate synthase, and 3-
hydroxylacyl-CoA dehydrogenase (which are PPARα target enzymes) were all observed in the 
ageing heart, and were prevented by swim training [124]. The metabolic changes associated 
with ageing are similar to those seen in HF [125].  
The energy pool in the heart consists of ATP and PCr; which acts as a transporter and buffer 
system for ATP, and this is an important determinant of cardiac function and performance [21]. 
It was found that the PCr:ATP ratio is significantly correlated with diastolic function, peak 
cardiac power output, and peak oxygen consumption, and that is decreased significantly with 
ageing, as well as being  inversely correlated with heart rate [126] 
Depletion of cardiac energy reserves has been associated with heart failure and left ventricular 
dysfunction, and a number of trials aimed at preserving this energy and counteracting the 
depletion using drugs; such as Angiotensin-converting enzyme (ACE) inhibitors, CPT 
inhibitors, and β-blockers have all shown to improve cardiac function and performance [127-
129].  
1.6.3 Calcium Homeostasis and Excitation-Contraction Coupling in 
the Ageing Heart 
With ageing, contraction is prolonged, and relaxation is incomplete [130]. A number of factors 
lead to this change in EC coupling and change in contractility including a change in 
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myofilament proteins where they shift from α-myosin heavy chains to β-myosin heavy chains, 
which in turn decreases the myosin ATPase activity [131]. In addition to myofilament proteins, 
other proteins involved in calcium handling are altered with ageing and contribute to the change 
in EC coupling. L-type calcium channels have shown to increase in number and activity in the 
ageing heart with a decrease in their inactivation, all which prolongs the action potential [12]. 
Additionally, proteins of the SR controlling calcium release and reuptake are altered with 
ageing. Calsequestrin; the major SR calcium binding protein that stops the action of RyR2, 
showed no change in the ageing heart compared to the adult heart [132]. On the other hand, 
RyR2 showed a reduction in the ageing heart [133, 134]. The regulation of RyR2 by 
phosphorylation by Ca2+/calmodulin‐dependent kinase II (CaM kinase II) was also reduced in 
ageing which may affect calcium release from the SR as well [135]. All of these changes 
indicate slower calcium release from the SR in the ageing heart.  
Another important protein is SERCA2a, which is affected in the ageing heart in activity and 
regulation [136, 137]. Decreased expression of SERCA2a; which helps in the SR reuptake of 
calcium, may cause the prolongation of contraction seen in the ageing heart, and also its 
regulation by PLB; an endogenous inhibitor that increases in ageing myocytes, contributes 
furthermore to the slowing of calcium reuptake [132]. Furthermore, phosphorylation of PLB 
by PKA increases the activity of SERCA2a and thus speeds relaxation, but this phosphorylation 
is decreased with ageing, which also prolongs contraction [135]. Additionally, CaM kinase II; 
which phosphorylates SERCA2a increasing its activity, is reduced in the ageing heart [135]. 
Finally, another component of interest in the EC coupling is NCX, which functions in removing 
calcium from the myocyte during relaxation. Studies on NCX activity in the ageing heart show 
contradictory findings where it is either decreased or remains unchanged with ageing [138, 
139]. However, a recent study showed an increase in NCX activity in ageing ventricular 
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myocytes, which may aid in removing calcium from the myocytes during relaxation and 
compensate for the decrease in SERCA2a activity [140]. 
All of these changes are expected to slow SR calcium reuptake, reduce SR calcium content, 
and prolong the calcium transient, which subsequently leads to the contractile dysfunction seen 
in the ageing heart. Figure 1.12 shows changes in EC coupling and calcium homeostasis in the 
ageing heart.  
 
1.6.4 Mitochondria in the Ageing Heart 
1.6.4.1 Mitochondrial Morphology 
Numerous studies have looked at the effects of ageing on mitochondrial function and 
morphology, with regards to their different subpopulations (interfibrillar (IF), Subsarcolemmal 
(SSL), and perinuclear (PN)). Some of the age-related changes reported include a decrease in 
mitochondrial number, oxidative phosphorylation, and cytochrome oxidase enzyme activity in 
rats [141]. However, these changes were only seen in IF mitochondria and not in SSL ones. 




Another study in Fischer 344 rats described the variations in mitochondrial subpopulation 
cristae. SSL mitochondria mainly had lamelliform cristae (in situ) and after isolation, whereas 
IF mitochondria mainly had tubular or a mixture of tubular and lamelliform cristae (in situ) and 
mainly a mixture of both with the more lamelliform cristae after isolation. This showed that 
unlike SSL mitochondria, IF mitochondria tend to change after isolation [142]. Even though 
there was no change in cristae with ageing; suggesting their lack of involvement in the 
mitochondrial defect seen in ageing, the inner mitochondrial membrane per unit volume of 
mitochondria decreased significantly in aged rats of both Wistar and OXYS strains [143, 144].  
Changes in mitochondria showing only in IF subpopulation were also observed in conditions 
other than ageing such as diabetes mellitus and cardiomyopathy [145, 146] 
1.6.4.2 Mitochondrial Electron Transport Chain and Oxidative 
Phosphorylation 
Oxidative phosphorylation in the mitochondria is changed with ageing mainly due to changes 
in ETC complex activity, protein levels, and inner mitochondrial membrane phospholipids 
[147]. SSL mitochondria have been found to maintain respiratory capacity in the ageing heart 
in rodents, however IF mitochondria appeared to consume less oxygen [141, 148-150]. This 
decline in oxygen consumption associated with a defect in ETC complex III and IV [151]. 
Additionally, the mitochondrial biogenesis and biogenesis regulatory proteins such as 
peroxisome proliferator‐activated receptor‐gamma coactivator‐1alpha (PGC‐1alpha) are 
decreased in the ageing heart [152-155]. 
Cardiolipin is a phospholipid in the inner mitochondrial membrane which is important for 
regulating ETC complex proteins and is found to be decreased with ageing, making it a target 
of intervention for preventing age-induced mitochondrial dysfunction [156].  
Complex IV (cytochrome oxidase) defect with ageing is mainly due a defect in its inner 
membrane environment and a defect in its subunits. There is a 25 % decrease in the complex 
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IV subunit VIIa in the ageing heart, only in IF mitochondrial [157]. A possible decrease in 
cardiolipin content in the immediate complex environment may affect its organisation into 
supercomplexes and thus affecting its enzyme activity [158]. These defects decrease energy 
production, increase ROS production, and increase cell stress responses.  
1.6.4.3 Reactive Oxygen Species 
ROS can be generated in the cytosol by xanthine oxidases, the plasma membrane by NADPH 
oxidases, and most importantly in the mitochondria [147]. In the mitochondria, ROS are 
generated from complex I, II, and III, and from monoamine oxidases (MAO) that transfer 
electrons from amine groups to oxygen generating hydrogen peroxide and p66Shc [159, 160]. 
Due to the defects in the ETC mentioned earlier, electrons leak from the ETC and react with 
oxygen generating superoxide anions which in turn can be reduced to hydroxyl radicals and 
hydrogen peroxide [147]. 
Reports on ROS production in ageing heart are controversial, as some studies report increase 
production while others report no change in ROS production [161-164]. Hydrogen peroxide 
production was reported to increase with ageing in both SSL and IF mitochondria. Some studies 
report higher hydrogen peroxide production in SSL mitochondria, while others report higher 
production in in IF mitochondria [151, 165]. On the other hand, other studies report no 
difference in the ROS production in ageing between the two mitochondrial subpopulations 
[160]. Additionally, MAO-A and MAO-B were reported to be elevated in aged rat hearts and 
mice hearts respectively [166]. Also, mitochondrial p66Shc was reported to increase with ageing 
in SSL mitochondria [167]. 
Increased ROS formation has been linked to reduced life expectancy; however, this has not 
always been proven. When it comes to the antioxidant catalase, mice overexpressing catalase 
were reported to have better lifespan compared to their wild type counterparts [168]. This was 
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not the case with antioxidant manganese superoxide dismutase-2, as overexpression or 
reductions in the antioxidant did not affect lifespan or cell death in mice [169, 170].  
1.6.4.4 Mitochondrial Permeability Transition Pore  
 The mPTP under normal non-stressed conditions remains closed and is opened by ROS, 
increased calcium concentration, mitochondrial membrane depolarisation. Once opened, it 
leads to mitochondrial swelling, rupture of the mitochondrial outer membrane, and the release 
of pro-apoptotic factors into the cell and eventually cell death (as mentioned earlier in the 
introduction – page 37). 
The opening of the mPTP is affected by ageing. The calcium retention capacity of the mPTP 
was not found to be different between adult and aged rat hearts in SSL mitochondria [171]. 
However, it was reduced in IF mitochondria in aged rat hearts [172].  
Additionally, cyclosporin-A is an mPTP inhibitor which was found to be effective in delaying 
ROS-induced mPTP opening in young but not aged rat hearts [173]. 
1.6.5 Ischaemia/Reperfusion Injury in the Ageing Heart 
Ageing has been associated with increased vulnerability to I/R injury. It has been reported that 
the ageing heart has reduced oxidative phosphorylation as well as a decrease in complexes III 
and IV activity of the mitochondria, which contributes to this increased intolerance to 
ischaemia in the ageing heart [174]. Additionally, a study in Fischer 344 aged rats (24 months 
old) reported increased vulnerability of the isolated perfused heart to I/R compared to young 
(6 months of age) hearts. This was demonstrated by decreased functional recovery, increased 
tissue damage and CK release as well as LDH release [175]. Also, in another rat study using 
F344 BN rats (19 months vs. 4 months), ageing hearts were shown to be more vulnerable to 
myocardial I/R and this was associated with increased apoptosis characterised by increased 
expression of BAX to Bcl-2 ratio [176]. The ischaemic tolerance was shown to decrease in 
middle age (50 weeks of age) in Fischer 344 rats and progressed with increasing age, and was 
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suggested to be related to higher levels of  intracellular sodium pre-ischaemia in middle aged 
and aged hearts, which led to a higher increase in sodium levels in the cell at the end of 
ischaemia [177]. Similarly, female Wistar rats aged 8-10 months and 24-28 months were used 
for comparing cardiac vulnerability, and increased vulnerability of the ageing heart to I/R 
injury was associated with Ca2+  homeostasis (increased sarcolemmal permeability for Ca2+ and 
decreased Ca2+ accumulating capacity of SR) [178]. In addition to studies using rats, mice were 
also studied for examining the vulnerability to I/R with ageing. C57BL/6 mice (6-8 months vs. 
22-24 months) were used for I/R experimentation, and ageing hearts had larger infarction, 
myofiber tears, DNA fragmentation, and mitochondrial disruption [179]. Authors in the study 
suggested a decrease in coronary circulation and collateral flow as factors associated with this 
increased vulnerability in the ageing heart. Increased susceptibility to I/R injury was also 
reported to start during middle age in mice (12 months) with impaired ventricular contractility 
[180]. Authors in the study used 5 age groups (2-4 months, 8 months, 12 months, 18 months, 
and 24-28 months) and reported that diastolic dysfunction and impairments in functional 
recovery after I/R appeared since adulthood. LDH release from the heart during reperfusion 
showed a different pattern where it increased until middle age and then fell with further ageing 
to a level similar to that found in young adult hearts (2-4 months).  Additionally, another study 
reported increased vulnerability of the ageing heart to I/R injury and associated this to the 
protein sestrin2 [181]. Sestrin2 is a stress-inducible protein that is important for AMPK 
activation. In this study, C57BL/6 mice were used (3-4 months vs. 10-12 months vs. 24-26 
months) and ageing hearts had decreased tolerance to I/R as they had larger infarction, and this 
was associated with a decrease in sestrin2 levels. Also, hearts from 18 months old wild type 
mice compared to 7 months old hearts were shown to be more vulnerable to I/R injury, and this 
was exacerbated by decreased activity of SIRT3 (Silent information regulator of transcription 
3) [182].  
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In contrast to previous studies, 13 months old C57BL/6 mice showed no difference in 
vulnerability to I/R injury measured by infarct size compared to 3 months old controls [183]. 
The difference seen was after ischaemic preconditioning when aged mice did not respond as 
adult mice did, and this was attributed to decreased levels of Connexin 43.  
Conflicting results were also reported in human myocardium with regards to vulnerability to 
I/R in ageing, however, ischaemic preconditioning was not affected in the ageing heart as it 
was in mice [184, 185]. 
A number of studies have been looking at interventions to increase the ageing heart’s tolerance 
to I/R injury. Caloric restriction was shown to reduce the ageing heart’s vulnerability to I/R in 
mice and was associated with the AMPK-SIRT1 signalling pathway [186]. Additionally, 
elevated intracellular creatine levels in CrT-OE aged mice hearts (78 ± 5 weeks of age) showed 
better tolerance to ischaemia compared to their wild type littermates [187].  
1.7 High-Fat Diet and Cardiovascular Health 
It is well established that high fat diets contribute to obesity and the development of chronic 
diseases such as diabetes, metabolic syndrome, various types of cancer [188-190]. High fat 
diets are also linked to the development of cardiovascular diseases, and this is related more to 
the type of fat in the diet rather than the percentage of fat intake from total energy [191]. The 
way dietary fats affect cardiovascular health is not only confined to raising serum levels of 
cholesterol, but through different mechanisms including hypertension, insulin resistance, and 
inflammation [192]. HFDs typically comprise of 32-60 % calories from fat, and even though it 
is unlikely for a human diet to contain 60 % calories from fat, this is used in experiments to 
reduce the experimental time course [193]. These diets can either be obesogenic or atherogenic. 
Obesogenic diets are accompanied by weight gain and a development of a diabetic phenotype, 
while atherogenic HFDs are not [194]. 
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1.7.1 High-Fat Diet and Cardiovascular Remodelling 
HFD is known to affect the heart structurally and functionally. These diets are associated with 
changes in adiposity, glucose tolerance, insulin resistance, and hyperleptinemia [195]. It has 
been shown that a diet high in fat leads to cardiomyocyte hypertrophy and increased myocardial 
interstitial fibrosis, and unlike metabolic changes associated with HFD (e.g. hyperglycaemia); 
these structural changes occur even in the absence of obesity [196]. In a study using Wistar-
Kyoto rats, HFD was associated with increase in body weight, metabolic changes, increase in 
systolic blood pressure, cardiac hypertrophy with no change in cardiomyocyte size, increased 
interstitial fibrosis, and a shift from α to β myosin heavy chain (MHC) expression [197]. Again, 
these structural cardiac changes were directly related to the fat intake independent of obesity. 
Martins et al. (2015) reported that Wistar rats fed HFD for 20 weeks showed significantly 
higher levels of glucose, larger left atrium diameter, larger myocyte cross sectional areas, and 
increased interstitial collagen fraction compared to their ND controls [196]. Additionally, 
another study using Dahl salt sensitive rats fed either a low fat or high fat diet for 12 weeks 
reported that increased dietary lipid intake is associated with cardiac growth, remodelling of 
the left ventricle, contractile dysfunction, and alterations in gene expression, but this effect was 
diminished in the presence of hypertension [198].  
HFD cardiac remodelling was also studied in mice and showed similar findings. Calligaris et 
al. (2013) studied the effects of HFD on C57BL/6 mice for a period of 16 months [199]. The 
HFD fed mice were characterised by increases in weight, hyperglycaemia, insulin resistance, 
hyperinsulinemia, and hypercholesterolemia starting from the 8th month of feeding. By 16 
months of feeding, they showed vasoconstriction, contractility dysfunction, increased heart 
mass, cardiomyocyte hypertrophy, fibrosis, and cardiac metabolic compensation compared to 
their ND controls [199]. Additionally, a study in rabbits reported that high fat feeding for 18 
weeks induced a type II diabetes phenotype, which was associated with cardiac changes such 
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as LV hypertrophy, abnormalities in repolarization and arrhythmias during hyperkalaemia 
[200]. 
Additional structural remodelling of the heart with HFD includes collagen deposits, 
intercellular spaces, disorganisation of cardiomyocytes, deposition of fat under the pericardium 
as well as around vessels and between cardiomyocytes, and a thicker vascular wall with 
reoriented nuclei [201]. The same previously mentioned study, which was done on rabbits, 
found ultrastructural remodelling of the heart with HFD manifested in a decrease of myofibrils 
that became degenerated, sarcomere disorganization, larger intracellular junctions, decreased 
mitochondria distribution, damaged junctional complexes, and multiple vacuolization. The 
damage in the mitochondria resulted in them swelling, becoming elongated, with variations in 
size and cristae organisation. 
The consumption of  HFD has adverse effects on the heart even in the case of short periods of 
exposure [202]. In this study, the researchers used C57BL/6 male mice and fed them a ND or 
HFD for 9 days, and then performed a transverse aortic constriction (TAC) before continuing 
the feeding for another 28 days. HFD feeding for a short duration induced insulin resistance 
alongside increased LV remodelling and dysfunction after TAC. 
Cardiac remodelling associated with HFD has been attributed to a number of cellular/molecular 
changes. Prolonged exposure to HFD has been associated with a reduction in collagen type I 
expression with no change in collagen type III [203]. However, other studies report 
upregulation of the expression of collagen I and III and TGF-β1 (transforming growth factor 
β1) with HFD [204]. Additionally, HFDs affect the calcium handling proteins expression and 
upregulates them in the SR [205]. In rats fed HFD for 15 weeks, obesity was associated with 
increased plasma insulin, glucose, and leptin concentrations. In addition, SERCA2a, RyR2 and 
PLB mRNA were all increased, but no changes were found in Cacna1c (α-1C subunit of the 
voltage-gated L-type Ca2+ channel) and NCX. However, another study in rats showed that HFD 
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and obesity do not alter the expression of PLB or its phosphorylation [206]. Also, SERCA2 
activation was reduced via calmodulin kinase in HFD-induced obesity, which was related to 
the cardiac dysfunction seen in obesity [207]. 
HFD associated cardiac remodelling and dysfunction was also related to SIRT3 [208]. In this 
study, the role of SIRT3 was assessed by using WT and SIRT3 knockout mice. These mice 
were fed either a normal diet or a HFD for a period of 16 weeks. Mice on the HFD showed a 
significant decrease in SIRT3 expression in the heart, as well as an increase in ROS formation, 
impairment in HIF (hypoxia inducible factor) signalling, and a decrease in capillary density in 
the heart. KO mice on HFD in this study also showed increased ROS production and further 
reduction in cardiac function compared to their ND controls.  
Wang et al. (2015) suggested that cardiac hypertrophy and fibrosis caused by prolonged 
feeding with a HFD is mediated by GSK-3β (Glycogen synthase kinase 3 beta) inhibition [209]. 
This study used 7-week-old CD1 male mice, either given a ND or HFD for a period of 11 
months.  Additionally, Roberts et al. (2015) reported that metabolic adaptation favouring lipid 
metabolism and downregulation of glucose metabolism (noted by a reduction in pAMPK, 
GLUT4, and hexokinase2), which offered protection to the heart from obesity related 
cardiomyopathy (hypertrophy, cardiomyocyte lipid droplets, and metabolic alterations) in 
C57BL/6 mice fed HFD [210]. Also, Duda et al. (2007) reported that a low carbohydrate/high-
fat diet in rats for 2 months in addition to abdominal aortic binding (AAB) attenuates pressure 
overload-induced LV hypertrophy and dysfunction compared with high-carbohydrate diets 
[211]. This was also accompanied by lower levels of insulin and leptin which suggests they 
may contribute to this LV remodelling.  
Another factor associated with HFD cardiac remodelling and dysfunction is toll-like receptor 
4 (TLR4). A study by Hu and Zhang (2017) reported several cardiac changes due to 12 weeks 
of HFD feeding in WT mice. These changes included decreased fractional shortening and 
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cardiomyocyte contractility, alterations in intracellular Ca2+ release and clearance, and elevated 
ROS generation and oxidative stress [212]. These effects were all attenuated when TLR4 
knockout mice were used, and authors suggested this could have been done through a NF-
κB/JNK-dependent activation of autophagy. Additionally, Birse et al. (2010) concluded that 
HFD induces cardiac dysfunction by deregulation of the insulin-TOR signalling pathway. This 
study was conducted in Drosophila flies and exhibited similar cardiac changes to mammalians 
fed HFD. These flies showed increased triglycerides, alterations in insulin/glucose 
homeostasis, cardiac lipid accumulation, reduced cardiac contractility, and severe structural 
pathologies. Once the insulin-TOR signalling pathway was inhibited, these effects no longer 
existed [213]. Ouwens et al. (2005) also suggested that HFD induced cardiac dysfunction is 
related to myocardial insulin signalling. In their study, rats were fed either a ND or HFD for 7 
weeks. HFD rats had higher levels of glucose, cardiac structural changes, and triglycerides 
accumulation. HFD altered several enzymes involved in the insulin signalling including 
insulin-stimulated IRS1-associated phosphatidylinositol 3′-kinase, protein kinase B, glycogen 
synthase kinase-3β, endothelial nitric oxide synthase, and forkhead transcription factors. 
Additionally, HFD reduced the insulin mediated phosphorylation of phospholamban, which is 
essential in cardiac contractility [214]. 
1.7.2 High-Fat Diet and Cardiovascular Remodelling in Ageing 
In addition to studying the effects of HFD on the heart, a few researchers have compared this 
effect in young and aged hearts. Young and aged (3 and 18 months) C57BL/6 mice were fed a 
normal diet, a low-fat diet, and a high fat diet for 16 weeks. Results of this study showed that 
the aged heart is less able to adapt to a high fatty acid load, and this led to more predominant 
structural alterations and accumulation of lipid intermediates in the cardiomyocytes [155]. 
Another study by Shiou et al. (2017) looked at the effects of HFD in ageing rat hearts with 
hypertensive disease. 44 week old spontaneously hypertensive rates and Wistar Kyoto rats were 
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given either ND or HFD for 27 weeks [215]. Results of this study showed that HFD aggravates 
hypertensive heart disease associated with ageing, worsened atrial and ventricular remodelling, 
and led to impairment of left ventricular systolic function. 
1.7.3 High-Fat Diet and Mitochondria 
HFD has been associated with cardiac remodelling and dysfunction. Part of the underlying 
cause is how the diet affects the mitochondria, which play an important role in heart 
performance. Numerous studies report the effect of HFD on mitochondrial oxidative functions 
in the presence of obesity and/or insulin resistance [216-220]. A study on rats fed HFD for 28 
weeks showed alterations in the mitochondrial biogenesis, dynamics, morphology and function 
[221]. Authors reported changes in gene expressions involved in mitochondrial dynamics, a 
decrease in mitochondrial DNA, a reduction in the activities of complex I‐III and citrate 
synthase; which led to a decrease in mitochondrial respiration, and morphological alteration 
(disappearance of the z line, lower mitochondrial density, decrease in size, disruption of the 
cristae). Additionally, mitochondrial fusion genes mfn1, mfn2, and opa1 and the mitochondrial 
fission genes drp1 and fis1 were all downregulated after HFD. Another study in C57BL/6J 
mice reported that HFD causes impairment in mitochondrial oxidative phosphorylation 
characterised by a reduction in complexes 1 and 3 activity [222]. However, the authors 
concluded that this impairment was associated with the high calorie content of the diet rather 
than the high fat, as they observed similar dysfunction in another group of mice fed with high 
calorie low fat diet. The composition of HFD and duration of feeding are important 
determinants of the diet’s effect on mitochondrial function [223].  
1.7.4 High-Fat Diet and Vulnerability of the Heart to 
Ischaemia/Reperfusion Injury 
Similar to ageing, HFD effects on cardiac vulnerability and tolerance to I/R injury are 
contradictory. Even though obesity is a risk factor for cardiac disease and failure, it has been 
associated with lower mortality risk as well (the obesity paradox) [224]. A study on B6D2F1 
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mice fed HFD for 6 months reported a decrease in infarct size and improved overall left 
ventricular function in the absence of hyperglycaemia and hypertension [225]. Another study 
using three different strains of mice fed HFD for 16 weeks also found that HFD is effective 
against I/R injury as it delays the normalisation of pH during the start of reperfusion [226]. 
However, this beneficial effect was seen in two of the three strains used, indicating the role of 
genetics in the dietary effect.  
High fat diet has been shown to be cardioprotective against I/R injury when consumed acutely 
for a period of 24 hours to 2 weeks prior to ischaemia [227]. The authors found that with acute 
HF feeding there is a decrease in injury (infarct size) by more than 50% and this was associated 
with an increase in autophagy and reduction in apoptosis. Additionally, in a study where  rats 
were fed either HFD, HSD (high-sucrose diet), or a normal diet for a period of 16 weeks, and 
were subjected to regional ischaemia for 35 mins followed by one hour of reperfusion, showed 
that the two special obesogenic diets had cardioprotective effects with reducing infarct size 
compared to the control group [228]. However, pre-conditioning of these hearts; measured by 
functional recovery and improvements in infarct size, was not as effective as it was in the 
control hearts. Authors of this study suggested that insulin resistance and elevated insulin levels 
might have been the reason for the cardio protection seen in the diet-induced obese hearts, as 
insulin is known to activate the RISK pathways [64]. Similarly, a study in mice fed HFD for 8 
weeks showed a reduction in the intolerance to I/R after 30 mins of ischaemia, associated with 
a decrease in transcriptional factor of activated mitochondria (Tfam) [229]. Another study in 
rats reported cardioprotective effects of HFD for 16 weeks, associated with an improvement in 
mitochondrial oxidative phosphorylation (measured by glutamate, malate and palmitoyl-
carnitine) and a reduction in mitophagy ( measured by PINK1 (PTEN-induced kinase 1) and 
p62 expression) [230]. 
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In contrast to the previous studies, rats fed a HFD for 32 weeks showed decreased tolerance to 
I/R after 40 mins of ischaemia followed by 120 mins of reperfusion, with larger infarct sizes 
and lower functional recovery compared to their controls [231]. Decreased tolerance was 
associated with a decrease in the total and phosphorylated Akt, GSK‐3β, and eNOS expression. 
Similarly, mice fed HFD for 12 weeks showed reduced tolerance to I/R which was associated 
with overexpression of NOD-like receptor pyrin domain containing 3 (Nlrp3) inflammasome 
(a protein that induces interleukin 18 and interleukin-1β), reduction in hypoxia inducible factor 
2α, and components of the pro-survival signalling pathway (RISK) [232]. Additionally, HF 
feeding for 90 days increased susceptibility to I/R injury in Guinea pigs and was associated 
with increased inflammatory markers (tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-
6)) after reperfusion [233]. Also, HFD was associated with increased susceptibility to I/R in 
HGI (hypertensive glucose intolerant) rats, which significantly increased infarct size compared 
to their controls and was associated with increased levels of plasma triglycerides and 
lipotoxicity [234]. Similarly, HF fed rats for 12 weeks developed ischaemic intolerance and 
demonstrated larger infarct size and mitochondrial dysfunction compared to their controls 
[235]. In addition, Littlejohns et al. (2014) reported increased vulnerability of the heart to I/R 
injury in C57BL/6J male mice that were fed HFD for 20-21 weeks. These hearts showed lower 
functional recovery, increased CK release and an infarct size compared to their controls [236]. 
In another study by Liu et al (2014), a high fat low carbohydrate diet fed to 12 week-old adult 
male Sprague-Dawley rats (for as little as 2 weeks) increased their vulnerability to I/R injury 
and increased incidences of fatality by ventricular arrhythmias and cardiac failure. This was 
done using an in vivo I/R model where the rats were stabilized for 20 mins, followed by a 30 
min occlusion of the LAD (left anterior descending) artery, and 120 mins of reperfusion [237]. 
The same authors studied the effects of high fat low carbohydrate diet again in an in vitro model 
in 2016, where isolated hearts of the Adult male Sprague Dawley rats were subjected to low 
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flow ischaemia for 60 mins (0.3 ml/min) followed by 60 mins of reperfusion. Similarly, 
findings of this study reported an impaired recovery in the function of the hearts fed HFD due 
to the effect of the diet on the myocardial properties [238].   
Few studies have explored the combined effects of HFD and ageing on the vulnerability of the 
heart and the results show conflicting findings. One study on female mice looked at the effects 
of AMPK alpha-2-subunit deletion with high fat diet on the aged heart. WT and KO adult and 
aged mice were used (6 and 18 months old respectively). Generally, ageing seemed to have a 
positive effect on ischaemic tolerance, but this was lost with 6 months of HFD feeding [239]. 
Another study on Wistar rats reported that HFD induced obesity did not affect the hearts 
vulnerability to regional ischaemia with ageing, but it improved it in young hearts [240].  
1.8 Summary 
It is evident that age and HFD can alter vulnerability to ischaemia and reperfusion. The 
underlying mechanisms are not presently known especially in aging hearts with the added 
cardiovascular burden of HFD. Understanding cardiac remodelling at the molecular, metabolic, 
and structural level during aging and in response to HFD will enable better design of 
therapeutic interventions to protect hearts form cardiac insults during ageing and obesity. 
1.9 Hypothesis & Aims 
1.9.1 Hypothesis 
1. Ageing-related cellular, molecular, structural, and functional remodelling of the 
heart increases its vulnerability to ischaemia/reperfusion injury. 
2. HFD-related cellular, molecular, structural, and functional remodelling of the 
ageing heart increases its vulnerability to ischaemia/reperfusion injury. 
1.9.2 Aims 
1. To study the effects of ageing on cardiac metabolic remodelling, 
proteomics/phosphoproteomics with emphasis on mitochondrial, metabolism, 
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structural, ionic transport, antioxidant, and apoptosis proteins. And to study the 
effects of ageing on myocardial structure including myocytes, vasculature, tissue 
fibrosis, and subcellular organelles such as mitochondria.  
2. To study the effect of HFD in ageing on cardiac metabolic remodelling, 
proteomics/phosphoproteomics with emphasis on mitochondrial, metabolism, 
structural, ionic transport, antioxidant, and apoptosis proteins.  And to study the 
effect of HFD in ageing on myocardial structure including myocytes, vasculature, 
tissue fibrosis, and subcellular organelles such as mitochondria. 
3. Finally, to investigate the effects of ageing and HFD on cardiac function (coronary 























2.1.1 Reagents Used 
Experimental reagents used and their companies of origin are listed below:  
Agar Scientific (Essex, UK)  
Glutaraldehyde solution (25 %)  
Bio-Rad (Hertfordshire, UK)  
Precision Plus Protein™ All Blue Standards  
Quick Start™ Bradford 1 x Dye Reagent  
BOC Healthcare (Surrey, UK)  
95 % oxygen/5 % carbon dioxide medical gas mixture  
BOC Industrial Gases (Surrey, UK)  
Liquid nitrogen  
Fisher Scientific UK Ltd (Leicestershire, UK)  
D-glucose anhydrous  
Magnesium sulphate (MgSO4·7H2O)  
Sodium chloride (NaCl) 68  
Sodium dodecyl sulphate (SDS)  
Merck (New Jersey, USA)  
Magnesium chloride (MgCl2)  
Randox (County Antrim, UK)  
CK-NAC assay (CK113)  
CK-NAC assay (CK522)  
Roche (Sussex, UK)  
cOmplete, EDTA-free protease inhibitor cocktail tablets  
PhosSTOP phosphatase inhibitor cocktail tablets  
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Sigma-Aldrich™ (Dorset, UK)  
2, 3, 5-triphenyl-tetrazolium chloride (TTC)  
2-mercaptoethanol  
Albumin from bovine serum (BSA)  
Calcium chloride solution (1 M) (CaCl2) 69  
Chelerythrine Chloride  
Dimethyl sulphoxide (DMSO)  
Ethylene glycol-bis(2-aminoethylether)-N,N,N’,N’-tetraacetic acid (EGTA)  
Folin and Ciocalteu’s phenol reagent  
Formaldehyde solution (36.5-38 %)  
Glycine  
Methanol  
Lowry reagent  
Nonidet™ P 40 substitute solution  
Phosphate buffered saline (PBS) tablets  
Sodium deoxycholate  
Sodium hydroxide (NaOH)  
Tocris Bioscience (Bristol, UK)  
TWS 119  
Dorsomorphin Dihydrochloride  
VWR International Ltd (Leicestershire, UK)  
4-(2-Hydroxyethyl) piperazin-1-ylethanesulphonic acid (HEPES)  
Di-sodium hydrogen phosphate (Na2HPO4)  
Hydrochloric acid fuming (37 %) (HCl)  
Potassium chloride (KCl)  
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Potassium dihydrogen phosphate (KH2PO4)  

























C57BL/6 male mice aged either 8 or 80 weeks were purchased from Charles River (Margate, 
UK). The animals were housed at the University of Bristol animal unit, allowed to recover from 
transit and then used when required. The aged mice were fed either a ND or HFD (described 
in section 2.3). All mice were given ad libitum access to food and water and maintained on a 
12-hr light/dark cycle. All animals were treated in accordance with the United Kingdom Home 
Office regulations, Animals (Scientific Procedures) Act of 1986.  
The animals were humanely killed using Schedule 1 procedure; stunning followed by cervical 
dislocation or euthanized by an intraperitoneal injection of 20 mg of pentobarbital sodium 
(which were provided by fellow researcher Dr. Helen Williams and used to prepare histological 
samples). Hearts were excised right away and used for various experiments, and the animals 
and their epididymal fat pads were weighed after sacrifice.  
2.3 Diet 
Adult mice were only fed a normal standard murine chow diet (Special Diets Services, UK, 
code: 801900). This diet consists of 22 %, 13 %, and 65 % of calories from protein, fats, and 
carbohydrates respectively (appendix 7.1). Ageing mice were either fed a ND or a HFD 
(Special Diets Services, UK, code: 821424). The HFD group were purchased around 50-60 
weeks old and were switched to the HFD for 20-24 weeks before they were used.  
 The HFD composition was 45 %, 18 %, and 37 % calories from fat, carbohydrates, and 
proteins respectively (appendix 7.1). The energy content of the diets was 16.26 mJ/kg and 









2.4.1 High Performance-Liquid Chromatography 
2.4.1.1 Cardiac Tissue Extraction 
Hearts were collected from freshly sacrificed mice, snap frozen immediately in liquid nitrogen, 
and stored at - 80° C until extraction. The apex was used for the extraction to measure amino 
acids and energy metabolites. 
LP3 tubes were prepared and labelled with accordance to samples being processed. 500 µL of 
perchloric acid (PCA) (4.8 % PCA, prepared with 8 mL of 60 % PCA and made up to 100 mL 
with distilled water) was added to the tubes, which were kept in an ice box throughout the 
whole experiment. Tubes were weighed twice, making sure the difference between the two 
weighing is less than 0.001 gm, and the average was calculated. Samples were kept and 
processed in liquid nitrogen throughout the whole experiment. The tissue was first crushed into 
fine powder using a pestle and mortar, added to the labelled tubes, and vortexed (Rotamixer 
7871, Hook & Tucker Instruments). Samples were then centrifuged at 4000 rpm for 10 min at 
4° C (Allegra X-22R, Beckman Coulter). Tubes were weighed again as they were the first time 
to determine the weight of the tissue added. The supernatant was collected (400 µL) into 
Figure 2.1: Age of experimental animals and their feeding regime. 
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another LP3 tube, 400 mL of K2CO3 (0.44 M potassium carbonate, prepared with 6.08 gm 
K2CO3 and made up to 100 mL with distilled water) was added to neutralise the extract, and 
the tubes were vortexed twice with a 2 min interval between. Samples were centrifuged once 
more as they were the first time to remove the insoluble potassium perchlorate, and the 
supernatant was collected into two different Eppendorf tubes. In the first tube, 100 µL of 
supernatant was added with 100 µL of hydrochloric acid (HCL), vortexed and then dried in a 
savant (AS160 Automatic Speed Vac) to a pressure less than 400 U, and finally stored at - 20° 
C until used for amino acid analysis. The rest of the supernatant (400-500 µL) was collected 
into a bigger Eppendorf tube and stored at - 20° C until used for energy metabolite analysis.  
2.4.1.2 HPLC 
The HPLC instrumentation consists of four main components which are the pump (Beckman 
System Gold 125 Solvent Module Pump), the autosampler (Beckman System Gold 507e 
Autosampler, Beckman Coulter Ltd, UK), the separation column (changeable depending on  
the measured components), and the detector (Beckman System Gold 166 Detector, Beckman 
Coulter Ltd, UK). 
There are two phases in the HPLC analysis: the stationary phase, and the mobile phase. The 
stationary phase is when the sample is injected and binds to the separation column, and the 
mobile phase is when the pump forces the HPLC eluent solution through the separation column. 
The elution time of the measured compound depends on the solubility of that compound in the 
stationary phase, and then it is measured by absorbance. Figure 2.2 demonstrates the principle 










2.4.1.3 Metabolites Analysis 
The separation column used was a 3 μm octadecyl silane Hypersil column (150 mm x 4.6 mm) 
(Thermo Scientific, UK). The composition of the mobile phase is important for the elution of 
metabolites. Two eluents were used in the mobile phase, eluent A (150 mM KH2PO4 and 150 
mM KCl, set at pH 6.0 with KOH) and eluent B (eluent A with 15 % (v/v) HPLC grade 
acetonitrile added). The composition of the mobile phase was controlled using a low-pressure 
gradient mixing device. Eluent B changed linearly during sample analysis between the time 
points (table 2.1). Temperature was constant (in the range 17-19° C) for the analytical column, 
and absorption was measured at 254 nm.  
Table 2.1: Composition of the mobile phase over time of metabolite analysis. 
Time (min) Flow speed 
(mL ∙ min-1) 
Eluent A (%) Eluent B (%) 
0 0.9 100 0 
0.1 0.9 97 3 
3.0 0.9 91 9 
7.0 0.9 0 100 
8.5 0.9 100 0 
 




The metabolites measured were ATP, ADP, AMP, GTP, GDP, GMP, IMP, xanthine, 
hypoxanthine, β-NAD, inosine and adenosine. 10 μL of standard samples (prepared as 
described previously in Ally and Park 1992) or 20 μL of the extracted samples were injected 
into the system which then bound to the column. Depending on the composition of the mobile 
phase as mentioned previously, the metabolites were eluted at different time points. The area 
under the peak for each metabolite was determined, compared to the standard sample and then 







Figure 2.3: High-performance liquid chromatographs of measured metabolites from 
a standard (top) and a sample (bottom). (Credit: Ben Littlejohns). 
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2.4.2 Nuclear Magnetic Resonance Spectroscopy 
2.4.2.1 Sample Collection 
Blood samples were collected from mice of different age groups (adults, aged, aged HFD), by 
scooping or pipetting blood from the thoracic cavity after heart extraction for other experiments 
into ethylenediaminetetraacetic acid (EDTA)-coated Eppendorfs. Eppendorfs were kept in ice 
until samples were centrifuged for 10 mins at 10000 RPM in 4º C. Plasma samples were stored 
at -80º C until they were sent to the NMR facility at The University of Bristol Chemistry 
School.  
2.4.2.2 NMR Spectroscopy 
NMR principle revolves around the mechanical properties (spinning and electrical charge) of 
the nucleus of the atom, using an external magnetic field that is exposed towards the nuclei of 
the biomolecule which leads to energy transfer when this field is removed. This magnetic field 
is exposed towards hydrogen nuclei In the 1H-NMR. [241]. This occurs at a wavelength which 
is recorded and interpreted based on the properties of the molecule (the type and number of 
hydrogen nuclei and their interactions within the molecule) [242].  
Samples were analysed in the School of Chemistry at The University of Bristol, using model 
(700 MHz Bruker AVANCE HD, Bruker BioSpin GmbH, Germany) NMR spectroscope. Once 
defrosted, plasma was transferred into 1.7mm CryoProbe and dissolved with NMR buffer (1 
PBS tablet, 0.16 g Trimethylsilylpropanoic acid (TSP), 0.2 g sodium azide NaN3 in 170 ml 
type I water and 20 ml deuterium oxide (D2O), adjusted to pH 7.4) and kept at 4˚C during the 
process of NMR. 
The NMR spectroscope consists of liquid handling robots, a sample holder, and a 
radiofrequency (RF) pulse transmitter and receiver. A signal is obtained from the RF receiver, 
amplified, and strengthened by a recorder that transforms the spectrum for analysis. The spectra 
are transformed using Bruker TopSpin software (Bruker, Germany) into 1D-1H Carr–Purcell–
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Meiboom–Gill (CPMG) pulse sequence which is used for analysis. Figure 2.4 shows a 
schematic diagram for the NMR spectroscope principle.  
 
2.4.2.3 Metabolite and Data Analysis 
Data obtained from NMR samples were analysed using the software MestReNova (Mnova, 
MestReNova Research SL, Spain). A reference of Trimethylsilylpropanoic acid (TSP) was 
used for the samples, at a concentration of 4.6 mM. Metabolites analysed included lipid and 
carbohydrate metabolites, which were compared between the various age or diet groups by 
choosing the peak area annotated to each metabolite from Mnova (peaks referenced to available 
literature, figure 2.5 [10]) and then comparing their averages.  
 
  





Figure 2.5: 1H NMR plasma spectra. Acquired using (A) standard 1D pulse sequence (B) 




2.4.3 Liquid Chromatography Tandem Mass Spectrometry  
2.4.3.1 Sample Collection 
Left ventricles were used for protein extraction and analysis. Samples were collected from 
freshly sacrificed mice and snap frozen in liquid nitrogen until they were used for protein 
extraction.  
2.4.3.2 Protein Extraction 
50 mg of tissue was weighed (cut into small pieces) into 1 ml universal tubes with 50 beads, 
and 10 µL/mg of RIPA buffer (1 PBS tablet, 1 % Nonidet p-40, 0.5 % Sodium deoxycholate, 
0.1% SDS, pH 7.4) was added to each tube, with 1 tablet of each Protease inhibitor cocktail 
(Roche 04693159001) and Phosphatase inhibitor cocktail (Roche 04906845001). The tissue 
was then homogenised 4 times; 10 seconds each, using Minilys tissue homogenizer (Bertin 
technologies, France) at 25000 rpm, and left to rock on a shaker (Labnet International Inc., 
USA) while in the ice box for 30 min at 4° C. Samples were then pipetted out of the tubes into 
regular Eppendorf tubes, and centrifuged at 13.000 x g for 10 min at 4° C. The supernatant was 
removed and split into 3 tubes (100 µL each). One of the three tubes was used for the protein 
quantification of the samples, while the other two were stored in the -80º C freezer.  
2.4.3.3 Protein Quantification 
The total protein content of the samples was determined using the Bradford assay (Bradford 
1976). 
Using a 5mg/mL standard BSA solution to plot the standard curve, 5 LP4 tubes were prepared 
(in duplicates), and 1, 2, 3, 4, and 5 µL of the solution was pipetted into them. A blank tube 
with no added solution was used for zeroing of the spectrophotometer. Then, 3 mL of the 
Bradford reagent was added to each LP4 tube, vortexed, and left for 15 min before reading the 
absorbance. The samples were prepared in a similar way after being diluted with water (1:3 
dilution), with 5 µL of each sample added into an LP4 tube (in duplicate), and 5 µL of RIPA 
buffer used as blank. 3 mL of the Bradford reagent was added to all of the tubes, vortexed, and 
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left for 15 min before readings were taken. Absorbance was read using the spectrophotometer 
(Bibby Scientific Limited, UK) after setting the temperature to 20ºC, and at 595 nm 
wavelength. Microsoft Excel was used to plot the standard curve and calculate protein 
concentrations in the samples (figure 2.6).  
From the curve, the amount of protein in the samples was calculated using the equation (y = 
0.0216x + 0.0124). This was divided by 5 (the volume of sample used) to obtain the 
concentration of each sample proteins, then multiplied by 3 to correct for dilution. Protein 
























Figure 2.6: Standard curve for protein quantification showing protein concentration 




2.4.3.4.1 Total Proteins 
For the proteomics analysis, we needed to send 60 µl of sample at a concentration of 2 µg/µl. 
samples were prepared according to these calculations and made up to 60 µl with distilled 
water. They were stored in the -80º C freezer until they were sent off for analysis at the Medical 
School. Analysis of proteins in ventricular tissue samples was performed by the University of 
Bristol Proteomics Facility using tandem mass tags (TMTs) (Thermo Fisher Scientific, UK).  
The samples were first digested with trypsin (Promega, UK), and the resultant peptides in each 
sample were tagged with a unique TMT. Each TMT consists of a mass reporter, a mass 
normaliser, and a NH2 reactive group (figure 2.7). 
 
Each mass reporter (there are 10 mass reporters, figure 2.6B) has a unique mass and binds to a 
specific sample (to label each individual sample). The mass normaliser normalises the mass 
Figure 2.7: A: Structure of the amine-reactive TMT Reagents. B: TMT10plex 




reporter to ensure all tags have a constant mass. And the NH2 reactive group allows for amine-
specific binding to the peptides.  
In the first run, 4 adult samples were tagged (126, 127N, 127C, and 128N), 5 aged samples 
(128C, 129N, 129C, 130N, and 130C), and a pooled sample was created from all the previous 
samples (131). In the second run, 5 aged ND samples and 5 aged HFD samples were run 
without a pool.  
During LC-MS/MS, the mass reporter is cleaved by collision induced dissociation (CID), 
which allows the cluster and detection of these reporters at the low mass end of the MS/MS 
spectra, where each reporter indicates the abundance of peptides in each sample (tagged by that 
reporter) (figure 2.8).    
 





For the analysis of phospho-proteins, a phosphorylation enrichment step is added to the 
previously described technique. After pooling the samples, they are passed through a titanium 
dioxide column, where phospho-peptides bind to the column and the non-phosphorylated 
peptides elute. The phospho-peptides are eluted afterwards and analysed using the LC-MS/MS.  
The peptides identified were searched against UniProt/SwissProt Mouse database using the 
SEQUEST (Ver. 28 Rev. 13) algorithm to determine which protein they came from. Proteins 
and peptides were analysed using Thermo Proteome Discoverer 1.2.0.208 software (Thermo 
Scientific, UK).  
2.4.4 Histology 
2.4.4.1 Light Microscopy  
2.4.4.1.1 Tissue Fixation 
Hearts were excised from freshly sacrificed mice and put in cold Krebs-Henseleit buffer (120 
mM NaCl, 25 mM NaHCO3, 11 mM D-glucose anhydrous, 1.2 mM KH2PO4, 1.2 mM 
MgSO4.7H2O, 4.8 mM KCl and 2 mM CaCl2). The hearts were then cannulated and perfused 
with the same buffer for 10 mins, and then cut horizontally into 3 pieces, and placed in a small 
tube with fixative solution (10 % paraformaldehyde in PBS).  The hearts were left in fixative 
overnight (24 hours) before processing and embedding. Adult and aged ND hearts were 
processed by Dr. Hellen Williams.  
2.4.4.1.2 Tissue Processing and Embedding 
After fixation, heart sections were placed in a cassette and kept in PBS for processing. The 
processing was done using ThermoFisher Scientific ExcelsiorTM AS Tissue Processor, which 
dehydrates the tissue by using ethanol to remove water from the sections and allow the paraffin 
wax to infiltrate it during embedding.  
Embedding was done using Thermo Scientific™ HistoStar™ Embedding Workstation. 
Specific metal moulds were used to pour paraffin wax into before placing the tissue in them 
82 
 
(orienting it in the desired position), then allowing the wax to solidify by placing the metal 
mould onto an ice block. Finally, a cassette with the tissue label was placed on the block, and 
more wax was added on top to attach the two parts together. This was left to solidify and cool 
before removing the block from the metal mould.   
2.4.4.1.3 Cutting the Blocks and Preparing the Slides 
The blocks were cooled prior to cutting by placing them on the ice block. They were then 
sectioned into 5 µm sections with the Thermo Scientific™ Shandon™ Finesse™ 325 Manual 
Microtome. After cutting a section, it was placed in the water bath and picked up using a slide 
and labelled with the sample name, date, and thickness of section. The slides were then placed 
in the oven at 37°C to dry overnight before staining.  
2.4.4.1.4 Staining the Slides 
A. H&E Staining 
Eosin is an acidic dye which stains basic components of the cell such as proteins and 
cytoplasmic structures. These are called acidophilic or eosinophilic and when stained appear 
pink in colour. Haematoxylin is a basic dye which stains acidic components of the cell such as 
nucleic acid (DNA and RNA). These structures are called basophilic and are stained in a blue 
purplish colour.  This staining provides a detailed view of the tissue and allows examination of 
the organisation or disorganisation of the cells, and any abnormalities such as nuclear changes.  
The slides were first prepared by rinsing them in clearene to dissolve the wax, and then different 
preparations of alcohol to remove the clearene. They were then rinsed and hydrated with water 
so that the dyes can penetrate the tissue properly. Haematoxylin dye was used to stain the nuclei 
and other component, and it initially stained them a reddish-purple colour. Then a weak 
alkaline solution was added to make the dye a dark blue colour. After that, the second Eosin 
dye was added to stain the rest of the cellular component in different shades of pink. Finally, 
the slides were rinsed, dehydrated with alcohol, and cleared with clearene. Once all of this was 
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done, the slides were covered with mounting media (DPX) and a cover slip and left to dry 
under the fume hood overnight.  
This staining was not used to measure anything specific, but rather to show a representation of 
how the cardiomyocytes appear in longitudinal and cross-sectional areas in each age and diet 
group.  
B.  EVG Staining 
This stain is used to identify elastic fibres. The iron-haematoxylin compound in the dye attaches 
to elastin, then a counterstain (most likely Van Gieson’s stain) is used to contrast the principle 
stain. Elastic fibres and nuclei are stained black, collagen fibres are stained red, and the rest of 
the cell components are stained yellow. This stain is commonly used to examine blood vessels 
and skin.  
The slides were first prepared by rinsing them in clearene to dissolve the wax, and then different 
preparations of alcohol to remove the clearene. They were then rinsed and hydrated with water 
so that the dyes could penetrate the tissue. Then, they were decolourised with 1% oxalic acid, 
and rinsed with water. These steps are called the Mallory bleach sequence. The slides were 
then rinsed in 70% industrial methylated spirits (IMS) and stained with Miller’s stain for 
around 1 hr. Slides were then washed with 70% IMS, rinsed with water, and stained with Van 
Gieson’s counterstain. Finally, the slides were rinsed, dehydrated with alcohol, and cleared 
with clearene. Once all of this was done, they were covered with mounting media (DPX) and 
a cover slip and left to dry under the fume hood overnight.  
This staining was used to examine arteries and how they compare or change with ageing and 
then with HFD. Measurements were done using ImageJ software and included total artery size 
(micrometers2), lumen size (micrometers2), and then the thickness of the arterial wall was 




C. The Auto-Stainer (Thermo Scientific™ Varistain™ 24-4 Automatic Slide Stainer) 
H&E and EVG staining were done using the auto-stainer. The first staining took around 51 
min, and the second one took around 2 hours and 3 min. The auto-stainer contains 24 
compartments, 14 of which were used in the H&E staining, and 18 were used in the EVG 
staining. Slides were arranged in a metal rack and placed in the first compartment of the 
machine. The machine was switched on, and set on 1 for H&E or 2 for EVG. After around 20 
mins in the first setting, tap water was run and checked regularly to avoid overflow. With the 
second staining, this step occured after 1 hour and 42 min. After the staining, the slides were 
covered in mounting media and a cover slip and left to dry under the fume hood overnight.  
D. Masson’s Trichrome Staining 
This staining is used to detect the collagen fibres in the tissue such as the skin and heart. The 
fibres are stained blue, the nuclei are black, and the remaining cellular components are stained 
red. 
The slides were placed in the oven for 20 mins prior to staining. They were then rinsed in 
clearene for 15 mins, and in 100 %, 95 %, and 70 % IMS for 3 mins, 3mins, and 10 mins 
respectively, and finally rinsed in distilled water. This is to deparaffinise and hydrate the tissue. 
The staining process started by staining in Mayer’s hematoxylin for 1 min, and then washing 
the slides in running warm water for 10 min before rinsing them with distilled water. After that, 
the slides were soaked in Biebrich scarlet-acid fuchsin solution (3 ml glacial acetic acid, 2.4 
gm of biebrish scarlet, 0.3 gm of acid fuchsin, and 300 ml distilled water) for 15 mins, and 
rinsed in distilled water again. They were then differentiated in phosphomolybdic-
phosphotungstic acid solution (25 gm of 5 % phosphomolybdic acid, 25 gm of 5 % 
phosphotungstic acid, and 1000 ml distilled water) for 15 min, and stained with aniline blue 
afterwards (2.5 gm aniline blue, 1 ml glacial acetic acid, and 100 ml distilled water) for 1-2 
min and differentiated in 1 % acetic acid solution for 5 min. Slides were rinsed for the final 
time in distilled water.  
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Finally, the slides were soaked in 90 % or 95 % IMS and 100 % IMS (20 seconds each) and 
soaked again in clearene. The slides were ready after this to mount with resinous medium and 
covered and left under the fume hood to dry overnight.  
This staining was used to measure fibrous tissue expressed as a percentage. Using ImageJ 
software, the threshold of the image was altered so that the blue colour (fibrous tissue) was 
highlighted then measured as an area, divided then by the total tissue area in the image and 
expressed as a percentage. Four images from four random areas were measured per heart.  
E. Immunohistochemistry Staining (Isolectin Biotin 4) 
Isolectin biotin 4 (IB4) staining was done. Slides were deparaffinised by placing them in 
cleareane (3 times for 5 mins each), and then in graduated alcohol (100 %, 90 %, and 70 % 
IMS) for 5 mins each. After that, they were rinsed in distilled water, and placed in 10 mM 
citrate buffer (2.1 g/1 L dist.H2O) for 6 mins in the microwave for heating (this is done for 
antigen retrieval). The citrate buffer was then topped up with distilled water and the slides were 
heated in the microwave again for 6 mins. After that, the slides were left to cool at room 
temperature for 30 mins before rinsing them in PBS buffer (3 times). Bloxall solution was 
added on the tissue sections on the slides for 10 mins in order to inhibit endogenous peroxidase 
activity, and then rinsed again in PBS for 3 times. Then, 10 % goat serum was pipetted onto 
the tissue sections to block the non-specific Antigens and was left to incubate at room 
temperature for 30 mins. 50 µl of The IB4 antibody (primary antibody) was pipetted onto the 
tissue sections (diluted in PBS, 1:400) and left to incubate overnight at 4ᵒ C. 
The following day, slides were washed in PBS (3 times). Then, 50 µl of PBS (instead of 
secondary antibody) was pipetted onto the sections and incubated at room temperature for 30 
mins. This is because the primary antibody used here is conjugated with biotin, and thus does 
not need a secondary antibody. Sections were then washed once again in PBS (3 Times) and 
50 µl of Extravidin-horseradish peroxidase (diluted 1:200 in PBS) was pipetted onto them and 
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incubated at room temperature for 30 min. Slides were then washed in PBS, and DAB (3, 3-
diaminobenzidine) solution was pipetted onto them for 10 mins at room temperature. Slides 
wer washed in tap water after that, counter stained with Myors hematoxylin for 3 mins, and 
washed again in tap water for 5 mins. Finally, they were dehydrated in graduated alcohol and 
then clearene (to remove the alcohol) and mounted with DPX.  
With this staining, capillaries are stained with a brown/black colour, and the cardiomyocytes 
appear light blue with the nuclei stained with a dark blue colour. This staining was used to 
count capillaries, which were expressed as a ratio to cardiomyocyte number. 3-4 different 
images from the LV were used per heart for the counting.  
2.4.4.2 Electron Microscopy  
2.4.4.2.1 Tissue Fixation 
The hearts were extracted from freshly sacrificed animals and put into ice cold cardioplegic 
solution. The composition of the Krebs cardioplegic solution was (120 mM NaCl, 25 mM 
NaHCO3, 11 mM glucose anhydrous, 0.22 gm Na pyruvate, 1.2 mM KH2PO4, 1.2 mM 
MgSO4.7H2O, 4.8 ml KCL, 1.2 mM CaCl2, + 20 mM KCl). The hearts were then cannulated 
through the aorta and perfused with the cardioplegic solution at a rate of 1 ml/min, till the blood 
was washed out. After that, the hearts were perfused with a fixative solution at the same rate 
for 2-3 mins. The fixative solution (100 ml) was prepared as follows using 0.1 M phosphate 
buffer + 1 % glutaraldehyde + 1 % paraformaldehyde + 0.5 mM CaCl2 and 1.7 mM D-glucose 
anhydrous. The phosphate buffer was prepared as follows: 76.76 gm HNa2O4P, 22.5 gm 
NaH2PO4.2H2O, and 100 ml distilled water; pH = 7.4.  25 % glutaraldehyde and 4 % 
paraformaldehyde were used. Finally, hearts were kept in the fixative solution for at least an 
hour before they were washed with phosphate buffer and cut into small cubes so that they could 
be processed into blocks. The processing of these blocks was done by the Bioimaging facility 
in the Biomedical School, University of Bristol.   
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2.4.4.2.2 Tissue Processing 
Processing and staining of the tissues were done by the Bioimaging facility in the Biomedical 
School, University of Bristol.  The hearts were post-fixed in 1 % (w/v) OsO4 in  
phosphate buffer for 90 min. They were then washed in phosphate buffer (3 times for 10 mins 
each), followed by washing with distilled water. The tissues were then stained in the dark in 3 
% (w/v) uranyl acetate in distilled water for 30 min. This was followed by rinsing in distilled 
water again for 10 mins, dehydration in 70 %, 80 %, and 90 % ethanol (10 mins each). 
Afterwards, tissue was rinsed with propylene oxide (3 times for 10 mins each) and stored 
overnight in a sealed container. Finally, tissue was stored in EPON epoxy resin for 24 hours 
before embedding in EPON epoxy resin and polymerised at 60º C for 48-72 hours.  
The tissue was cut and stained with uranyl acetate and lead citrate (94 mM lead nitrate, 140 
mM sodium citrate and 0.19 mM NaOH), and was ready for imaging.  
2.4.4.2.3 Imaging and Analysis 
Electron micrographs were taken using a Tecnai 12 bioTWIN transmission electron 
microscope (FEI, Netherlands) in the Wolfson Bioimaging Facility at the University of Bristol. 
Three different areas from each heart/sample were imaged, with various magnifications. 
Images were used to measure sarcomere length, mitochondria density (for the three 
subpopulations: perinuclear, interfibrillar, and subsarcolemmal), mitochondrial morphometry 
(including length, width, area/size, and calculating roundness and aspect ratio (length:width)), 




2.4.5 Langendorff Perfusion 
2.4.5.1 Pressure & Flow Rate Calibration 
For pressure calibration, the pressure was measured through channel 3 in chart 5. It was first 
zeroed, then the Sphygmomanometer was attached to the transducer, and the readings (in mV) 
were recorded at 20, 40, 60, 80, 100, and 140 mmHg. This was repeated 2 or 3 times. These 
readings were then plotted against the pressure points in excel, where two points are chosen, 
and their values are calculated from the equation (y = 0.0362x - 0.0278). They were then used 
to calibrate the pressure in chart 5 and the scale was set to -50 and 140 mmHg. Figure 2.9. 
 
Flow rate was calibrated in a similar way. The pump flow rate was zeroed (channel 4) when 
the pump was switched off. After that, the pump was switched on, and the rate was set at 0.5, 
then effluent was collected for a minute and measured. This was done at different flow rates 
(1.0, 1.5, and 2.0) in duplicates. These readings were plotted in excel again, and two points 
were chosen and calculated using the equation (y = 3.99x + 0.2) to use for the calibration in 
chart 5. Finally, the scales were set to -5 to 20 ml/mn. Figure 2.10.  
 




















2.4.5.2 Ischemia/Reperfusion Injury 
The Langendorff setup was prepared by switching on the temperature, the oxygen, and the 
MacLab. Krebs solution was added into the first compartment and run through the setup until 
it reached the needle without any bubbles. The pump was switched off for the pressure to be 
set, once that was done, the pump was switched back on and the rate was set at 1.0 ml/min. 
The heart was excised from a freshly sacrificed animal and immersed in ice-cold Krebs-
Henseleit solution (in mM: 120 NaCl, 25 NaHCO3 , 11 D-Glucose anhydrous, Na pyruvate, 1.2 
KH2PO4, 1.2 MgSO4 , 4.8 KCl, 1.2 CaCl2). The heart was then cannulated through the aorta 
and retrogradely perfused with 37° C Krebs solution, gassed with 95 % O2 and 5 % CO2. The 
filling pressure (60 mmHg) was detected by a transducer, which sent a signal that was amplified 
by a MacLab Quad bridge amplifier and detected by a MacLab/4s. This was kept constant 
through a negative feedback control between the MacLab/4s controller and the peristaltic pump 
(Ismatec, Germany), regulated by a STH Pump Controller. This was continued for a 20 min 
stabilising period, followed by 35 min of global ischaemia, and 60 min reperfusion.  




























Flow Rate set by maclab
Flow Rate
Figure 2.10: Standard curve for calibrating flow rate.  
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The heart effluent was collected 1 min before ischemia, and then during reperfusion at 1, 5, 10, 
20, 30, and 60 mins. This was collected and kept in an ice box to be used for creatine kinase 
measurement afterward. Figure 2.11 shows the Langendorff perfusion setup.  
 
Figure 2.11: Langendorff Perfusion System. (Credit: Ben Littlejohns). 
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2.4.5.3 Triphenyl Tetrazolium Chloride Staining 
At the end of reperfusion, hearts were frozen for 1 hour, then cut transversely into 4 slices (~2-
mm-thick), immersed in 1 % (W/V) triphenyltetrazolium chloride (TTC) PBS solution, and 
incubated at 37° C for 20 min. the slices were then preserved in 4 % (V/V) formaldehyde PBS 
solution at 4° C overnight. Finally, they were rinsed in PBS, and imaged using a scanner 
(Epson, UK). Infarct size was calculated using ImagePro® Plus Version 6.2.0.424 software 
(Media Cybernetics, USA). The total area of each slice was measured (in pixels), followed by 
measuring the white infarcted area, and the pale pink area separately. Both of these areas were 
calculated as a percentage of total. This was done for each slice on both sides, and then 
averaged to get the final infarct size. Figure 2.12 shows an example of a mouse heart sliced and 
stained with TTC. 
 
2.4.5.4 Measuring of Cardiac Enzyme (Creatine Kinase) Release 
in Effluent 
To measure CK, a commercially available kit from Randox, UK (CK113) was used. The 
substrate solution was prepared by adding 30 ml of solution into one vial of substrate. Then, 
40 µL of effluent was added into 37° C incubated (5 min) 1 mL of solution and allowed to mix 
Figure 2.12: TTC staining of representative cross-sections of mouse hearts. A: Viable 




for 2 min. Creatine kinase was then measured by measuring absorbance using the 
spectrophotometer (Bibby Scientific Limited, UK) at 340 nm, 37° C, and for 4 min. The 
reaction of this CK assay is shown in figure 2.13. 
Mean difference in absorbance was then calculated and multiplied by 4047.5 to give the 
creatine kinase in international unit per L. 
  
2.5 Statistical Analysis of the Data 
Data were analysed using Microsoft Excel and IBM SPSS software (version 26) and were 
presented as mean ± SEM where appropriate. Proteomic data were presented as fold change 
between HFD and ND ageing hearts, and plasma metabolites as well as coronary artery sizes 
were presented as quartiles (showing the minimum, maximum, and 3 percentiles in between – 
25th, 50th and 75th). Quartiles were used because plasma metabolites were calculated as area 
under the curve which caused large variations in the data. Similarly, coronary arteries measured 
ranged in size which would have been mispresented if mean ± SEM was used. 
For the statistical tests used, the variance was first tested using the F-test followed by the 
Student’s t-test, with Welch’s correction if the data had unequal variance.  
Figure 2.13: The reactions for the creatine kinase assay. CK = creatine kinase, HK = 
hexokinase and G6P-DH = glucose-6-phosphate dehydrogenase. 
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When comparing the three subpopulations of mitochondria within one age group, one-way 
ANOVA was used followed by Bonferroni post-hoc test, or Games-Howell post-hoc test if the 
data did not have equal variance. Finally, repeated measures ANOVA was used when 
comparing flow rate and CK release at different time points of ischaemia/reperfusion. All tests 























3.1.1 Overall Effect of Ageing on the Myocardium 
Ageing is the most important risk factor for CVD; the leading cause of death in the population 
aged 65 years and older [8]. Ageing is associated with changes in the myocardium that 
eventually render the heart more vulnerable to insults. In the mouse, ageing is associated with 
a decrease in stroke volume and cardiac output [243]. The information below is focused on key 
aspects that are relevant to work presented in this thesis. 
3.1.2 Age-Related Cardiac Structural and Functional Changes 
Important myocardial changes include apoptotic and necrotic cardiomyocyte death, fibrosis, 
and hypertrophy [12]. Fibrosis is also seen in arteries which become stiff and thicker. 
Additionally, the presence of atherosclerosis with ageing makes the heart and blood vessels 
ischemic leading to an increase in the rate of apoptosis and necrosis [8]. Cardiac changes also 
affect heart rate which is decreased and can increase arrhythmias [12]. These changes are 
general changes that occur with ageing in all mammals, but the extent of these changes can be 
different.  
3.1.3 Calcium Handling and Excitation-Contraction Coupling in the 
Ageing Heart 
EC coupling describes how electrical activity (action potential) causes an increase in 
intracellular Ca2+ and contraction. EC coupling changes with ageing due to many reasons 
(Reviewed in [4]). The decrease in Ca2+ influx, Ca2+ release, and expression and activity of 
certain proteins involved in this phenomenon lead to prolongation of the action potential 
duration, contraction duration, and Ca2+ decay. Protein changes include the shift from α-myosin 
heavy chain to β-myosin heavy chain resulting in a decrease in myosin ATPase activity. 
Reduced expression of SERCA2 or reduced its activity - by increased PLB and/or its 
phosphorylation by PKA - leads to slowing in Ca2+ reuptake and prolonged contraction. 
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Additionally, the decrease in cAMP production leads a decrease in β-adrenergic stimulation. 
All of these changes contribute to the age-related decline in cardiac contractility. 
3.1.4 Cardiomyocyte Metabolism in Ageing 
The myocardium requires a consistent and sufficient supply of metabolites as it is constantly 
contracting. In the adult disease-free heart, glucose and FFAs comprise the main cardiac 
metabolic substrates to generate ATP; with FFAs accounting for 50-75 % of this energy supply 
via mitochondrial β-oxidation [109]. The ageing heart is associated with metabolic remodeling; 
where there is a decrease in FFAs oxidation and thus an increase in glucose utilization to total 
metabolic substrate [120]. This change was observed in human hearts as well as mouse and rat 
hearts [123]. The decrease in FFA oxidation is due to an impairment of FFA transport in aged 
hearts, as well as alterations in various metabolic proteins such as PDK, CPT1 and PPAR-α. 
[243] Another possible reason for this shift in metabolism is an increase in glucose uptake 
evident by increased myocardial GLUT-4 expression [244]. However, the opposite of this 
increase in expression was reported in other studies [120, 121]. 
3.1.5 Mitochondrial Function and Oxidative Phosphorylation in the 
Ageing Heart 
Mitochondria possess many important functions; including metabolic and signaling pathways 
in the cell, but the primary function is production of ATP via a process called oxidative 
phosphorylation. With ageing, the mitochondria undergo morphological alterations that lead to 
functional decline. Mitochondria in aged tissue appear to be rounder, decrease in number, 
decrease in respiratory chain (RC) complex capacity [245]. Additionally, with ageing there is 
increase in Mitochondrial DNA (mtDNA) mutation, increase production of ROS, and thus 




3.1.6 Reactive Oxygen Species and Antioxidant Defense Mechanisms 
in The Ageing Heart 
ROS (e.g superoxide anion (O2−)) are generated in the cell as by-products of anabolic and 
catabolic processes, and in response to external stimuli such as ionizing radiation, chemical 
toxins, and transition metals [247]. They are mainly generated in the mitochondria from the 
ETC [163]. ROS react with macromolecules like lipids, proteins, and nucleic acids and cause 
damage to them [248]. They are neutralized in the body by antioxidants such as catalase, 
glutathione peroxidase, thioredoxin peroxidase, and superoxide dismutase. Denham 
Harman proposed a theory more than fifty years ago on ROS and ageing, stating that ageing is 
caused by ROS damage in the tissue, and the ability of the body to cope with this damage 
determines the lifespan [249]. In ageing, changes occurring in the mitochondria include 
increased production of ROS and impairment in antioxidant defense mechanisms [250, 251]. 
A few studies investigating antioxidant enzyme levels reported contradictory finding. One 
study noted an increase in glutathione peroxidase activity in the aged rat heart [252]. The same 
enzyme was investigated in aged women and showed that for every 1-year increase in age there 
was 2.9 micromol/min/L decrease in activity [253]. Another study investigating antioxidant 
enzymes in cultured hepatocytes reported a reduction in both superoxide dismutase expression 
by 60 %,  and catalase expression by 50 % in cells from senescent animals [254], however 











Several techniques have been used to obtain the results in this chapter. These techniques are 
described in detail in chapter 2, page 59 (Materials & Methods). 
3.2.1 High Performance Liquid Chromatography  
HPLC was used for analysis of cardiac ventricular tissue to measure cardiac energy metabolites 
and AA content in the heart. Five samples for each age group were used. Details on this are 
found in chapter 2 under this method’s section (page 64). 
3.2.2 Nuclear Magnetic Resonance Spectroscopy  
NMR was used to analyse plasma samples for blood lipid and glucose profile. Four adult and 
four ageing samples were used. For details on this technique and analysis see chapter 2 under 
this method’s section (page 68). 
3.2.3 Liquid Chromatography Tandem Mass Spectrometry  
LC-MS/MS was used to detect proteins and phospho-protein levels in cardiac tissue. Five 
samples for each age group were sent for analysis, but only 4 adult samples were used because 
a pool sample was created and added to the run (10plex). This was done in case of the need to 
compare these samples with other samples from different runs. For details on this technique 
and analysis see chapter 2 under this method’s section (page 71). 
3.2.4 Light Microscopy  
Hearts from adults and ageing mice were collected, fixed, processed, embedded, cut, and 
stained with four different stains (H&E, EVG, Masson’s trichrome, and IHC-IB4) to examine 
cardiovascular structure and how it remodels with ageing. For details on techniques, imaging, 
and analysis see chapter 2 under this method’s section (page 75).  
3.2.5 Electron Microscopy  
Hearts from adults and ageing mice (4 for each group) were collected, fixed, processed, 
embedded, cut, and stained to examine cardiac ultrastructure and how it remodels with ageing. 
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3.3.1 General Characteristics of Animals 
3.3.1.1 Changes in Body and Heart Weights of Mice with Ageing 
Animal weights significantly increased (P < 0.001) with ageing, with an approximate 38% 
increase in ageing mice weights. (Table 3.1). Epididymal fat pads also showed a significant 
increase (213% increase) with ageing (P < 0.001), with their percentage of total body weights 
increasing significantly in the ageing animals as well (P = 0.001). 
 
 
Wet and dry hearts weights also increased with ageing. Heart weights increased significantly 
with ageing, with a 25% (1.2 folds) increase in wet weight (P = 0.009), and a similar 25% (1.3 
folds) increase in dry weight (P = 0.002). Despite this significant increase in heart weights, 
their percentages of total body weights were not different between the two age groups due to 
the simultaneous increase in body weights of the animals seen with ageing.  
3.3.1.2 Changes in Plasma Metabolites with Ageing 
Several carbohydrate and lipid metabolites were measured in the plasma using NMR analysis 
(figure 3.1). These metabolites have been measured and expressed as area under the curve 
(AUC). Lipid metabolites in the plasma increased with ageing, and so did lactate, but none of 
these changes were significant. Additionally, pyruvate and glucose were decreased with 




Body weight (gm) 23.79 ± 0.41 32.74 ± 0.83 ** 
Epididymal fat pad weight (gm) 0.29 ± 0.02 0.91 ± 0.11 * 
Epididymal fat pads % of total body weight 1.22 ± 0.09 2.73 ± 0.28 * 
Heart Wet Weight (gm) 0.15 ± 0.01 0.19 ± 0.01 * 
Heart wet weight % of total body weight 0.62 ± 0.31 0.59 ± 0.03 
Heart Dry Weight (gm) 0.03 ± 0.001 0.04 ± 0.001 * 
Heart dry weight % of total body weight 0.11 ± 0.004 0.109 ± 0.01 
Table 3.1: Characteristics of the adult and ageing mice. Data are presented as mean ± 
SEM. Data were analysed using the unpaired t-test. * = P < 0.05, ** = P < 0.001 vs. adult 
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ageing, with glucose reducing significantly (P = 0.002) compared to adult mice. Figure 3.2 







Figure 3.1: Plasma lipid and carbohydrate metabolites in adult and ageing mice. 
Data are presented as box plots showing minimum value, 25th, 50th, and 75th percentiles, 
and maximum value. Data were analysed using the unpaired t-test.  




































































































3.3.2 Metabolic Changes 
3.3.2.1 Changes in Cardiac Energy Metabolites with Ageing 
Table 3.2 shows values for different energy metabolites in adult and ageing hearts. Some of 
these metabolites increase while others decrease. The only metabolites that changed 
significantly with ageing were guanosine monophosphate (GMP), inosine, and hypoxanthine. 
The first two increased in the aged heart and the last one was decreased.  
 
 
Metabolite Adult Hearts (μmole/gm 
tissue) 
Ageing Hearts (μmole/gm 
tissue) 
P-Value 
GTP 0.16 ± 0.02 0.13 ± 0.01 0.20 
GDP 0.08 ± 0.01 0.09 ± 0.01 0.64 
GMP 0.03 ± 0.001 0.04 ± 0.002 0.009 * 
IMP 0.18 ±0.05 0.13 ± 0.07 0.60 
ATP 2.24 ± 0.25 1.98 ± 0.33 0.55 
ADP 1.62 ± 0.14 1.77 ± 0.15 0.50 
Hypoxanthine 0.21 ± 0.02 0.10 ± 0.01 0.0008 ** 
AMP 0.56 ± 0.06 1.02 ± 0.25 0.14 
β-NAD 0.47 ± 0.04 0.55 ± 0.07 0.33 
Inosine 0.15 ± 0.02 0.27 ± 0.03 0.009 * 
Adenosine 0.10 ± 0.01 0.10 ± 0.01 0.82 
 
Phosphorylation ratios (phosphorylation potential) for adenosine and guanosine energy 
metabolites were calculated and they were generally lower in the aged heart compared to the 
adult heart. However, only guanosine ratios were significantly reduced in the aged hearts, with 
a reduction from 2.01 ± 0.2 to 1.5 ± 0.08 for GTP/GDP ratio, and from 5.97 ± 0.87 to 3.53 ± 
0.37 for GTP/GMP ratio. Cardiac energy charge [EC = (0.5 * ADP + ATP)/ (ATP + ADP + 
AMP)] was also calculated for both age groups and was lower in the aged heart compared to 
Table 3.2: Cardiac energy metabolites in adult and ageing mice hearts.  
Data are presented as mean ± SEM. Data were analysed using the unpaired t-test.  
* = P < 0.05, ** = P < 0.001. N = 5 for each age group. 
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the adult heart, but this reduction was not significant. Additionally, adenosine metabolites pool 
(ATP + ADP + AMP) was calculated and showed an increase in the aged heart compared to 










3.3.2.2 Changes in Cardiac Amino Acids with Ageing 
As seen in figure 3.4, 12 amino acids were detected, mostly non-essential ones except for the 
AAs histidine and threonine. Total AA pool decreased significantly with ageing (P = 0.003) 
from an average of 43.3 ± 1.1 nmole/mg in adult hearts to 37.1 ± 0.5 nmole/mg in aged hearts. 
Taurine contributes to more than half of the AA pool in both age groups (61% and 63% in adult 
and aged hearts respectively), and even though the percent of taurine from total AA pool was 
not significantly different with ageing; the amount of taurine was significantly reduced (P  = 
0.008) in the aged hearts from an average of 26.3 ± 0.6 nmole/mg to 23.3 ± 0.6 nmole/mg. All 
other AAs were also found in lower amounts in the aged heart compared to the adult heart, 
with significant changes (P < 0.05) in arginine, asparagine, histidine, serine, threonine, and 
alanine. Values of these significant AAs can be found in table 3.3. 
Figure 3.3: Cardiac phosphorylation potential, energy charge, and adenosine 
metabolites pool in adult and ageing hearts. Data are presented as mean ± SEM and 
were analysed using unpaired t-test.  




















Figure 3.4: A) Amino acids in adult and ageing mice hearts. B) Taurine in adult and 
ageing mice hearts. C) Total amino acids pool. D) Taurine percent of total amino 
acids pool. Data are presented as mean ± SEM. Data were analysed using unpaired t-test.  





























































































Amino Acid Adult Hearts (n = 5) Aged Hearts (n = 4) 
Arginine 0.49 ± 0.02 0.36 ± 0.02 * 
Asparagine 1.36 ± 0.08 0.84 ± 0.08 * 
Histidine 0.55 ± 0.06 0.28 ± 0.01 * 
Serine 0.66 ± 0.04 0.46 ± 0.06 * 
Threonine 0.32 ± 0.02 0.23 ± 0.03 * 
Alanine 2.08 ± 0.17 1.54 ± 0.13 * 
 
3.3.3 Myocardial Proteome/Phosphoproteome Changes 
3.3.3.1  Changes in Cardiac Proteome Profile with Ageing 
As demonstrated in figure 3.5, proteomics analysis for adult and aged hearts yielded a total of 
6022 proteins. Of those, 1678 proteins were significantly different with ageing; with 98 being 
downregulated in the aged heart (6 %) and the remaining 1580 proteins being upregulated (94 
%). In order to avoid false positive results, proteins with fold change smaller than 0.8 and 
greater than 1.3 were selected. 720 significant proteins fell within the selected fold change, and 
these were further categorised using the PANTHER classification system according to 
molecular function and biological processes (figure 3.6). the majority of these proteins are 
involved in binding and catalytic activity (based on molecular function), and cellular and 
metabolic processes (based on biological processes).  Significant proteins within selected folds 
were further grouped into mitochondrial proteins, carbohydrate and lipid metabolism and 
transport proteins, ionic transport related proteins, antioxidant proteins, apoptosis related 
proteins, and structural proteins (collagen).  
Table 3.3: Significantly different amino acids between adult and aged hearts. Data are 


























0.3 (1.3 FD)-0.3 (0.8 FD)
1.3 = P < 0.05
Figure 3.5: Volcano plot showing changes in proteins of ageing/adult mice hearts. X 
axis represents log2 of the FD (aged/adult) and Y axis represents -log10 
 of the P-value. Proteins above the horizontal red line are significantly different between 
the two age groups. Proteins on the right of the Y axis are upregulated with ageing (with 
the ones on the right of the vertical red line having a FD > 1.3), and proteins on the left 
side of the Y axis are downregulated with ageing (with the ones on the left of the second 
vertical red line having a FD < 0.8). Data were analysed using the unpaired t-test. N= 4 
and 5 for adult and aged hearts, respectively.  
 
Molecular Function Biological Processes 
Figure 3.6: Classification of significantly different proteins within selected fold 
change (< 0.8 and > 1.3) between adult and ageing hearts using the PANTHER 




3.3.3.1.1 Mitochondrial Proteins 
26 mitochondrial proteins changed significantly in the aged heart compared to the adult heart. 
All proteins were upregulated with ageing with the exception of aldehyde dehydrogenase X, 
10-formyltetrahydrofolate dehydrogenase, and trimethyllysine dioxygenase. These proteins are 
involved in detoxification from alcohol-derived acetaldehyde, folate metabolism, and AA 
lysine metabolism respectively. Mitochondrial proteins were further categorised into lipid 
metabolism, AA metabolism, transport, and energy production (figure 3.7). Lipid metabolism 
proteins include acyl-coenzyme A synthetase ACSM5, enoyl-CoA hydratase domain-
containing protein 2, and sterol 26-hydroxylase, mitochondrial, and were all upregulated in old 
age. AA metabolism proteins include 4-aminobutyrate aminotransferase, and serine beta-
lactamase-like protein LACTB, mitochondrial, which were also upregulated in the aged heart. 
Mitochondrial transport proteins include mitochondrial import inner membrane translocase 
subunit Tim17-A, and mitochondrial dicarboxylate carrier. Finally, energy production proteins 
include ATP synthase subunit e, and succinyl-CoA ligase [GDP-forming] subunit beta. (For 













Figure 3.7: Significant mitochondrial proteins in adult and ageing mice hearts. A) 
Mitochondrial lipid metabolism proteins. B) mitochondrial amino acid metabolism 
proteins. C) mitochondrial energy production proteins. D) mitochondrial transport 
proteins. Data are expressed as mean ± SEM (of the relative protein expression 
normalised to a pool sample). Data were analysed using the unpaired t-test. All proteins 
selected fall within a FD < 0.8 and > 1.3. * = P < 0.05, ** = P < 0.001 vs. adult. n = 4 and 





3.3.3.1.2 Ionic Transport-Related Proteins 
Ionic transport related proteins include proteins involved in the ionic transport into and out of 
the cell such as Na+, Ca2+, Cl-, and K+ transport proteins (channels, pumps & exchangers). All 
proteins were upregulated in the aged heart compared to the adult heart (figure 3.8). Three 
sodium-related proteins increased with ageing including Sodium channel subunit beta-2, 
Sodium channel subunit beta-4, and Electrogenic sodium bicarbonate cotransporter NBCe1 
variant D. Potassium-related proteins that were upregulated with ageing included Inward 
rectifier potassium channel 13 and Voltage-gated potassium channel Kv1.7. Finally, 
Sodium/calcium exchanger and Ryanodine receptor 2 were also upregulated with ageing and 





Figure 3.8: Significant ionic transport related proteins (calcium, sodium, and 
potassium) in adult and ageing mice hearts. Data are expressed as mean ± SEM (of the 
relative protein expression normalised to a pool sample). Data were analysed using the 
unpaired t-test. All proteins selected fall within a FD < 0.8 and > 1.3. * = P < 0.05, ** = P 














































3.3.3.1.3  Antioxidant Proteins 
Extracellular superoxide dismutase, and glutathione peroxidase I and III are all proteins with 
antioxidant activity and are all upregulated in expression with ageing. Additionally, a group of 
6 glutathione proteins involved in the defence against ROS were also upregulated with ageing 
(figure 3.9).   
 
Figure 3.9: Significant antioxidants and defence related proteins in adult and ageing 
mice hearts. Data are expressed as mean ± SEM (of the relative protein expression 
normalised to a pool sample). Data were analysed using the unpaired t-test. All proteins 
selected fall within a FD < 0.8 and > 1.3. * = P < 0.05, ** = P < 0.001 vs. adult. n = 4 and 5 









































































































3.3.3.1.4 Apoptosis Related Proteins 
Three apoptosis related proteins were identified and were all upregulated in the aged heart. 
Two of these proteins are pro-apoptotic and one is anti-apoptotic (BCL2-associated athanogene 
3). (figure 3.10). 
 
3.3.3.1.5 Structural Proteins (Collagen) 
Collagen proteins from the proteomics analysis showed a significant increase in expression 
with ageing, with one protein decreasing in expression (collagen alpha-1 XIV chain) (figure 










PRKC apoptosis WT1 regulator
protein


































Figure 3.10: Significant apoptosis related proteins in adult and ageing mice hearts. 
Data are expressed as mean ± SEM (of the relative protein expression normalised to a 
pool sample). Data were analysed using the unpaired t-test. All proteins selected fall 
within a FD < 0.8 and > 1.3. * = P < 0.05, ** = P < 0.001 vs. adult. n = 4 and 5 for adult 




3.3.3.1.6 Lipid and Carbohydrate Metabolism and Related Transport 
Proteins 
Lipid metabolism and related transport proteins were all upregulated in expression in the aged 
heart (figure 3.12A). Proteins included long-chain acyl-CoA synthetase, acyl-CoA 
dehydrogenase family member 11, and mitochondrial proteins (mentioned earlier) such as acyl-
coenzyme A synthetase ACSM5. Carbohydrate-related proteins also followed a similar pattern 
of upregulation with ageing with the exception of the protein gamma-enolase that was 
downregulated in the aged heart (figure 3.12B). Gamma-enolase is involved in the pyruvate 




























































Figure 3.11: Significant collagen proteins in adult and ageing mice hearts. Data are 
expressed as mean ± SEM (of the relative protein expression normalised to a pool 
sample). Data were analysed using the unpaired t-test. All proteins selected fall within a 
FD < 0.8 and > 1.3. * = P < 0.05, ** = P < 0.001 vs. adult. n = 4 and 5 for adult and 







































































































Figure 3.12: Significant lipid and carbohydrate metabolism and transport proteins 
in adult and ageing mice hearts. Data are expressed as mean ± SEM (of the relative 
protein expression normalised to a pool sample). Data were analysed using the unpaired t-
test. All proteins selected fall within a FD < 0.8 and > 1.3. * = P < 0.05, ** = P < 0.001 
vs. adult. n = 4 and 5 for adult and ageing hearts, respectively.  
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3.3.3.2 Changes in Cardiac Protein Phosphorylation with 
Ageing 
Phospho-proteomics analysis yielded 2243 peptides with various modifications. Of these 
peptides we selected the phosphorylated ones and 71 phosphorylated peptides were found to 
be significantly different with ageing. Within selected fold change, 3 of these peptides were 
downregulated in phosphorylation, and the remaining were upregulated in the aged heart (33 
peptides) as shown in figure 3.13.  
These peptides were used to identify their relative proteins which were then further classified 






Figure 3.13: Volcano plot showing changes in protein modification of ageing/adult 
mice hearts. Proteins above the horizontal red line are significantly different between the 
two age groups. Proteins on the right of the Y axis are upregulated with ageing (with the 
ones on the right of the vertical purple line having a FD > 1.3), and proteins on the left 
side of the Y axis are downregulated with ageing (with the ones on the left of the second 
vertical purple line having a FD < 0.8). Data were analysed using the unpaired t-test. N= 4 






















1.3 = P < 0.05















Downregulated phospho-proteins with ageing 
Sodium channel protein type 5 






0.71 0.042 * 
Upregulated phospho-proteins with ageing 
Signal recognition particle 
receptor subunit alpha 
GN=Srpr  












Q91ZJ7 S282 1.31 0.047 * 
Histidine rich calcium binding 




S421 1.36 0.039 * 
Cardiac signalling and apoptosis 
Bcl-2-like protein 13 
GN=Bcl2l13  
P59017 S387 
1.38 0.022 * 
BCL2-associated athanogene 3 
GN=Bag3  




Heat shock protein HSP 90-beta 
GN=Hsp90ab1  




Heat shock protein beta-6 
GN=Hspb6  










Table 3.4: Selected phospho-proteins that change significantly with ageing. Table 
shows proteins with their accession number, phosphorylation site, fold change 
(aged/adult), and P-value. Data were analysed using the unpaired t-test. * = P < 0.05, ** = 
P < 0.001 vs. adult. 
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Cysteine and glycine-rich 
protein 3 
GN=Csrp3  

























forming] subunit beta, 
mitochondrial  
GN=Sucla2  





















Small muscular protein 
GN=Smpx  




SRSF protein kinase 3 
GN=Srpk3  





One protein relating to ionic transport was downregulated in phosphorylation in the aged heart 
(Sodium channel protein type 5 subunit alpha) at Ser-460. The remaining phosphorylated 
proteins were all upregulated in the aged heart and were further categorised into several groups 
including ionic transport, cardiac signalling and apoptosis, metabolism and energy production, 
and structural proteins. These proteins are all mentioned in table 3.4 with their phosphorylation 
site and fold change between the two age groups. The biggest change with ageing is seen in the 
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phosphorylation of heat shock protein beta-6 at Ser-16, which is doubled in the ageing heart 
compared to the adult heart.  
3.3.4 The Effects of Ageing on Cardiac Histology 
3.3.4.1 Changes in Cardiac Structure with Ageing 
H&E staining is a basic stain used here only to provide a comprehensive picture of the heart 
sections from both age groups as shown in figure 3.14.  
 
3.3.4.2 Changes in Coronary Arteries with Ageing 
EVG staining was used to highlight the arteries and show the elastin (stained in black) around 
them. Figure 3.15 shows representative images of large coronary arteries and some of the 
smaller arteries in both age groups and how they compare. 
 
Figure 3.14: Haematoxylin and eosin staining of adult and ageing mice heart 
sections. Images show the left ventricle (objective lens magnification x4), and 
longitudinal and cross-sectional cardiomyocytes from the LV (objective lens 







Using EVG stained sections, measurements of total artery size, artery lumen size, artery wall 
thickness, and arterial wall/total artery and lumen size ratios were taken. Figures 3.16 and 3.17 




Figure 3.15: Verhoeff-van Gieson Staining of adult and ageing mice heart sections. 
Images show different size arteries (objective lens magnification x20). Black colour 







Arteries of various sizes in the stained sections have been measured for their total size and 
lumen size, and quartiles (minimum value, 25th, 50th, 75th, and maximum value) have been 
calculated (excluding the outlier values). These values for both age group are presented in table 
3.5. with ageing there is a significant increase in total artery size (P = 0.011) and lumen size 
(P = 0.001) compared to adults.  
Quartile values shown in table 3.5 show a trend of increase in the aged group that goes up to 
200% in some of the values. Values for total artery size change by 2.3, 1.5, 1.6, 1.9, and 1.7 
folds respectively. Values for lumen size change by 3.1, 2.2, 1.9, 2.1, and 2 folds respectively 








Figure 3.16: A) Total artery size (µm)2 and B) Artery lumen size (µm)2 in adult and 
ageing mice hearts. Data are presented as quartiles showing the minimum value, 25th 
percentile, 50th percentile, 75th percentile, maximum value, and the outliers. Data were 
analysed using the unpaired t-test.  








regarding arterial wall, four different sides of the artery wall were measured then averaged to 
express the wall thickness. These measurements showed no change with ageing. However, 
when expressing arterial wall area/total artery size, this ratio was significantly reduced in the 
aged heart (P < 0.001) from an average of 0.38 ± 0.02 in adults to an average of 0.28 ± 0.01 in 
aged hearts. Similarly, arterial wall area/lumen size ratio was also reduced significantly with 
ageing (P < 0.001) from an average of 0.7 ± 0.1 in adult hearts to 0.4 ± 0.03 in aged hearts. 
(figure 3.17). 
Quartiles Total Artery 
Size in Adult 
Hearts (µm)2 
N = 8 
Total Artery 
Size in Ageing 
Hearts (µm)2 
N = 5 
Artery 
Lumen Size in 
Adult Hearts 
(µm)2 
N = 8 
Artery 
Lumen Size in 
Ageing Hearts 
(µm)2 
N = 5 
Min 
Value 
734 1650 328 1026 
25 
Percentile 
1807 2772 927 1995 
50 
Percentile 
2713 4214 1550 3026 
75 
Percentile 
4651 8608 3104 6429 
Max 
Value 
10717 18096 7025 14074 
Outlier 11178 23605 8092 
8187 
18425 
Table 3.5: Quartile values of total artery size and artery lumen size in adult and 
ageing mice hearts. Values include the minimum value, 25th percentile, 50th percentile, 





3.3.4.3 Changes in Fibrous Tissue with Ageing 
When measuring fibrous tissue using histological sections stained with Masson’s Trichrome 
stain, adult hearts had a low percentage of fibrous tissue in heart sections (1.5 ± 0.3 %), which 
was slightly increased with ageing (1.8 ± 0.3 %). However, this change was not statistically 



























Artery Wall area/Artery Total 
area
**
Figure 3.17: Ratios of arterial wall/total artery size and lumen size in adult and 
ageing mice hearts. Data are presented as mean ± SEM. Data were analysed using the 
unpaired t-test.  























Figure 3.18: Fibrous tissue % in adult and ageing mice hearts. Quantification was 
done using Masson’s Trichrome stained heart sections. Data are presented as mean ± 
SEM. Data were analysed using the unpaired t-test. N= 6 and 5 for adult and ageing hearts 
respectively. A) Example of adult heart. B) Example of aged heart. Images taken using 


















3.3.4.4 Changes in Capillary/Myocyte Ratio with Ageing 
Immunohisochemistry staining Isolectin biotin 4 (IB4) was used to stain capillaries with a 
brown colour. Images taken from the left ventricle of the hearts were used to measure 
capillary/cardiomyocyte ratio, and this ratio was significantly increased (P < 0.001) from an 
average of 1.5 ± 0.06 to 2.3 ± 0.03 in aged hearts (figure 3.19). 
 
 
Figure 3.19: Capillary/myocyte ratio in adult and ageing mice hearts. Quantification 
was done using Isolectin biotin 4 (IB4) stained heart sections. Data are presented as mean 
± SEM. Data were analysed using the unpaired t-test.  
** = P < 0.001 vs. adult. N= 5 and 5 for adult and ageing hearts respectively. 3-4 images 
from the LV from each heart were used for the analysis.  
A) Example of adult heart. B) Example of ageing heart. Images taken using objective lens 



























3.3.5 Ultra-Structural Changes 
3.3.5.1 Changes in Diastolic Sarcomere Length with Ageing 
Diastolic sarcomere length increased with ageing from an average of 1.99 ± 0.05 μm in the 
adult heart to an average of 2.02 ± 0.1 μm in the aged heart, however this change was not 
significant (figure 3.20). 
 
3.3.5.2 Changes in Mitochondrial Sub-Population Distribution 
with Ageing 
The distribution or density of mitochondria and their individual subpopulations was measured 
in both age groups. In the adult heart, mitochondria covered 36 % of total myocyte area. The 
majority of mitochondrial area comprised of interfibrillar mitochondria (IF) covering 26 %, 
followed by subsarcolemmal (SSL) mitochondria (9 %), and finally the perinuclear (PN) 
mitochondria covering only 1 % of total myocyte area. With ageing, the total mitochondrial 
area was reduced to 32 %, with the IF comprising 25 % of total myocyte area, followed by the 
SSL mitochondria comprising 6 % of this area, and finally the PN mitochondria covering only 























Figure 3.20: Diastolic sarcomere length in adult and ageing mice hearts. 
Lengths were measured in electron micrographs using ImageJ. Data are 
presented as mean ± SEM. Data were analysed using the unpaired t-test. N= 4 





Comparing these figures to understand the effects of ageing on the mitochondrial density, no 
significant change was found between the percent of myocyte area covered by total 
mitochondria nor the distribution of each mitochondrial subpopulation between the two age 
groups despite the reduction seen with ageing (figure 3.22). 
Figure 3.21: Mitochondrial sub-population distribution in adult and ageing mice 
hearts. Figure shows the percentage of myocyte covered by mitochondria, and the 
percent of each mitochondrial sub-population in both age groups.  














Myocyte Area Covered By 





























Figure 3.22: Mitochondrial distribution in adult and ageing mice hearts. A)  
Mitochondrial distribution as a percentage of total myocyte area. B) Mitochondrial 
distribution by sub-population as percentage of total myocyte area. Data are presented as 
mean ± SEM. Data were analysed using the unpaired t-test.  




3.3.5.3 Changes in Mitochondrial Sub-Population Morphometry 
with Ageing 
Before comparing the mitochondrial subpopulation morphometry between the two age groups, 
we compared the different subpopulations with one another within one age group.  
3.3.5.3.1 Mitochondrial Sub-Population Morphometry in Adult Hearts 
Several mitochondrial measurements were taken including length, width, size of the 
mitochondria, aspect ratio (length/width) and the roundness. When comparing the three 
subpopulations of mitochondria in the adult heart, the PN mitochondria appeared to be smaller 
in size and shorter in length and width, plus they were more rounded in shape compared to the 
other two subpopulations (figure 3.23). Additionally, SSL mitochondria seemed to be the 
biggest in size. However, the only significant difference was in the length (P = 0.028 vs. IF and 
P = 0.42 vs. SSL). PN mitochondria length averaged 0.82 ± 0.01 μm compared to 0.95 ± 0.03 
μm and 0.94 ± 0.03 μm for IF and SSL mitochondria, respectively.  
Figure 3.23: Mitochondrial sub-population morphometry in adult hearts. A) 
Mitochondrial length and width. B) Mitochondrial size. C) Mitochondrial roundness and 
aspect (L/W) ratio. Data are presented as mean ± SEM. Data were analysed using one-
way ANOVA followed by the Bonferroni and Games-Howell post-hoc tests. * = P < 0.05 
vs. SSL and IF mitochondria.  
N= 4 hearts, and ≈ 300 mitochondria for each subpopulation.    
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3.3.5.3.2 Mitochondrial Sub-Population Morphometry in Ageing Hearts  
In the ageing heart, the IF mitochondria were larger in size compared to the two other subtypes 
(figure 3.24). IF mitochondria average size was 0.46 ± 0.01 μm2 compared to 0.25 ± 0.02 and 
0.37 ± 0.02 μm2 for PN and SSL mitochondria, respectively. Also, there was a significant 
difference in size between the PN and SSL mitochondria (P = 0.006).   
Additionally, a similar difference was noted in the width of the mitochondria. The PN 
mitochondria had a width of 0.42 ± 0.01 μm, which was smaller compared to the other two 
subtypes that averaged 0.51 ± 0.01 μm  for SSL and 0.57 ± 0.002 μm for IF mitochondria (P = 
0.002 vs SSL and P < 0.001 vs. IF), and the SSL mitochondria was also shorter in width 
compared to the IF mitochondria (P = 0.009). Finally, PN mitochondria were also shorter in 
length with an average of 0.67 ± 0.04 μm compared to 0.9 ± 0.02 μm (P = 0.007) for IF 
mitochondria. 
 
Figure 3.24: Mitochondrial sub-population morphometry in ageing hearts. A) 
Mitochondrial length and width. B) Mitochondrial size. C) Mitochondrial roundness and 
aspect (L/W) ratio. Data are presented as mean ± SEM. Data were analysed using one-way 
ANOVA followed by the Bonferroni and Games-Howell post-hoc tests. * = P < 0.05 vs. 
IF, ** = P < 0.05 vs SSL and IF, † = P < 0.05 vs IF mitochondria.  




3.3.5.3.3 Differences in Mitochondrial Sub-Population Morphometry 
Between Adult and Ageing Heart 
I. Perinuclear Mitochondria 
With ageing, PN mitochondria became significantly smaller with a decrease in both length and 
width and became less rounded in shape (figure 3.25). Length of aged PN mitochondria 
averaged at 0.67 ± 0.04 μm compared to 0.82 ± 0.01 μm in adult hearts (P = 0.028). Width of 
PN mitochondria decreased from an average of 0.64 ± 0.01 μm in adult hearts to 0.42 ± 0.01 
μm in ageing hearts (P < 0.001). PN mitochondrial size also decreased from 0.46 ± 0.02 μm2 
to 0.25 ± 0.02 μm2 in adult and ageing hearts respectively (P = 0.002). Finally, the aspect ratio 
of the PN mitochondria was increased from 1.3 ± 0.01 in adult hearts to 1.7 ± 0.1 in ageing 
hearts (P = 0.019), indicating less roundness in ageing mitochondria (the closer the aspect ratio 
to 1 the more rounded the mitochondria are), and this was also confirmed by the roundness 
measurement which decreased in the ageing group from 0.83 ± 0.01 in adults to 0.7 ± 0.03 (P 
= 0.023).  
Figure 3.25: PN mitochondria morphometry in adult and ageing hearts. A) 
Mitochondrial length and width. B) Mitochondrial size. C) Mitochondrial roundness and 
aspect (L/W) ratio. Data are presented as mean ± SEM. Data were analysed using 
unpaired t-test.  
* = P < 0.05 vs. adult, ** = P < 0.001 vs adult. N= 4 for adult and aged hearts each, and ≈ 




II. Subsarcolemmal Mitochondria 
Similar to PN mitochondria, SSL mitochondria also became significantly smaller with a 
decrease in both length and width and became less rounded in shape with ageing (figure 3.26). 
Length of ageing SSL mitochondria averaged at 0.8 ± 0.03 μm compared to 0.94 ± 0.03 μm in 
adult hearts (P = 0.03). Width of SSL mitochondria decreased from an average of 0.72 ± 0.04 
μm in adult hearts to 0.51 ± 0.01 μm in ageing hearts (P = 0.009). SSL mitochondrial size also 
decreased from 0.59 ± 0.05 μm2 to 0.37 ± 0.02 μm2 in adult and ageing hearts respectively (P 
= 0.015). Finally, the aspect ratio of the SSL mitochondria was increased from 1.4 ± 0.04 in 
adult hearts to 1.6 ± 0.5 in ageing hearts (P = 0.015), indicating less roundness in ageing 
mitochondria (the closer the aspect ratio to 1 the more rounded the mitochondria are), and this 
was also confirmed by the roundness measurement which decreased in the ageing group from 
0.8 ± 0.01 in adults to 0.7 ± 0.02 (P = 0.044).  
 
Figure 3.26: SSL mitochondria morphometry in adult and ageing hearts. A) 
Mitochondrial length and width. B) Mitochondrial size. C) Mitochondrial roundness and 
aspect (L/W) ratio. Data are presented as mean ± SEM. Data were analysed using 
unpaired t-test.  
* = P < 0.05 vs. adult. N= 4 for adult and aged hearts each, and ≈ 300 mitochondria for 




III. Interfibrillar mitochondria 
IF mitochondria morphometry also showed a similar pattern to that observed in the two 
previous subpopulations, where in ageing hearts the mitochondria became smaller with a 
decrease in both length and width and became less rounded in shape (figure 3.27). However, 
none of the differences in measurements between the two age groups were statistically 
significant in this type of mitochondria. 
  
3.3.5.4 Mitochondrial Fission and Fusion Proteins 
Generally, mitochondria in the ageing heart appeared to become less rounded (more elongated), 
and this goes accordingly with the significant increase in mitochondrial fusion proteins Opa1 
and Mfn2 in ageing hearts compared to adults (figure 3.28). Fission proteins Mff and Fis1 were 
also increased in the ageing heart but not significantly.  
Figure 3.27: IF mitochondria morphometry in adult and ageing hearts. A) 
Mitochondrial length and width. B) Mitochondrial size. C) Mitochondrial roundness and 
aspect (L/W) ratio. Data are presented as mean ± SEM. Data were analysed using 
unpaired t-test.  





3.3.5.5 Changes in Lipid Content (Lipid Droplet Count) with 
Ageing 
Lipid content (droplet count) accumulation in the myocyte was determined by the number of 
lipid droplets/μm2. With ageing, there was a significant increase in lipid droplets from an 






































Figure 3.28: Significant mitochondrial fusion proteins in adult and ageing mice 
hearts. Data are expressed as mean ± SEM (of the relative protein expression normalised 
to a pool sample). Data were analysed using the unpaired t-test. All proteins selected fall 
within a FD < 0.8 and > 1.3.  
* = P < 0.05. n = 4 and 5 for adult and ageing hearts, respectively. Opa1 (Dynamin-type 




























Lipid Content in The Myocyte
*
Figure 3.29: Lipid content (lipid droplet count) in adult and ageing hearts. Data are 
presented as mean ± SEM. Data were analysed using unpaired t-test.  
* = P < 0.05 vs. adult. N= 4 for adult and ageing hearts each. 3-4 fields from each heart 
were analysed. Image shows electron micrographs of examples of lipid droplets (red 







3.4.1 Key Findings 
A significant increase in body weight, epidydimal fat pads, and cardiac hypertrophy were seen 
with aging. There was also an increase in lipid deposits in the heart and an increase in 
capillary/myocyte ratio. There was an increase in total size and lumen size of coronary arteries, 
with decreased artery wall/total artery size and lumen size ratios. There were also changes in 
mitochondrial morphometry (mitochondria became smaller in size and more elongated) but not 
mitochondrial distribution.  
Ageing was associated with changes in cardiac energy metabolites and a decrease in total 
protein amino acids pool as well as taurine. Most of the cardiac protein groups were upregulated 
during aging. These include mitochondrial proteins, ionic channel proteins, antioxidant 
enzymes, apoptosis-related proteins, structural (collagen) proteins, and proteins involved in 
lipid and carbohydrate metabolism. Phospho-proteins were also mainly upregulated with 
ageing. Ageing was associated with decreased plasma glucose levels. Ageing was not 





3.4.2 Ageing was Associated with Increase in Body Weight, 
Epidydimal Fat Pads, and Cardiac Hypertrophy 
The first finding in this work is that mice had a significant increase in body weight (38% 
increase) with ageing, with a 213% increase in epidydimal fat pads compared to adult mice. 
This increase in total body weight in aged mice indicates obesity compared to their adult 
counterparts, but not within their age group as this is normal weight gain in C57BL/6 mice 
(figure 3.30). 
  
This change in body weight with ageing in C57BL/6 mice was also reported in a study by 
Lessard-Beaudoin et al. 2015, who showed that body weight in C57BL/6 mice  increases until 
the age of 12 months (48 weeks) and then it plateaus [255]. Similarly, studies on different mice 
strains and different species also reported body weight changes with ageing [256-260]. The 
increase in fat pads observed in our work has also been reported by others with ageing, where 
they showed that body fat percentage in C57BL/6 mice remains constant until 6 months of age 





and then increases between 6-12 months [259]. The reasons for total body weight and fat 
percentage increase with ageing are the various physiological changes that accompany ageing 
such as decreased metabolic rate, decreased activity level, loss of muscle mass, changes in 
adipose function and hormone secretion [261, 262]. Even though caloric intake was not 
measured in these two age groups so there is no way of knowing if the aged mice consumed 
more calories that contributed to their significant weight gain,  however, Lipman and Grinker, 
1996 reported that caloric intake was not the sole variable controlling weight gain when looking 
at weight changes in middle-aged female C57BL/6J mice [263].  
Another finding in this work is the significant increase in heart weight in ageing mice compared 
to their adult controls. This is consistent with what others reported as heart weights of C57BL/6 
mice increase until plateauing between 23-28 months of age [255]. This increase in heart 
weight is most likely due to the hypertrophy of the heart as with ageing several structural 
changes occur in the heart such as increase in cardiomyocyte size and increase in fibrosis. And 
even though the fibrosis was not present in these ageing hearts as seen from the results, 
cardiomyocytes did appear larger in size in the histological examination compared to the adult 
hearts.  
3.4.3 Ageing was Associated with Decreased Plasma Glucose Levels 
Ageing mice in our study had significantly lower plasma glucose levels compared to adult 
mice. This is consistent with what Leiter et al. 1988 reported when comparing adult (4-5 
months) with aged (21-25 months) C57BL/6J male mice. The decrease in plasma glucose 
happened due to the increase in pancreatic β-cells size (with no fibrosis) accompanied with 
increased insulin secretion which resulted in increasing glucose uptake from the blood as well 
as improvement in glucose clearance when administered orally or interperitoneally, as authors 
in the study explained [264]. Gregg et al. 2016, also reported enhanced insulin secretion with 
ageing in mice which helps preserve glucose tolerance [265].  
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3.4.4 Ageing was Associated with Changes in Cardiac Energy 
Metabolites 
Ageing hearts had significantly higher levels of GMP and inosine, and significantly lower 
levels of hypoxanthine and guanosine phosphorylation ratios.  
A possible explanation for the increase in inosine levels and decrease in hypoxanthine levels 
is that both of these metabolites are purine by-products of ATP catabolism (figure 3.31 shows 




Because hypoxanthine serves as a reserve for salvaging purine levels in high-energy demand 
tissues such as the heart and provides a reserve for about 95% of the body’s recycled 
nucleotides; it is possible that its low levels in the ageing hearts is caused by its incorporation 
Figure 3.31: Cardiac ATP catabolic pathways during ischaemia. Abbreviations: ATP: 
adenosine triphosphate; ADP: adenosine diphosphate; AMP: adenosine monophosphate; IMP: 
inosine monophosphate; ENT: equilibrative nucleoside transporters; CNT: concentrative 
nucleoside transporters. [14]. 
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into making ATP [266-268]. The fact that inosine levels are higher in the ageing heart could 
indicate an impairment or lower ability of the ageing heart to produce ATP, which was lower 
but not significantly compared to the adult heart. Additionally, decreased phosphorylation 
potential seen in our ageing hearts is another sign of this impairment in energy production 
associated with ageing [269].   
3.4.5 Ageing was Associated with Decreased Total Amino Acid Pool 
and Taurine 
Total amino acid pool in the heart decreased with ageing, with a decrease in taurine, arginine, 
asparagine, histidine, serine, threonine, and alanine. 
Concentrations of AAs in cardiac tissue have been shown to change with various diseases and 
insults, however there are no studies that looked at the change in AAs concentrations with 
ageing in the heart [270]. The importance of this relates to the changes in cardiac metabolites 
or ionic state  that occur during I/R, so investigating the metabolic state of the heart and how 
that changes with ageing would aid in explaining any changes in the hearts tolerance to I/R. 
The relationship between amino acids and CVD has become a topic of interest in recent years, 
with contradictory reports on their role in preventing or contributing to heart disease [271].  
A decrease in AA pool in the ageing heart could indicate an increase in the hearts vulnerability 
as AAs have been used to assess metabolic status of the myocytes [272]. Additionally, they 
play an important role in the heart as they modulate metabolic enzymes; specially for glucose 
metabolism, improve the oxidative state by acting as precursors for some anti-oxidants, 
regulate gene expression and hormonal activity in the cells, and more importantly; serve as a 
primary source of fuel for energy production in conditions of energy starvation and metabolic 
remodelling such as ischaemia and heart failure [273]. Furthermore, taurine (which is 
decreased in the ageing heart) is the main osmolyte in the heart and has many important 
functions in the cardiomyocytes. It is essential for normal contractile function via the 
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modulation of Ca2+ transporters, as well as an osmoregulator in some species as it controls Na+ 
movement [270]. In addition, taurine is implicated in the regulation of oxidative stress, 
modulation of kinases and phosphatases, and stabilisation of membranes through interacting 
with phospholipids [274]. 
Even though a number of the AAs associated with increased risk of CVD were found to be 
lower in ageing hearts in our work, reports on their association to CVD are contradictory. For 
example, glutamate, tyrosine, glutamine, and methionine (mainly through its metabolite 
homocysteine) were all reported to be associated with higher risk of heart disease [275-278].  
These studies show that the contribution of these AAs to CVD is through mechanism involved 
in plaque formation, impairment of antioxidant activity, lipid peroxidation, and formation of 
macrophage foam cells. However, a study in postmenopausal women reported the opposite of 
this, where after adjustment for traditional CHD risk factors; glutamine was associated with 
decreased risk of CHD while glutamate levels were still a risk factor for CHD [279]. Also, 
other AAs have been found to have a protective role against CVD such as glycine and arginine 
[280]. Both of these AAs were involved in decreasing homocysteine levels and improving 
endothelial function [280]. A contradictory study associated arginine levels with 
atherosclerotic plaques [281]. So, we cannot conclude whether this decrease in AA pool in the 
ageing heart is protective or renders it more vulnerable to insults. 
3.4.6 Proteins in the Ageing Heart were Mainly Upregulated 
Ageing hearts showed a change in proteome profile compared to adult hearts, with 1678 
proteins changing significantly. The majority of the proteins were upregulated with ageing, 
while only 6 % were downregulated. Not many studies have looked at the change in proteome 
profile with ageing. In aged female rats, cardiac mitochondrial proteomic analysis revealed a 
change in 67 proteins mainly related to cellular metabolism and energy production, oxidative 
stress, cell death, and muscle contraction [282]. in this study, ageing was associated with 
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decreased expression of mitochondrial ATP production, and increased expression of heat shock 
proteins as well as the antioxidant superoxide dismutase [282]. Changes in proteomics were 
also studied in humans and revealed a change of 217 plasma proteins with ageing [283]. Altered 
proteins were mainly involved in blood coagulation, chemokine and inflammatory pathways, 
axon guidance, peptidase activity, and apoptosis. Another study of the ageing heart proteome 
profile in A.BY/SnJ mice showed a significant change in lipid metabolism and fatty acid 
transport. Lipid metabolism and transport were higher in ageing, and ATP synthase was 
decreased [284]. Mitochondrial function and metabolism proteins are some of the main proteins 
altered with ageing, and can be preserved by inhibiting the mTOR signalling pathway [285].  
3.4.6.1 Mitochondrial Proteins were Mainly Upregulated with 
Ageing  
With ageing, there was an upregulation in mitochondrial proteins with the exception of a few 
that were downregulated. Proteins were involved in lipid metabolism, AA metabolism, energy 
production, and mitochondrial transport. Keeping in mind that the changes we have shown do 
not reflect protein activity but rather its expression in cardiac tissue, so an upregulation in 
expression in mitochondrial proteins could indicate a compensation mechanism for the 
decrease in mitochondrial efficiency in the aged heart compared to the adult heart.  
A change in cardiac mitochondrial proteins with ageing has been reported in other studies. One 
study in aged mice (23-25 months of age) revealed a change in 24 mitochondrial proteins [147]. 
some of the proteins were upregulated such as energy production proteins, ketone body 
metabolism, and ETC proteins, while others were downregulated with ageing such as stress 
resistance proteins. Another study in aged female rats (24 months of age) found 35 
mitochondrial proteins that changed with ageing, mainly involved in energy production [282]. 
There was a downregulation in ETC complex proteins and the antioxidant catalase. 
Upregulated proteins included cell stress resistance and cell death proteins. Additionally, a 
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study in aged mice (24 months of age) found that the majority of mitochondrial proteins are 
downregulated with ageing and only a few are upregulated [286]. Other studies on 
mitochondrial proteomics report contradicting findings, but that could be due to the variations 
in methods used, species, and genders [287-289].  
3.4.6.2 Ionic Transport Related Proteins were Upregulated with 
Ageing 
Eight ionic channel-related proteins were upregulated with ageing. Three sodium channel 
proteins were upregulated including the sodium channel subunit beta-2 which is important for 
regulating the activity and function of sodium ion channels. The sodium channel subunit beta-
4 which modulates and regulates the activity and activation of certain sodium alpha channels. 
The electrogenic sodium bicarbonate cotransporter NBCe1 variant D which regulates 
intracellular pH by regulating the influx/efflux of bicarbonate ions across the cell membrane. 
Additionally, two potassium channel proteins were upregulated, the inward rectifier potassium 
channel 13 which allows potassium to enter the cell depending on the extracellular potassium 
concentration, and the voltage-gated potassium channel Kv1.7 which regulates voltage-
dependant potassium permeability into the cells. Also, the chloride channel protein was 
upregulated in the ageing heart. This protein mediates the exchange of chloride ions for 
protons. And finally, the sodium/calcium exchanger 1 which regulates intracellular calcium by 
exchanging calcium ions for sodium ions across the cell membrane, and the ryanodine receptor 
2 which mediates the release of calcium from the SR into the cytosol of the cell. These two 
calcium regulating proteins could be upregulated in the ageing heart as a compensation for the 
dysregulation and delays in calcium release and clearance from the cell that occur with ageing 
during EC coupling. 
With ageing, the known changes reported in ion channel proteins include voltage-Ca2+-
activated K+ channels in coronary smooth muscle, which decreased with ageing [290]. 
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Additionally, long-lasting L-type Ca2+ voltage dependent channels and high-conductance 
BKCa channels, which also decreased with ageing [291]. Sodium channel subunit beta-2 has 
been increased in expression in dilated cardiomyopathy in humans, however, this increase was 
seen in gene expression and not in protein level [292].  
None of the ion channel proteins that changed in this work with ageing were indicated in any 
age-related diseases [293].  
3.4.6.3 Antioxidant Enzymes were Upregulated with Ageing 
Antioxidant enzymes were upregulated in the ageing heart. As mentioned in the introduction 
(page 38), ageing is associated with increased oxidative stress. It has been shown that changes 
in antioxidants and oxidative level in ageing is tissue-specific [294]. Some studies report a 
decrease in antioxidant enzyme expression and/or activity with ageing, contributing to the age-
related decline and dysfunction [295, 296]. Other studies report no change in antioxidants with 
ageing [297, 298]. On the other hand, some studies report an upregulation in antioxidant levels 
and activity with ageing. A study of oxidative stress and antioxidant levels in aged rats revealed 
an increase in both ROS and antioxidant enzymes (SOD and catalase) in kidneys, with no 
change in markers of damage or dysfunction [299]. This was also seen in the soleus muscle of 
aged rats where expression and activity of antioxidants (SOD, catalase, and glutathione 
peroxidase) were all upregulated [300]. Similarly, increased expression of antioxidants was 
also reported in aged rat hearts in response to an increase in ROS production by the 
mitochondria [165]. The increased expression in our work does not reflect activity of these 
enzymes but could indicate a protective mechanism associated with the increased ROS 
production known to be associated with ageing.  
3.4.6.4 Apoptosis-Related Proteins were Upregulated with 
Ageing 
In the ageing heart, the expression of three apoptotic proteins increased, two were pro-apoptotic 
and one was anti-apoptotic. PRKC apoptosis WT1 regulator protein is a pro-apoptotic protein 
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inducing apoptosis in cancer cells. Mitochondrial diablo homolog promotes apoptosis by 
activation of caspases and inhibition of the inhibitor of apoptosis protein (IAP). BCL2-
associated athanogene 3 is an anti-apoptotic protein that acts as co-chaperone to HSP70 and 
HSC70.  
Several studies have investigated apoptosis with ageing in various tissues and different 
species[301-309]. These studies have looked at several apoptosis related proteins including the 
expression of anti-apoptotic protein BCL-2, pro-apoptotic proteins Bax, cleaved caspase-3, 
caspase-9, and Bak, and results showed contradictory findings with ageing.  
A possible explanation for the increase in pro-apoptotic proteins in the ageing hearts is the 
increase apoptosis in old age as mentioned earlier. The increased anti-apoptotic protein BCL2-
associated athanogene 3 can be a compensatory mechanism to the increase in pro-apoptotic 
proteins.  
3.4.6.5 Structural (Collagen) Proteins were Upregulated with 
Ageing 
Collagen proteins were mainly upregulated in the ageing heart in this work. In the literature, 
collagen expression and synthesis in normal disease-free ageing has been shown to either 
decrease or remain unchanged in the heart in rats and sheep, especially collagen 1 and 3 [310-
312]. The fibrosis seen in ageing was suggested to be attributed to post-synthetic or degradative 
processes [313]. Additionally, another study in rats reported that collagen synthesis was 
decreased by 10 folds in aged hearts [314]. Also, collagen 1 expression was reduced in middle 
aged and senescent mice hearts, but remained unchanged in old mice hearts compared to the 
young controls [315]. In this study, there was no difference in collagen expression between the 
young and old mice (same age as the mice used in our work). However, the young mice used 
in the study mentioned were older (6-9 months) than adult mice used in our work (2 months), 
which could explain the difference reported in the change of collagen expression.  
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Even though elevated levels of collagen expression have been reported in animals and humans 
when cardiovascular disease was present [316, 317], this does not mean that the elevation in 
collagen expression with ageing in our work reflects disease or vulnerability of the ageing 
heart, especially due to the fact that there was no significant change or increase in fibrosis as 
seen in the histological examination of cardiac sections. 
3.4.6.6 Lipid and Carbohydrate Metabolism Proteins were 
upregulated with Ageing 
Lipid and carbohydrate metabolism proteins were upregulated in the ageing heart in our work.  
Regarding the upregulation of carbohydrate enzymes, as mentioned earlier in the introduction 
(cardiac metabolism in ageing, page 42), there is a shift from FA utilisation to glucose 
utilisation in the aged heart. Glucose utilisation is enhanced as seen by the increased content 
of GLUT-4 (the glucose transporter) [318, 319]. Additionally, energy production from 
glycolysis was reported to be enhanced with ageing, and PFK activity (which determines 
glycolysis activity) is not affected by ageing [320]. In human hearts, the utilisation of glucose 
as a source of energy for the heart did not increase, but when comparing it as a percentage of 
total energy metabolite it was increased as FA utilisation decreases [321]. So, the increase in 
carbohydrate metabolism enzymes could be justified.  
Regarding FA metabolism, cardiac FA oxidation is known to decrease with ageing, evident by 
the increased serum concentration of NEFA (non-esterified fatty acids), decreased CPT-1 
activity (rate limiting enzyme for LCFA uptake), and decreased mitochondria oxidative 
phosphorylation [322]. The increase we see in our results in the expression of FA metabolism 
enzymes (which does not reflect their activity) could be a compensatory mechanism of the cells 
for the decrease in the utilisation of FAs.   
3.4.7 Phospho-Proteins were Mainly Upregulated with Ageing  
Most of the phosphorylated proteins that changed in the ageing heart compared to the adult 
heart were upregulated. These proteins were categorised into several groups including ionic 
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transport-related proteins, cardiac signalling and apoptosis, metabolism and energy production, 
and structural proteins. Many of the proteins detected have no or little information available in 
the literature on their phosphorylation sites. Ionic transport-related proteins included sodium-
calcium exchanger, which is a protein responsible for regulating cytoplasmic calcium levels as 
it  mediates the exchange of calcium and sodium ions across cell membrane [323]. Another 
calcium regulator is the histidine rich calcium-binding protein which is important for cardiac 
function and contraction [324]. Apoptotic proteins included pro-apoptotic protein Bcl-2-like 
protein 13, and anti-apoptotic protein BCL2-associated athanogene 3, which were both 
upregulated in phosphorylation at S387 and S360 consecutively. Additionally, cysteine and 
glycine-rich protein 3, which is a regulator of myogenesis and is involved in cardiac stress 
signalling, is phosphorylated by PKC/PRKCA (protein kinase C and its subunit alpha) [325]. 
Metabolism proteins included long-chain-fatty-acid--CoA ligase 1, which is involved in fatty 
acid metabolism, and succinyl-CoA ligase [ADP-forming] subunit beta, mitochondrial, which 
is involved in the TCA cycle and energy production. Both proteins were upregulated in 
phosphorylation in S230 and S176 consecutively in the ageing heart. Structural proteins 
included Reticulon-4 (involved in the formation and stabilisation of ER) and Dystonin (which 
integrates intermediate filaments with actin and microtubule cytoskeleton networks) [326]. 
Both proteins’ phosphorylation was also upregulated in the ageing heart at S165 and S2148 
consecutively.  
Additional proteins that were upregulated in phosphorylation with ageing included heat shock 
protein HSP 90-beta and heat shock protein beta-6. Heat shock protein HSP 90-beta is a 
chaperone protein which is required for the function and regulation of other proteins [327]. Its 
phosphorylation at S255 (which is upregulated in the ageing heart) inhibits its interaction with 
AHR (aryl hydrocarbon; a client of HSP90 that promotes carcinogenesis) [328]. Also, heat 
shock protein beta-6 is a chaperone protein that is involved in regulating muscle function and 
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cardiac contractility [329]. Its over-expression may indicate cardioprotection from apoptosis 
[330]. Phosphorylation at S16 by PKA activates the protein, and this effect is increased in the 
ageing heart.  
Finally, sodium channel protein type 5 subunit alpha was downregulated in phosphorylation at 
S460 in the ageing heart. This protein is involved in mediating the passage of sodium ions 
across the cell membrane and thus the action potential and is regulated by intracellular calcium 
levels [331]. No data are available in the literature on the phosphorylation of this protein at 
S460.  
3.4.8 Ageing was Associated with Increased Size of Coronary 
Arteries and Their Lumen, and Decreased Artery Wall/Total 
Artery and Lumen Size Ratios 
Ageing mice in this study had significantly larger arteries (total artery size and lumen size), 
and a lower artery wall/total artery and lumen size ratios, indicating a decrease in arterial wall 
thickness. 
Generally, ageing is associated with increased artery wall thickness, specifically in the middle 
intima media layer. Most studies have been done on the carotid artery, but other central and 
peripheral arteries were investigated as well [332-336]. A possible reason for not observing 
this in the ageing mice in this study is that they are not considered aged (senescent).  
With ageing, there is also an increase in the size of arteries, specifically the lumen [336]. Even 
though this increase in size was suggested to happen because of plaque formation, lumen size 
increased with ageing in the absence of plaque formation [337]. This increase in size was 
suggested to be an expansion in the artery due to loss of elastic fibres with ageing, and an 
adaptation to the stiffening of the vessels [338, 339]. 
3.4.9  Ageing was not Associated with a Change in Cardiac Fibrosis 
Ageing mice in this study did not exhibit any difference in fibrous tissue percentage in the heart 
compared to their adult controls.  
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It has been reported in the literature that fibrosis is a characteristic of the aged heart and occurs 
due to the loss of myocytes, hypertrophy of the remaining myocytes, increased collagen content 
and deposition, increase in activity of TIMPs 1 and 4, and decrease in MMPs 1, 2, 3, and 14 
(regulators of the fibrotic process) [340, 341]. A possible reason for fibrosis not occurring in 
our ageing hearts in this study is that these mice are not considered exactly aged (senescent). 
This is explained later in chapter 5 discussion (Ageing Does Not Alter Cardiac Vulnerability 
to Ischaemia/Reperfusion Injury), showing the mice used in this work are considered to be 
older adults rather than aged according to the Kaplan-Meier survival curve for C57Bl/6 mice. 
3.4.10   Ageing was Associated with Increased Cardiac 
Capillary/Myocyte Ratio 
Capillary/myocyte ratio increased significantly in the ageing heart.  
The importance of measuring this lies in the fact that capillary/myocyte ratio is an important 
determinant for the myocyte oxygen supply [342]. It has been reported in the literature that 
capillary density is not affected by the normal physiological growth in the heart. However, with 
pathological hypertrophy the capillary proliferation mechanisms are not constant and this leads 
to capillary/myocyte mismatch [343, 344]. This defect in adaptive mechanisms is age-
dependant as it is not seen in children where capillary angiogenesis is proportional to cardiac 
hypertrophy [345].  
One possible reason why the ratio here increased in the ageing heart is that the capillary number 
remained constant, but myocyte numbers decreased (loss of myocytes with ageing), leading to 
a bigger capillary/myocyte ratio in a measured area. 
3.4.11   Ageing was not Associated with a Change in Cardiomyocyte 
Diastolic Sarcomere Length 
The importance of studying sarcomere length lies in the role of it in muscle function. Sarcomere 
length is indicated in the contractility force of the heart according to the Frank-Starling 
relationship which describes the relationship between the end-diastolic volume and cardiac 
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ejection volume, and explains that the responsiveness of myofilaments to activation by calcium 
depends on the sarcomere length (myofilament length dependent activation) [346].  
The sarcomere in the ageing mice myocytes did not change in length compared to those of 
adult mice. This is consistent with what Nance et al. 2015 reported that cardiomyocyte 
sarcomere length in aged mice (24-28 months) was not different compared to adult mice (3-6 
months) and only showed impaired lengthening in response to various filling pressures which 
could explain stiffening and cardiac dysfunction seen with ageing [47]. This was also proven 
in aged hamsters of different strains (Bio 14.6 and F1b Syrian hamsters) where sarcomere 
length in cardiomyocytes did not change with ageing [347]. On the other hand, a study in aged 
female Fischer 344 rats showed that cardiomyocyte sarcomere length decreased significantly 
between 6 and 18 months, but did not change between 18 and 22 months of age  [348]. 
Similarly, cardiomyocyte sarcomere length in male Wistar rats was shown to decrease between 
the ages of 2 and 6-9 months, 2 and 24-25 months, but was not found to be different between 
6-9 and 24-25 months of age [349]. These differences in sarcomere length change with ageing 
could be due to the differences in species as they seem to change in rats but not in mice or 
hamsters.  
3.4.12  Ageing was Associated with Changes in Mitochondrial 
Morphometry but not Mitochondrial Distribution 
Results from this work show that mitochondrial distribution (generally and within 
mitochondrial subpopulation) did not change in the ageing heart compared to the adult heart. 
This is consistent with what Schmucker and Sachs, 1985 reported where mitochondrial 
volume/myocyte in aged male Fischer 344 rats (6, 16, and 30 months of age) did not change 
[350]. Similarly, in aged Wistar rats (6, and 22-24 months of age), mitochondrial total volume 
did not change, however they appeared to increase in size with aging and thus decrease in 
numbers [351]. On the other hand, a study in aged C57BL/6J mice (9, 18, and 36 months of 
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age) showed that the total mitochondrial volume as well as numbers were decreased with 
ageing (at 36 months) in both heart and liver tissue [352]. Additionally,  another study in 
C57BL/6 mice aged 2 and 11 months showed a decrease in total mitochondrial volume and 
numbers in aged mice in both skeletal and cardiac tissue [353]. It is possible that the difference 
seen in mitochondrial distribution in aged animals (36 months of age) in Tate and Harbener’s 
study is due to their senescence. These animals were a lot older than the ones used in this study 
and that could indicate that these ultrastructural changes occur at an older age in mice. Authors 
of the second study also indicated that the ultrastructural changes they described often occur at 
an older age and stated the need for further investigation.  
The second observation from our work on mitochondria in ageing was the change in 
mitochondrial morphometry, where they became smaller and more elongated (which indicates 
fusion of mitochondria, supported by the increased expression of mitochondrial fusion proteins 
Opa1 and Mfn2 in aged hearts) for all three subpopulations but only significantly in SSL and 
PN mitochondria.  
Studies on morphometric changes of mitochondria with ageing have shown that there are some 
age-related changes including a decrease in size in a hamster model as well as human samples 
[354, 355]. The inner mitochondria membrane area in aged hamsters fell compared to the adult 
controls, and in human samples the overall density of mitochondria in cardiac tissue samples 
did not change with ageing while the numerical density increased (indicating a decrease in 
mitochondria size). In the mouse, studies looking at the effect of ageing on mitochondrial 
morphology mainly looked at disruption to cristae, and reported a loss of mitochondrial density 
and vacuolation occurring in the aged heart, as well as in liver tissue [352, 356].  
3.4.13  Ageing was Associated with Increased Lipid Deposits (Lipid 
Droplets) in the Heart 
Lipid droplets were significantly increased in the ageing heart compared to its adult control. 
148 
 
The importance of studying this arises from the role lipid droplets play, as they are dynamic 
cytosolic organelles that are composed of neutral lipids surrounded by a layer of phospholipids 
and surface proteins. They have many roles in lipid metabolism and energy homeostasis, 
metabolic gene expression, intracellular lipid and membrane trafficking, viral infection, and 
inflammatory responses [357]. 
The increase in lipid droplet count in these ageing hearts can be justified by the increase in 
lipid metabolism and storage evident by the upregulation of lipid metabolism proteins. 
Measuring the accumulation of lipids in the aged heart through gene expression of lipid 
metabolism and transport regulatory protein has been reported in the literature and was 
associated with heart dysfunction, however lipid droplets were not counted [358]. Additionally, 
the accumulation of lipid droplets are associated with heart disease in conditions characterised 
by hyperlipidaemia (which was not found in our ageing mice) [359, 360].  
3.5 Summary and Conclusion 
In conclusion, changes occurring with ageing in the mice used in this study (C57BL6/J) were 
increases in body weight, body fat, hypertrophy of the heart, and significant decrease in blood 
glucose levels.  
The remodelling of the heart that was observed with ageing included changes in cardiac energy 
metabolites and AA content. Ageing hearts had higher levels of inosine, lower levels of 
hypoxanthine, and a decreased phosphorylation potential (seen in guanosine metabolites). This 
could be an indication of a decreased ability of the heart to produce energy as well as a 
deficiency in mitochondrial capacity. Additionally, ageing hearts had a significantly lower total 
AA pool reflected by lower levels of most of the AAs examined such as taurine, arginine, and 
alanine. As mentioned in the discussion, AAs play an important role as energy metabolites in 
certain conditions as well as aiding in the control of the ionic state of the heart, so a decrease 
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in their content could be an indicator of increased vulnerability of the ageing heart, but reports 
on the relation of some of these AAs to CVD are contradictory.  
Age-related remodelling also included a change in the proteome and phospho-proteome 
profiles of the heart. The majority of proteins detected were all upregulated with ageing, as was 
their phosphorylation. Proteins were categorised into various groups chosen for their relation 
to I/R injury such as mitochondrial proteins, ionic transport proteins, apoptosis-related proteins, 
antioxidant proteins, and metabolism and transport proteins. Upregulation in mitochondrial 
proteins, ionic transport proteins, and lipid metabolism proteins could be a compensatory 
mechanism for the deficiency in mitochondrial function in the ageing heart and thus lipid 
utilisation, and ionic transport alterations. Antioxidant enzymes upregulation could be a 
compensatory mechanism for the increased ROS production associated with the ageing 
process. Upregulation in carbohydrate metabolism proteins and apoptosis-related proteins 
could possibly reflect normal ageing associated changes, such as the shift in metabolism and 
increased apoptosis. Expression of collagen proteins was also upregulated in the ageing heart, 
but this was not associated with increased collagen deposition (fibrosis) in the heart. Changes 
in phosphorylation of proteins included ionic transport, cardiac signalling and apoptosis, 
metabolism and energy production, and structural proteins, and were all upregulated in the 
ageing heart. Not much information is available on the specific phosphorylation sites detected, 
but from the changes seen, phosphorylation of heat shock protein beta-6 at Ser-16 could have 
a protective role in the aged heart.  
Structural remodelling of the ageing heart included larger coronary arteries with larger lumen 
sizes, a lower arterial wall/total artery size and lumen size ratios, and an increase in 
capillary/myocyte ratio. Because the capillary/myocyte ratio is an important indicator of 
myocyte oxygen supply, an increase in this ratio could indicate a protection in the ageing heart 
and improvement in oxygen delivery. However, as mentioned in the discussion this increase 
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could be due to the fact that the larger myocytes in the ageing heart led to the appearance of a 
lower myocyte number in the area used for the counting (as the same area size was used in 
adult heart images), thus the ratio seemed to be increased in the ageing heart.  
Finally, ultrastructural remodelling of the ageing heart included a change in mitochondrial 
morphometry, where mitochondria became smaller in size, and more elongated (indicating 
fusion of mitochondria), especially in PN and SSL mitochondria where these changes were 
significant in the ageing heart. Additionally, ageing hearts had significantly higher numbers of 
lipid droplets compared to their adult controls. No changes were seen in sarcomere length nor 
mitochondrial density (distribution). Figure 3.32 shows a diagram of this summary. 
 
  













4. Cardiac Remodelling 








4.1.1 High-Fat Diet and Cardiac Remodelling in Adulthood 
Consuming HFDs have effects on cardiac remodelling. Studies have shown that HFDs are 
associated with obesity, metabolic changes such as hyperglycaemia, and morphological 
changes of the heart such as cardiomyocyte hypertrophy and interstitial fibrosis; which were 
maintained even after adjusting for the adiposity [196]. Additionally, HFD leads to increased 
ROS in the heart, impaired hypoxia inducible factor (HIF), a reduction in capillary density, 
cardiac hypertrophy, cardiac dysfunction, and reduced SIRT3 expression in the heart (a 
mitochondrial protein associated with increased human life span and metabolism) [208]. Other 
effects of HFD on cardiac remodelling include cellular apoptosis and mitochondrial swelling 
and damage, insulin resistance, metabolic syndrome, increased protein expression of c-Jun N-
terminal kinase (JNK), activated protein  1 (AP-1), insulin receptor substrate 1 (IRS-1), caspase 
3, and reduced Akt phosphorylation [204]. Additionally, upregulation of the expression of 
collagen I and III and transforming growth factor β1 (TGF-β1) were all reported with HFD 
[204]. Also, mice fed a HFD have shown to develop cardiomyocyte lipid droplets, hypertrophy 
of the heart, and an ineffective metabolic adaptation [210]. Another study using rats fed HFD 
showed that they developed cardiac dysfunction and LV fibrosis, with increased 
phosphorylation levels of Smad2 and the expression of fibrotic genes; such as connective tissue 
growth factor, collagen-1α1 (Col1α1), Col3α1, and Col4α1 [361]. Additional structural 
remodelling of the heart with HFD includes collagen deposits, intercellular spaces, 
disorganisation of cardiomyocytes, deposition of fat under the pericardium as well as around 
vessels and between cardiomyocytes, and a thicker vascular wall with reoriented nuclei [201]. 
The same previously mentioned study, which was done on rabbits, found ultrastructural 
remodelling of the heart with HFD manifested in a decrease of myofibrils that became 
degenerated, sarcomere disorganization, larger intracellular junctions, decreased mitochondria 
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distribution, damaged junctional complexes, and multiple vacuolization. The damage in the 
mitochondria resulted in swelling, elongation, with variations in size and cristae organisation. 
Short term HF feeding was also shown to have effects on cardiac remodelling, as it leads to 
hyperglycaemia, adipose tissue remodelling, increased apoptosis level, interstitial fibrosis, and 
LV dysfunction; which all worsened with increased duration of HFD exposure [362]. On the 
other hand, HFD was shown to reduce cardiac growth, left ventricular remodelling, contractile 
dysfunction, and alterations in gene expression (myosin heavy chain β) but only in the presence 
of hypertension [198].  
4.1.2 High-Fat Diet and Cardiac Remodelling in Ageing 
In addition to studying the effects of HFD on the heart, some researchers have compared this 
effect on young and aged hearts. HFDs effects on cardiac remodelling seem to be exacerbated 
by ageing. Young and aged (3 and 18 months) C57BL/6 mice were fed a normal diet, a low-
fat diet, and a high fat diet for 16 weeks. Results of this study showed that the aged heart was 
less able to adapt to a high fatty acid load, and this led to more prominent structural alterations 
and accumulation of lipid intermediates in the cardiomyocytes [155]. Another study in aged 
rats with hypertensive disease looked at the effects of HFD on cardiac remodelling. 44 week 
old spontaneously hypertensive rates and Wistar Kyoto rats were given either ND or HFD for 
27 weeks [215]. Results of this study showed that HFD aggravates hypertensive heart disease 
associated with ageing, worsened atrial and ventricular remodelling, and led to left ventricular 
systolic function impairment. 
In this chapter, we studied the effects of HFD on the remodelling of ageing hearts, looking at 
metabolic, cellular (protein expression), and structural aspects that are related to I/R injury in 






Several techniques have been used to obtain the results in this chapter. These techniques are 
described in detail in chapter 2, page 59 (Materials & Methods). 
4.2.1 High Performance Liquid Chromatography 
HPLC was used for analysis of cardiac ventricular tissue to measure cardiac energy metabolites 
and AA content in the heart. However, AA data was not be obtained as drying of the samples 
could not be done. Five samples for ageing ND and four for ageing HFD were used. Details on 
this are found in chapter 2 under this method’s section. 
4.2.2 Nuclear Magnetic Resonance Spectroscopy 
NMR was used to analyse plasma samples for blood lipid and glucose profile. Four ageing ND 
and four ageing HFD samples were used. For details on this technique and analysis see chapter 
2 under this method’s section. 
4.2.3 Liquid Chromatography Tandem Mass Spectrometry 
LC-MS/MS was used to detect proteins and phosphoproteins levels in cardiac tissue. Five 
samples for each age group were sent for analysis (10plex). No pool sample was created for 
this run. For details on this technique and analysis see chapter 2 under this method’s section. 
4.2.4 Light Microscopy 
Hearts from ageing mice fed ND or HFD (5 samples for each) were collected, fixed, processed, 
embedded, cut, and stained with four different stains (H&E, EVG, Masson’s trichrome, and 
IHC-IB4) to examine cardiovascular structure and how it remodels with HFD. For details on 
techniques, imaging, and analysis see chapter 2 under this method’s section.  
4.2.5 Electron Microscopy 
Hearts from ageing mice fed ND or HFD (4 samples for each) were collected, fixed, processed, 
embedded, cut, and stained to examine cardiac ultrastructure and how it remodels with HFD. 




4.3.1 Animal Characteristic Changes 
4.3.1.1 Changes in Body and Heart Weights of Ageing Mice with 
High-Fat Diet 
Table 4.1 shows the general characteristics of the mice. Ageing mice became obese and their 
weights increased significantly (P < 0.001) with HFD, with an approximate 68 % increase 
compared to mice fed a normal diet. Epididymal fat pads also showed a significant increase (P 
< 0.001) after HF feeding, with a 244 % increase from the ND group, with their percentage 
from total body weight also increasing significantly with HFD (P < 0.001). 
Table 4.1: Body weight, body fat, and heart weights (wet and dry) in ageing mice with 
and without HFD. Data are presented as mean ± SEM. Data were analysed using the 
unpaired t-test. * = P < 0.05, ** = P < 0.001 vs. normal diet. 
 
Additionally, table 4.1 shows changes in heart wet and dry weights and their percentages from 
total body weight with HFD in ageing mice. Heart weights (wet and dry) did not change with 
HFD in ageing mice. However, their percentages from total body weight showed a significant 
difference between the two dietary groups only because total body weights were significantly 
different to start with.  
Measurement ND (n=10) HFD (n=5) 
Body weight (gm) 32.74 ± 0.83  54.93 ± 0.9 ** 
Epididymal fat pads weight (gm) 0.91 ± 0.11  3.1 ± 0.13 ** 
Epididymal fat pads % of total body weight 2.73 ± 0.3  5.64 ± 0.2 ** 
Heart Wet Weight (gm) 0.19 ± 0.01  0.22 ± 0.01  
Heart wet weight % of total body weight 0.59 ± 0.03 0.41 ± 0.03 * 
Heart Dry Weight (gm) 0.04 ± 0.001  0.03 ± 0.001 
Heart dry weight % of total body weight 0.11 ± 0.01 0.05 ± 0.002 ** 
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4.3.1.2 Changes in Plasma Metabolome in Ageing Mice with 
High-Fat Diet 
Several carbohydrate and lipid metabolites were measured in the plasma of animals from both 
dietary groups. Figure 4.1 shows samples of the NMR spectra for both groups. These 
metabolites were measured and expressed as area under the curve (AUC). Lipid metabolites 
increased with HFD in ageing mice plasma, with LDL and VLDL lipids increasing 
significantly (P = 0.008). Carbohydrate-related metabolites all decreased after HF feeding in 
ageing mice, with lactate, and glucose being significantly lower compared to the normal diet 
group (P = 0.02 for lactate, and P = 0.005 for glucose). Figure 4.2 shows the comparison of 
these metabolites between the two dietary groups expressed as area under the curve.  
 









Figure 4.2: Plasma lipid and carbohydrate metabolites of ageing mice with and 
without HFD. Data are presented as box plots showing the minimum, 25th, 50th, 75th 
percentile, and maximum values of area under the peak for each metabolite. Data were 
analysed using the unpaired t-test. * = P < 0.05 vs. ND. N = 4 for each group.  
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4.3.2 Metabolic Changes 
4.3.2.1 Changes in Cardiac Energy Metabolites in Ageing 
Hearts with High-Fat Diet 
Various energy metabolites were measured in the heart tissue of both dietary groups as shown 
in table 4.2. The majority of these metabolites decreased in the aged heart after HFD, with only 
GTP and adenosine increasing. However, only 3 metabolites changed significantly. Adenosine 
di-phosphate (ADP), β-nicotinamide adenine dinucleotide (β-NAD), and inosine all decrease 
significantly after HFD.  
Table 4.2: Cardiac energy metabolites in ageing hearts with and without HFD. Data are 
presented as mean ± SEM. Data were analysed using the unpaired t-test. * = P < 0.05. N = 5 
and 4 for ND and HFD groups, respectively. 
  
Metabolite ND (µmole/gm of tissue) 
 
HFD (µmole/gm of tissue) 
 
P-Value 
GTP 0.13 ± 0.01 0.15 ± 0.03 0.407 
GDP 0.09 ± 0.01 0.09 ± 0.01 0.728 
GMP 0.04 ± 0.002 0.03 ± 0.01 0.465 
ATP 1.98 ± 0.33 1.39 ± 0.21 0.197 
ADP 1.77 ± 0.15 0.94 ± 0.13 0.005 * 
AMP 1.02 ± 0.25 0.74 ± 0.08 0.369 
β-NAD 0.55 ± 0.07 0.32 ± 0.03 0.023 * 
Inosine 0.27 ± 0.03 0.09 ± 0.014 0.001 * 
Adenosine 0.10 ± 0.01 0.12 ± 0.03 0.543 
 
Phosphorylation ratios (phosphorylation potential) for adenosine and guanosine energy 
metabolites were calculated alongside the energy charge of the heart before and after HFD. 
Phosphorylation potential mostly increased after HFD; however, this was not significant. 
Cardiac energy charge decreased after HFD in the aged heart, also not significantly. On the 
other hand, total adenosine metabolites (adenosine metabolite pool) were significantly 
decreased from 4.8 ± 0.3 µmole/gm in ND aged hearts to 3.1 ± 0.4 µmole/gm in HFD aged 













4.3.3 Cellular (Protein Expression) Changes 
4.3.3.1 Changes in Proteome Profile in Ageing Heart with High-
Fat Diet 
A total of 4983 proteins were detected in the proteomics analysis and 1884 proteins changed 
significantly with HFD in the ageing mouse heart (figure 4.4). The majority of significant 
proteins (67 %) were downregulated with HFD, while the remaining 33 % (630 proteins) were 
upregulated. Specific fold changes were selected (FD < 0.8 and > 1.3) in order to avoid false 
positive results, and 762 proteins were within selected folds (385 were downregulated with 
HFD and 341 were upregulated), and these were further categorised using the PANTHER 
classification system according to molecular function and biological processes (figure 4.5). 
Similar to the classification seen with ageing compared to adult hearts, the majority of 
significant proteins that changed in the ageing heart with HFD fall under binding and catalytic 
Figure 4.3: Phosphorylation potential, cardiac energy charge, and total adenosine 
metabolites in ageing hearts with and without HFD. Data are presented as mean ± 
SEM. Data were analysed using unpaired t-test. N = 5 and 4 for ND and HFD, 
respectively. * P < 0.05 vs. ND. 
* 
Adenosine Metabolite Pool 
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Molecular Function Biological Processes 
Figure 4.5: Classification of significantly different proteins within selected fold 
change (< 0.8 and > 1.3) between ND and HFD in ageing hearts using the 
PANTHER classification system. Proteins are classified according to molecular 























0.3 (1.3 FD)-0.3 (0.8 FD)
1.3 = P < 0.05
Figure 4.4: Volcano plot showing changes in proteins of HFD/ND in ageing mice 
hearts. X axis represents log2 of the fold difference (HFD/ND) and Y axis represents -
log10 of the P-value. Proteins above the horizontal red line are significantly different 
between the two age groups. Proteins on the right of the Y axis are upregulated with HFD 
in the aged heart (with the ones on the right of the vertical red line having a FD > 1.3), and 
proteins on the left side of the Y axis are downregulated with HFD in the aged heart (with 
the ones on the left of the second vertical red line having a FD < 0.8). Data were analysed 
using the unpaired t-test. N= 5 for each group.  
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Proteins within selected fold change were further categorised into several groups including 
mitochondrial proteins, lipid and carbohydrate metabolism, ionic transport related proteins, 
antioxidant proteins, apoptosis related proteins, and structural (collagen) proteins.  
4.3.3.1.1 Mitochondrial Proteins 
60 significant mitochondrial proteins were within selected fold change, with only 8 being 
upregulated after HFD in the ageing heart and the remaining 52 were downregulated. These 
proteins were further categorised according to function into 6 groups, mitochondrial lipid 
metabolism, energy metabolism, AA metabolism and transport, ionic transport, structural, and 
mitochondrial transport proteins (figure 4.6). 
Upregulated mitochondrial proteins after HFD in the ageing heart included the lipid 
metabolism proteins (NAD-dependent protein lipoamidase sirtuin-4, mitochondrial  and 
Delta(3,5)-Delta(2,4)-dienoyl-CoA isomerase), the energy metabolism protein [Pyruvate 
dehydrogenase (acetyl-transferring)] kinase isozyme 4, the mitochondrial structural protein 
Coenzyme Q-binding protein COQ10 homolog B, the transport protein Uncoupling protein 3 
(Mitochondrial, proton carrier), and the AA transport protein Mitochondrial basic amino acids 











Figure 4.6: Significant mitochondrial proteins in ageing mice hearts with and without 
HFD. A) Mitochondrial lipid metabolism proteins. B) Mitochondrial energy metabolism 
proteins. C) Mitochondrial structural proteins. D) Mitochondrial ionic proteins. E) 
Mitochondrial transport proteins. F) Mitochondrial amino acid metabolism and transport 
proteins. Data are presented as fold change (HFD/ND). Data were analysed using the 
unpaired t-test. All proteins selected fall within a FD < 0.8 and > 1.3. * = P < 0.05, ** = P 










4.3.3.1.2 Ionic Transport-Related Proteins  
Six ionic transport related proteins changed with HFD in the ageing heart, 3 were 
downregulated and 3 were upregulated. Upregulated proteins were Sodium channel subunit 
beta-4, Voltage-dependent L-type calcium channel subunit alpha-1D which mediates the entry 
of calcium ions into excitable cells, and Store-operated calcium entry-associated regulatory 
factor which protects the cell from increased cellular calcium levels. Downregulated proteins 
were Potassium voltage-gated channel subfamily KQT member 1 potassium channel, 
Sodium/potassium-transporting ATPase subunit alpha which is involved in the exchange of 
sodium and potassium ions across cell membrane creating a gradient across the membrane, and 















































Figure 4.7 Significant ionic transport related proteins (calcium, sodium, 
chloride, and potassium) in ageing mice hearts with and without HFD. Data are 
presented as fold change (HFD/ND). Data were analysed using the unpaired t-test. 
All proteins selected fall within a FD < 0.8 and > 1.3. * = P < 0.05, ** = P < 0.001. 
N = 5 for each group. 
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4.3.3.1.3 Antioxidant Proteins 
 
Antioxidant proteins changed significantly in expression in the ageing heart after HFD, with 
some being downregulated and others upregulated. Glutathione peroxidase 7 and Glutathione 
S-transferase omega-1 were both downregulated with HFD, while catalase and superoxide 
dismutase were upregulated (figure 4.8). 
 
4.3.3.1.4 Apoptosis Related Proteins 
Three apoptosis-related proteins increased in the ageing heart with HFD. BCL2-associated 
athanogene 3 is an anti-apoptotic protein that acts as a co-chaperone to HSP70 and HSC70. 
Bcl-2-associated transcription factor 1 is a pro-apoptotic protein that promotes death by 
repressing transcription. Finally, Cell division cycle and apoptosis regulator protein 1, which 





























Figure 4.8: Significant antioxidant proteins in ageing mice hearts with and 
without HFD. Data are presented as fold change (HFD/ND). Data were 
analysed using the unpaired t-test. All proteins selected fall within a FD < 0.8 





4.3.3.1.5 Structural (Collagen) Proteins 
Various alpha chains (1, 2, and 3) of collagen type IV, VI, and XVIII were significantly 































Figure 4.9: Significant apoptosis related proteins in ageing mice hearts 
with and without HFD. Data are presented as fold change (HFD/ND). Data 
were analysed using the unpaired t-test. All proteins selected fall within a FD < 






























Figure 4.10: Significant structural (collagen) proteins in ageing 
mice hearts with and without HFD. Data are presented as fold change 
(HFD/ND). Data were analysed using the unpaired t-test. All proteins 
selected fall within a FD < 0.8 and > 1.3. * = P < 0.05, ** = P < 0.001. 




4.3.3.1.6 Lipid and Carbohydrate Metabolism and Transport Proteins 
Carbohydrate and lipid metabolism and transport proteins also changed significantly with HFD 
in the ageing heart (figure 4.11). All carbohydrate-related proteins were downregulated after 
HFD, while lipid metabolism proteins were mostly upregulated. An exception was 
downregulation of lipid metabolism proteins Acyl-coenzyme A thioesterase 11, N-acyl-
aromatic-L-amino acid amidohydrolase (carboxylate-forming), and Acyl-Coenzyme A binding 






Figure 4.11: Significant lipid and carbohydrate metabolism and transport 
proteins in ageing mice hearts with and without HFD. Data are presented as fold 
change (HFD/ND). Data were analysed using the unpaired t-test. All proteins selected 




4.3.3.2 Changes in Phosphoproteome Profile in Ageing Hearts 
with High-Fat Diet 
In the ageing mouse heart, 927 phosphorylated peptides were detected (figure 4.12), and 246 
changed significantly after HFD. Of the significantly changed peptides, 151 were 
downregulated in phosphorylation after HFD and the remaining 95 were upregulated in 
phosphorylation. Significant peptides were categorised using the IPA software.  
 
Over half of the significantly altered peptides detected in ageing hearts after HFD were 
downregulated in phosphorylation (61 %). Analysis using the IPA software categorised these 
peptides and the main groups of interest included ionic transport, cardiac signalling and 

























0.3 (1.3 FD)-0.3 (0.8 FD)
1.3 = P < 0.05
Figure 4.12: Volcano plot showing changes in phospho-proteins of 
HFD/ND in ageing mice hearts. X axis represents log2 of the FD (HFD/ND) 
and Y axis represents -log10 of the P-value. Phosphoproteins above the 
horizontal red line are significantly different between the two age groups. 
Phosphoproteins on the right of the Y axis are upregulated with HFD in the 
aged heart (with the ones on the right of the vertical red line having a FD > 
1.3), and phosphoproteins on the left side of the Y axis are downregulated 
with HFD in the aged heart (with the ones on the left of the second vertical 
red line having a FD < 0.8). Data were analysed using the unpaired t-test. N= 











Downregulated phospho-proteins in aged heart with HFD 
Ionic transport 
ATPase, Ca++ transporting, 
cardiac muscle, slow twitch 
2, isoform CRA_b 
(Fragment) GN=Atp2a2  
Q5DTI2 S680 0.75 0.044 * 




S2367 0.85 0.0007 ** 
Cardiac signalling and apoptosis 


































S15 0.63 0.003 * 
Structural proteins     
Microtubule-associated 
protein tau 
 GN=Mapt  
A2A5Y6 
 
S712 0.36 0.0005 * 
A kinase (PRKA) anchor 














S42 0.70 0.027 * 
Table 4.3: Changes in phosphoproteins in the ageing mouse heart with HFD.  Table 
shows protein description, accession number, altered phospho-site, fold change 
(HFD/ND), and P-value. Data were analysed using unpaired t-test. * = P < 0.05, ** = P < 












Protein phosphatase 1 






0.51 0.033 * 
Pyruvate dehydrogenase E1 
component subunit alpha, 




S293 0.46 0.018 * 
Upregulated phospho-proteins in aged heart with HFD 
Structural 
Actin-binding LIM protein 
1 GN=Ablim1  
E9QK41 
 
S475 2.34 0.004 * 
 
From the previous table, downregulated phosphorylated proteins in the ageing heart after HFD 
were divided into several groups including ionic transport, cardiac signalling and apoptosis, 
carbohydrate metabolism, transport, and enzymes. All these proteins were phosphorylated at 
serine sites, with some of them having more than one phosphorylated site that changed 
significantly with HFD.  Even though 39 % of significantly changed phosphoproteins with 
HFD in the ageing heart were upregulated, the only upregulated protein that was identified and 
marked for importance was Actin-binding LIM protein 1; a structural protein involved in the 
bundling of actin filaments. Phosphorylation of this protein at S475 was upregulated with HFD 
in the ageing heart.   
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4.3.4 Structural Changes 
4.3.4.1 Changes in Cardiomyocyte Structure in Ageing Hearts 
with High-Fat Diet 
H&E staining is a basic stain used here only provide a comprehensive picture of the heart 
sections from both diet groups as shown in figure 4.13. 
. 
 
Figure 4.13: Haematoxylin and eosin staining of ageing mice heart sections with and 
without HFD. Images show the left ventricle (objective lens magnification x4), and 
longitudinal and cross-sectional areas from the LV (objective lens magnification x40). 




4.3.4.2 Changes in Coronary Arteries in Ageing Hearts with 
High-Fat Diet 
EVG staining was used to highlight the arteries and show the elastin (stained in black) around 
them. Figure 4.14 shows representative images of large coronary arteries and some of the 
smaller arteries in both diet groups.  
Using EVG stained sections, measurements of total artery size, artery lumen size, artery wall 
thickness, and artery wall/total artery size and lumen ratios were taken. Figures 4.15 and 4.16 
show the comparison between the two groups.  
 
Figure 4.14: Verhoeff-van Gieson Staining of ageing mice heart sections with and 
without HFD. Images show different size arteries (objective lens magnification x20). 
Black colour around the arteries in the images represents elastic fibres. Yellow colour 
inside the artery shows atherosclerosis (lipid accumulation). Scale bar is 20 microns. 
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Arteries of various sizes in the stained sections have been measured for their total size and 
lumen size, and quartiles (minimum value, 25th, 50th, 75th, and maximum value) have been 
calculated (excluding the outlier values). These values for both diet group are presented in table 
4.4. Total artery size and lumen size decreased significantly with HFD in the ageing heart (P < 
0.001) (figure 4.15).  
 
Quartile values shown in table 4.4 show the decrease in HFD group Compared to the ND group.  
Coronary arteries in ND ageing hearts seem to be about 3.6 folds larger (50th percentile) 





Figure 4.15: A) Total artery size (µm)2 and B) Artery lumen size (µm)2 in ageing mice 
hearts with and without HFD. Data are presented as quartiles showing the minimum 
value, 25th percentile, 50th percentile, 75th percentile, maximum value, and the outliers. 





Arterial wall thickness measured from four different sides of the artery wall and averaging that 
measurement showed no significant difference between the two groups. However, wall 
thickness/total artery size was significantly increased in the HFD heart (P < 0.001) from an 
average of 0.28 ± 0.01 in ND hearts to an average of 0.56 ± 0.02 in HFD hearts (figure 4.16). 
Quartiles Total Artery 
Size in HFD 
Hearts (µm)2 
N = 5 
Total Artery 
Size in ND 
Hearts (µm)2 
N = 5 
Artery 
Lumen Size in HFD 
Hearts (µm)2 
N = 5 
Artery 
Lumen Size in 
ND Hearts (µm)2 
N = 5 
Min Value 160 1650 48 1027 
25 
Percentile 
644 2772 219 1995 
50 
Percentile 
1145 4214 471 3026 
75 
Percentile 
2612 8608 1491 6429 








Table 4.4: Quartile values of total artery sizes and artery lumen size in ageing mice 
hearts with and without HFD. Values include the minimum value, 25th percentile, 50th 




4.3.4.3 Changes in Fibrous Tissue in Ageing Hearts with High-
Fat Diet 
As mentioned earlier in the proteomics data (figure 4.10), collagen proteins expression 
increased significantly with HFD in ageing heart. This is also seen in the percentage of fibrous 
tissue in the myocyte calculated using Masson’s trichrome stain for collagen fibres. Figure 4.17 
shows that with HFD, the ageing heart had a significantly higher percentage of fibrous tissue 
(P = 0.005). Fibrosis increases from an average of 1.8 ± 0.3 % with ND to an average of 4.8 ± 
0.7 % with HFD. Figure 4.18 shows examples of fibrous tissue, around the arteries and between 






Figure 4.16: arterial wall to artery and lumen size ratios in ageing mice 
hearts with and without HFD. Data are presented as mean ± SEM. Data 
were analysed using the unpaired t-test. ** = P < 0.001 vs. ND. N= 5 for 





















Fibrosis % in Aged Hearts Before and After HFD
*
Figure 4.17: Fibrous tissue percentage in ageing mice hearts with and without 
HFD. Quantification was done using Masson’s Trichrome stained heart sections. 
Data are presented as mean ± SEM. Data were analysed using the unpaired t-test. * 
P < 0.05 vs ND. N= 5 for each group. 
Figure 4.18: Examples of fibrous tissue (blue colour) in ageing hearts with HFD. 
Objective lens magnification x4 and x20. Scale bar is 20 microns. 
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4.3.4.4 Changes in Capillary/Myocyte Ratio in Ageing Heart 
with High-Fat Diet 
Immunohistology staining Isolectin biotin 4 (IB4) was used to stain capillaries with a brown 
colour. Images taken from the left ventricle of the hearts were used to measure 
capillary/cardiomyocyte ratio, and this ratio was significantly decreased (P = 0.03) from an 
average of 2.3 ± 0.03 with ND to 2.1 ± 0.05 with HFD in ageing hearts (figure 4.19). 
  
Figure 4.19: Capillary/myocyte ratio in ageing mice hearts with and without HFD. 
Quantification was done using Isolectin biotin 4 (IB4) stained heart sections. Data are 
presented as mean ± SEM. Data were analysed using the unpaired t-test. * = P < 0.05 vs. 
ND. N= 5 for each group. Images show an example of ND and HFD hearts. Objective 































4.3.5 Ultra-structural Changes 
4.3.5.1 Changes in Diastolic Sarcomere Length in Ageing Hearts 
with High-Fat Diet 
Diastolic sarcomere length in ageing cardiomyocytes increased slightly but not significantly 
with HFD, from an average of 2.02 ± 0.1 μm in the ND hearts to an average of 2.3 ± 0.3 μm in 
the HFD hearts as seen in figure 4.20. 
 
4.3.5.2 Changes in Mitochondrial Sub-Population Distribution 
in Ageing Hearts with High-Fat Diet 
The distribution or density of mitochondria and each of its subpopulations was measured in 
both groups. In the ND hearts, the total mitochondrial area was 32 % of the myocyte, with the 
IF comprising 25 % of total myocyte area, followed by the SSL mitochondria comprising 6 % 
of this area, and finally the PN mitochondria covering only 1 %. With HFD, the total 
mitochondrial area was increased to 35 % of the myocyte, with IF mitochondria comprising 2 






















Diastolic Sarcomere Length (µm)
Figure 4.20: Diastolic sarcomere length in ageing mice hearts with and without HFD. 
A total of 200-300 sarcomeres were measured from 3-4 different areas in each heart. Data 
are presented as mean ± SEM. Data were analysed using the unpaired t-test. N= 4 for each 
group.  Image on the right shows electron micrographs from aged ND heart (top) and aged 




Comparing these figures to understand the effects of HFD on the mitochondrial density in the 
ageing heart, no significant change was found between the percentage of myocyte area covered 
by total mitochondria. However, the percentage of each subpopulation of total mitochondrial 
area is significantly increased for PN and SSL mitochondria with HFD (P = 0.01 for PN, and 
P = 0.029 for SSL) (figure 4.22). 
Figure 4.21: Mitochondrial sub-population distribution in ageing mice hearts with 
and without HFD. Figure shows the percentage of myocyte covered the percent of each 
mitochondrial sub-population in both groups. N= 4 for each group. 3-4 areas of each heart 
were used to measure the mitochondrial distribution. 
 
Figure 4.22: Mitochondrial % of total myocyte area and subpopulation % of total 
mitochondrial area in ageing hearts with and without HFD. Data are presented as 
mean ± SEM. Data were analysed using the unpaired t-test. * P < 0.05 vs. ND. N= 4 for 




4.3.5.3 Changes in Mitochondrial Sub-Population Morphometry 
Before comparing the mitochondrial subpopulation morphometry between the two groups, we 
compared the different subpopulations with one another within one group.  
4.3.5.3.1 Mitochondrial Sub-Population Morphometry in Ageing Normal Diet 
Hearts 
Mitochondrial morphometry in the ageing ND hearts has been described in detail in chapter 3 
results under the section (Mitochondrial sub-population morphometry in ageing hearts). 
4.3.5.3.2 Mitochondrial Sub-Population Morphometry in Ageing High-Fat Diet 
Hearts 
When comparing the three subpopulations of mitochondria in the ageing HFD heart, the PN 
mitochondria appeared to be smaller in size and shorter in length and width, and they were 
more rounded in shape compared to the other two subpopulations (figure 4.23). However, the 
only significant differences were the length of PN mitochondria compared to IF mitochondria 
(P = 0.005) and their size compared to IF mitochondria (P = 0.03). PN mitochondria length 
averaged 0.91 ± 0.04 μm compared to 1.2 ± 0.03 μm for IF mitochondria. In size, PN 
mitochondria in ageing HFD hearts averaged 0.55 ± 0.05 μm2 compared to 0.76 ± 0.04 μm2 in 
IF mitochondria. Additionally, SSL mitochondria were significantly shorter in length 













4.3.5.3.3 Changes in Mitochondrial Sub-Population Morphometry in Ageing 
Hearts with High-Fat Diet 
I. Perinuclear Mitochondria 
With HFD, PN mitochondria became significantly larger with an increase in both length and 
width and became more rounded in shape (figure 4.24). Length of PN mitochondria with HFD 
averaged 0.91 ± 0.04 μm compared to 0.67 ± 0.04 μm in ND ageing hearts (P = 0.009). Width 
of PN mitochondria increased to an average of 0.71 ± 0.04 μm in ageing HFD hearts compared 
to 0.42 ± 0.01 μm in ageing ND hearts (P = 0.004). PN mitochondrial size also increased to 
0.55 ± 0.05 μm2 in ageing HFD hearts compared to 0.25 ± 0.02 μm2 in ageing ND hearts (P = 
0.006). Finally, the aspect ratio and roundness of PN mitochondria did not change significantly 
with HFD in ageing hearts.  
Figure 4.23: Mitochondrial sub-population morphometry in ageing hearts with HFD. 
A) Mitochondrial length and width. B) Mitochondrial size. C) Mitochondrial roundness 
and aspect (L/W) ratio. Data are presented as mean ± SEM. Data were analysed using 
one-way ANOVA followed by the Bonferroni and Games-Howell post-hoc tests. * = P < 
0.05 vs. IF, ** = P < 0.05 vs IF mitochondria. N= 4. ≈ 100 mitochondria of each 





II. Subsarcolemmal Mitochondria 
SSL mitochondria also changed with HFD in the ageing heart as they appeared to be larger 
(longer and wider) and became more rounded (figure 4.25). Significantly, SSL mitochondria 
in ageing hearts increased in width, size, and roundness with HFD. Average width of SSL 
mitochondria in the ageing heart increased from 0.51 ± 0.01 μm to 0.73 ± 0.05 μm with HFD 
(P = 0.012). The size of SSL mitochondria also increased in the ageing heart from an average 
of 0.37 ± 0.02 μm2 to 0.63 ± 0.07 μm2 with HFD (P = 0.047). Finally, the roundness of SSL 
mitochondria increased from 0.71 ± 0.03 to 0.8 ± 0.01 in ageing hearts with HFD compared to 





Figure 4.24: PN mitochondria morphometry in ageing hearts with and without HFD. 
A) Mitochondrial length and width. B) Mitochondrial size. C) Mitochondrial roundness and 
aspect (L/W) ratio. Data are presented as mean ± SEM. Data were analysed using unpaired 
t-test. * = P < 0.05 vs. ND. N= 4 for each group. ≈ 100 mitochondria of each subpopulation 






III. Interfibrillar Mitochondria 
For IF mitochondria, HFD in the ageing heart seemed to have an effect on mitochondrial 
dimensions (length, width, and size) but not shape (figure 4.26). IF mitochondria became 
significantly larger with increase in both length and width with HFD. Length of IF 
mitochondria increased significantly from an average of 0.9 ± 0.01 μm to 1.17 ± 0.03 μm   in 
ageing hearts with HFD (P = 0.001). Additionally, the width of IF mitochondria also increased 
significantly from an average of 0.57 ± 0.002 μm to 0.77 ± 0.04 μm in ageing hearts after HFD 
(P = 0.008). The size of IF mitochondria in ageing HFD hearts increased to 0.78 ± 0.04 μm2 





Figure 4.25: SSL mitochondria morphometry in ageing hearts with and without 
HFD. A) Mitochondrial length and width. B) Mitochondrial size. C) Mitochondrial 
roundness and aspect (L/W) ratio. Data are presented as mean ± SEM. Data were analysed 
using unpaired t-test. * = P < 0.05 vs. ND. N= 4 for each group. ≈ 100 mitochondria of 







4.3.5.4 Mitochondrial Fission and Fusion Proteins 
With HFD, mitochondria seemed to become more rounded in the ageing heart (only 
significantly in the SSL mitochondria), and this indicate fission of mitochondria, which is 
supported by the significant decrease in mitochondrial fusion protein Opa1 in ageing HFD 
hearts (figure 4.27). Fusion protein Mfn2 was also downregulated with HFD, and Mfn1 was 
upregulated with HFD in the ageing heart, but none of these changes were significant.  On the 
other hand, fission proteins Fis1 and Mff were also downregulated with HFD in the ageing 
heart; with Mff reduction being significant.  
Figure 4.26: IF mitochondria morphometry in ageing hearts with and without HFD. 
A) Mitochondrial length and width. B) Mitochondrial size. C) Mitochondrial roundness 
and aspect (L/W) ratio. Data are presented as mean ± SEM. Data were analysed using 
unpaired t-test. * = P < 0.01 vs. ND. N= 4. ≈ 100 mitochondria of each subpopulation 






4.3.5.5 Changes in Lipid Content (Lipid Droplet Count) in 
Ageing Hearts with High-Fat Diets 
Lipid content (lipid droplet count) increased slightly in ageing hearts with HFD from an 
average of 0.05 ± 0.01 to an average of 0.06 ± 0.006 droplets/μm2 , but this change was not 
significant (figure 4.28). 
Figure 4.27: Mitochondrial fission and fusion proteins in ageing mice 
hearts with and without HFD. Data are expressed as fold change 
(HFD/ND). Data were analysed using the unpaired t-test. * = P < 0.05. n = 5 
for each group.  
Figure 4.28: Lipid content (droplet count) in ageing hearts with and without HFD. 
Data are presented as mean ± SEM. Data were analysed using unpaired t-test. N= 4 for 


































4.4.1 Key Findings 
Unlike earlier work with young adults, feeding aging mice HFD was associated with marked 
obesity and significantly higher plasma VLDL and LDL levels, but lower glucose and lactate 
levels. HFD was also associated with atherosclerosis, smaller coronary arteries with smaller 
lumen sizes, and a higher artery wall/artery size and lumen size ratios. Additionally, HFD 
reduced capillary/myocyte ratio and increased fibrosis in ageing hearts.  
Metabolic alterations in the ageing heart after HFD included reduced total energy rich 
phosphates, which was associated with altered mitochondrial morphometry in the ageing heart 
as they became larger in size and more rounded. Mitochondria also became more densely 
distributed (but only PN and SSL). 
For protein expression, the majority of proteins that changed with HFD decreased. These 
included mitochondrial proteins and carbohydrate metabolism. Proteins that increased with 
HFD included structural (collagen) proteins, and proteins related to apoptosis and lipid 
metabolism. Some of the antioxidant enzymes (e.g. catalase and superoxide dismutase) 
increased while others (e.g. glutathione peroxidase 7) decreased with HFD. Similarly, ionic 
channel-related proteins changed significantly with some being upregulated whilst others were 
downregulated after HFD in the ageing heart. Phospho-proteins were also mainly 
downregulated with HFD in the ageing heart and they included ionic transport, cardiac 








4.4.2 Ageing Mice Weights and Body Fat Increased Significantly 
with High-Fat Diet 
Ageing mice had significant weight gain with a significant increase in body fat with HFD, and 
no change in heart weight.  
An increase in body weight and fat percentage is commonly seen with HFDs that alter energy 
metabolism and cause various changes contributing to obesity, and this is seen in different 
animal species as well as humans [361, 363-366]. 
The energy content of the normal diet used here was 16.26 mJ/kg derived from 22 % protein, 
13 % fat, and 65 % carbohydrates. The energy content of the HFD used was slightly higher 
(19.67 mJ/kg), derived from 45 % fat, 18 % carbohydrates, and 37 % proteins.  
Even though food consumption was not measured for these animals, we cannot conclude that 
the weight gain in the HFD group was caused by increased intake. A study using the same diets 
was done previously by a colleague, and food consumption of the mice was not measured as 
well [367]. However, the HFD had a slightly higher energy content which could have 
contributed to the weight gain in mice. Additionally, a few studies on feeding behaviour in 
mice given HFD showed that switching from a normal diet to a palatable HFD changed feeding 
behaviours in mice and promotes hyperphagia, which could explain the obesity seen in our 
HFD mice [368, 369].  
4.4.3 Ageing Mice had Significantly Higher Plasma Lipids, and 
Significantly Lower Glucose and Lactate Levels with High-Fat 
Diet  
HFD mice had elevated plasma lipids with LDL and VLDL lipids significantly increasing, and 
low plasma carbohydrate metabolites, with glucose and lactate being significantly lower.  
Generally, HFDs with high saturated fats (like the diet used in this study) are associated with 
increased LDL and VLDL lipids in the plasma, and increased glucose levels as insulin 
resistance develops [370-372]. Lower levels of fasting plasma glucose (though not significant) 
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with HFD were reported in both adult and aged mice [373]. Another study also showed 
insignificant decrease in plasma glucose levels, but only in adult mice and not aged ones [374]. 
Similarly, lactate measured by metabolomics is usually found to be elevated with obesity and 
/or HFD in mice, rats, and in human subjects [375-377]. One study reported significant 
decrease in urine lactate in obese Zucker rats, and explained it could have been caused by a 
small cohort  number, which could possibly be the reason for the decrease in carbohydrate 
metabolites seen in our results [378].  
4.4.4 High-Fat Diet Decreased Cardiac Energy Metabolites in 
Ageing Hearts  
Three energy metabolites decreased after HFD in ageing hearts, ADP, β-NAD+, and inosine. 
Cardiac energy charge and phosphorylation ratios did not change with HFD in the ageing heart.  
Normally in the heart elevated ADP levels are associated with heart failure [379]. The reason 
for this is, the energy reserve in the heart (phosphocreatine) is used to donate a phosphate to 
ADP to generate ATP via creatine kinase (CK), and elevated ADP levels indicate a reduction 
in the phosphorylation capacity. Our results show that both ATP and ADP levels are lower in 
the HFD group (even though ATP change was not significant), and this may be attributed to 
the decreased efficiency of the mitochondria and its phosphorylation capacity associated with 
both ageing (as mentioned previously) and HFD [380]. However, a difference in the reduction 
between ATP and ADP levels may also indicate improved phosphorylation with HFD in the 
ageing heart. This has been shown in livers of mice fed HFD where oxidative phosphorylation 
has increased in response to HF feeding, and also in liver of obese diabetic patients [381, 382]. 
Our phosphorylation results show an increase in the HFD group though it was not significant.  
NAD+ has been studied in recent years for its role in combatting metabolic disturbances and 
mitochondrial dysfunction [383]. It has been shown to be reduced with ageing due to a 
reduction in its precursor nicotinamide mononucleotide (NMN) by increase in CD38 in mice 
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and humans, and this contributes to energy metabolic disturbances [384, 385]. NAD+ is also 
reduced with HFD due to a reduction in its synthesising enzyme nicotinamide 
phosphoribosyltransferase (NAMPT) [383]. 
Inosine is a metabolite that is important for nucleotide synthesis through the salvage pathways 
especially during stress such as ischaemia, as well as inducing other cell-protective activities 
[386, 387]. As explained in the discussion of energy metabolites in chapter 3 (page 127), 
inosine is a by-product of ATP metabolism. Lower inosine levels in the HFD ageing heart 
might be merely due to its breakdown to hypoxanthine, but since hypoxanthine levels were not 
measured here, we cannot make this conclusion. 
4.4.5 Majority of Cardiac Proteins were Downregulated with High-
Fat Diet in Ageing 
Ageing mice hearts’ proteome profile changed with HFD compared to the ND controls. 4983 
proteins were detected to be significantly different after HFD with the majority being 
downregulated and only 33 % were upregulated.  
A number of studies investigating the effects of HFD on the proteome profile have been done 
examining different organs and in various species. A study in mice fed HFD showed alteration 
in 15 proteins related to structure, energy metabolism and citric acid cycle, and fatty acid 
oxidation [388]. Effects of HFD on protein expression of the heart was also studied in rats and 
showed an alteration in proteins involved in mitochondrial dynamics, where they were mainly 
downregulated with HFD [380]. The effects of HFD on the proteome was also studied in 
skeletal muscle in mice, liver, the hypothalamus, and visceral white adipose tissue, with a 
number of changes in proteins involved in  metabolism (carbohydrate, tricarboxylic acid cycle, 
cellular amino acid and lipid metabolic processes), cytoskeleton and synaptic plasticity, stress 
response, and mitochondrial function [389-394].  
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Remodelling of the cardiac proteome profile after HFD was also studied in elderly mice [395]. 
The proteomic analysis revealed 417 proteins that have been altered with HFD in aged mice 
hearts, with most of the upregulated proteins being involved in oxidative phosphorylation, 
while downregulated proteins were mainly involved in cytoskeletal organisation.  
It is important to note that the effects of HFD on the proteomic remodelling varies between 
strains [396]. C57Bl/6J and 129Sv mice were subjected to high fat feeding for the same period, 
and the proteomics analysis showed a domination of the peroxisomal β‐oxidation proteins and 
lipogenesis proteins in both strains, respectively.  
4.4.5.1 Mitochondrial Proteins were Mainly Downregulated in Ageing 
Hearts after High-Fat Diet 
Mitochondrial proteins were mostly downregulated with HFD (87 %) in the ageing heart, with 
only 8 proteins being upregulated. This is consistent with other work in the literature as 
mitochondrial protein levels decrease with the decline in mitochondrial function seen with 
HFD [380]. The authors in this study reported a decline in most mitochondrial proteins in rat 
hearts involved in fatty acid oxidation, complex I and V, mitochondrial fusion, and energy 
metabolism.  
4.4.5.2 High-Fat Diet Upregulated and Downregulated Ionic 
Transport-Related Proteins in Ageing Hearts  
Six proteins changed with HFD in the ageing heart, 3 were downregulated and 3 were 
upregulated. Upregulated proteins were Sodium channel subunit beta-4, Voltage-dependent L-
type calcium channel subunit alpha-1D which mediates the entry of calcium ions into excitable 
cells, and Store-operated calcium entry-associated regulatory factor which protects the cell 
from increased cellular calcium levels. Downregulated proteins were Potassium voltage-gated 
channel subfamily KQT member 1 potassium channel, Sodium/potassium-transporting 
ATPase subunit alpha which is involved in the exchange of sodium and potassium ions across 
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cell membrane creating a gradient to actively transport nutrients across the membrane, and 
chloride channel protein.  
Ion channel proteins that have been indicated in models of HFD induced obesity are Potassium 
voltage-gated channel subfamily KQT member 1 potassium channel (KCNQ1), expression was 
increased but not protein levels in HF fed rats [397]. This specific protein was downregulated 
after HFD in our work, but animals used in the previously mentioned study were not aged.  
None of the other proteins were reported to be changed in expression or protein levels in models 
of HFD [398]. 
4.4.5.3 Antioxidant Enzymes Changed Significantly with High-Fat 
Diet in the Ageing Heart 
HFD’s effect on antioxidant proteins in the ageing mice hearts was not consistent, as some 
proteins were downregulated, and others were upregulated.  
A study on the effect of HFD on serum antioxidant proteins in rats showed somewhat similar 
results, as catalase was upregulated and glutathione peroxidase was downregulated with HFD 
[399]. However, superoxide dismutase in the study was also downregulated contradictory to 
the upregulation seen in our results with HFD. Another study showed a reduction in all 
antioxidant enzymes after HF-feeding in the liver, heart, kidney, intestines, and aorta in rats 
[400]. Another study in mice fed HFD showed an elevation in glutathione peroxidase in adipose 
tissue but not in the liver after HF-feeding, with no change in superoxide dismutase level [401]. 
Additionally, another study on the effects of HFD on antioxidant enzymes in rat liver, heart, 
and kidney showed a significant reduction in both glutathione peroxidase and glutathione s-
transferase (consistent with our findings), but no change in catalase except in the kidney where 
it was also reduced with HFD [402]. 
These conflicting findings may be attributed to the different samples/tissues used, and different 
methods/assays of measurements. Also, none of the studies referenced used ageing animals.  
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4.4.5.4 High-Fat Diet Upregulated Apoptosis Related Proteins in the 
Ageing Heart 
Three apoptosis related proteins increased in the ageing heart with HFD. BCL2-associated 
athanogene 3 is an anti-apoptotic protein that acts as co-chaperone to HSP70 and HSC70. Bcl-
2-associated transcription factor 1 is a pro-apoptotic protein that promotes death by repressing 
transcription. Cell division cycle and apoptosis regulator protein 1 is a pro-apoptotic protein 
that also acts on p53 activation.  
As discussed earlier in the previous chapter, apoptosis increases with ageing in the heart (page 
132). HFD has also been associated with increased pro-apoptotic proteins and reduced anti-
apoptotic proteins in various species.  
anti-apoptotic proteins such as BCL-2 with HFD [403-408]. 
The increased expression of the two pro-apoptotic proteins in our results can be justified as 
seen in the literature. The increased expression of the anti-apoptotic protein in our results on 
the other hand can be a compensatory mechanism for increased in pro-apoptotic proteins.  
4.4.5.5 Structural (Collagen) Proteins were Upregulated with High-
Fat Diet in the Ageing Heart 
With HFD, different alpha chains (1, 2 and 3) of collagen 4, 6 and 18 were all upregulated in 
the ageing heart after HFD. 
Data from the literature supports this effect of HFD on collagen expression. HFD increases 
cardiac fibrosis (perivascular and interstitial) [409]. Collagen protein expressions also tend to 
be upregulated in HFD. In Sprague–Dawley (SD) rats fed a normal or HFD for 24 weeks, hearts 
from the HFD group had significantly increased fibrosis and increased expression of collagen 
1, 2, 3 and 4, in addition to an increase in connective tissue growth factor [361]. Additionally, 
in C57BL/6 mice fed a HFD for 20 weeks, collagen deposition and expression of type 1 and 3 
were increased compared to ND fed mice [410].  
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4.4.5.6 Carbohydrates Metabolism Proteins were Downregulated with 
High-Fat Diet in the Ageing Heart, While Lipid Metabolism Proteins 
were Mainly Upregulated  
Carbohydrate metabolism and transport proteins were downregulated with HFD in the ageing 
heart, while the majority of lipid metabolism and transport proteins were upregulated.  
HFD usually leads to dyslipidaemia and insulin resistance, and this leads to decreased glucose 
uptake and increased lipid uptake for metabolism, which may explain the alterations seen in 
metabolism protein levels. This is consistent with other studies where HFD caused a 
suppression in glucose uptake and metabolism protein expression, and an adaptive elevation in 
FA uptake and metabolism proteins [199, 411]. 
Another study in mice also showed that carbohydrate uptake and metabolism protein GLUT4 
(which is already downregulated in ageing) and hexokinase II were downregulated with HFD 
[210]. FA enzyme acetyl-CoA carboxylase (which regulates CPT I by malonyl-CoA as 
mentioned in the introduction) was upregulated in HFD hearts indicating a shift towards 
decreasing FA uptake due to the heart being saturated with FAs. The increase in FA metabolism 
enzymes in our work (even though FA metabolism decreases in the aged heart), can be a 
compensation of the heart to the increased amounts of FFAs in the plasma to increase uptake 
and metabolism.  
4.4.6 High-Fat Diet Downregulated the Majority of Phospho-
proteins in Ageing Hearts 
As with the changes in proteome profile, the majority of phospho-proteins in the ageing heart 
were also downregulated with HFD. The effects of HFD on protein phosphorylation has been 
studied. A few studies reported these effects on mouse brain tissue, white adipose tissue, and 
liver [412-414]. However, no data was found on cardiac protein phosphorylation with HFD.  
Pospho-proteins were categorised into ionic transport, cardiac signalling and apoptosis, 
carbohydrate metabolism, transport, structural proteins, and enzymes. The only upregulated 
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phospho-protein was a structural protein (Actin-binding LIM protein 1), which is involved in 
the bundling of actin filaments, and phosphorylation at S475 of this protein was upregulated 
with HFD. There is no data in the literature on the phosphorylation at this specific site.  
For the downregulated phospho-proteins, calcium channel protein ryanodine receptor 2; which 
mediates the release of calcium from the sarcoplasmic reticulum into the cytoplasm, controlling 
cardiac contraction, was downregulated in phosphorylation at S2367 with HFD [415]. There is 
no information on the relevance of phosphorylation on this specific site. However, 
Phosphorylation on S2807 and S2813 increases the open probability of this channel; which is 
increased in heart failure [416, 417]. Additionally, phosphorylation at S2030 enhances the 
response to luminal calcium [416].  
SERCA2A is another important proteins that is involved in the regulation of contraction and 
relaxation, as it translocate calcium from the cytosol back to the SR using ATP [418].  HFD 
reduced phosphorylation at S680 in the ageing heart, but no data in the literature were found 
on this specific site.  
Pyruvate dehydrogenase E1 component subunit alpha, somatic form, mitochondrial is an 
enzyme that links the glycolytic pathway to TCA cycle as it catalyses the conversion of 
pyruvate into acetyl-CoA [419]. Phosphorylation at S293 inactivates the enzyme, and this was 
reduced in the ageing heart after HFD indicating increased activity of the enzyme and 
utilisation of glucose for oxidation. Another protein involved in carbohydrate metabolism is 
glycogen synthase which is involved in glycogen biosynthesis. Its phosphorylation at S657 was 
decreased after HFD, and this phosphorylation is required for inhibitory phosphorylation at 
S641, S645, S649 and S653. Heat shock protein 90 beta is another protein downregulated in 
phosphorylation at  S226 and S255 with HFD in the ageing heart. This is amolecular chaperone 
involved in cell survival. Phosphorylation at the two sites mentioned inhibits AHR interaction 
(AHR is a client of HSP90 and promotes carcinogenesis). Heat shock protein HSP 90-alpha is 
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another chaperone protein involved in survival signalling. Its phosphorylation at S231 and 
S263 decreased with HFD in the ageing heart, but there is no data in the literature on these 
phosphorylation sites.   
Several structural proteins have also been downregulated in their phosphorylation by HFD in 
the ageing heart. Microtubule-associated protein tau is a protein responsible for the integrity 
and stability of microtubules. Its phosphorylation at numerous serine and threonine sites leads 
to its detachment from microtubules and their disassembly. Phosphorylation in the ageing heart 
at S712 was downregulated, indicating more structural stability in these hearts with HFD. 
Finally, caveolae associated protein 1 plays a role in the formation and organisation of caveolae 
[420]. Its phosphorylation at S42 was downregulated with HFD in the ageing heart, but no 
information is available in the literature on this phosphorylation site.  
4.4.7 High-Fat Diet Decreased Sizes of Coronary Arteries and their 
Lumen, and Increased Artery Wall/Artery Size and Lumen Size 
Ratios in Ageing Hearts 
Coronary arteries in the ageing heart became smaller with HFD (total artery size and lumen 
size), and the wall/total artery size and lumen size ratios increased significantly indicating a 
thicker artery wall.  
The effect of HFD on the vasculature has been studied and showed endothelial dysfunction 
with HFD-induced obesity [421]. When it comes to the morphometry of the vessels, HFD 
increased the wall thickness (specifically the media) of the thoracic aorta in rats after 18 weeks 
of feeding, with a decrease in the lumen diameter [422]. This suggests that the artery size did 
not change but the wall became thicker. Another study in mice showed a significant increase 
in the tunica adventitia/tunica media ratio after 8 weeks of HFD [423]. In pigs fed HFD for 16 
weeks, there were no differences in the coronary artery sizes or wall thickness compared to the 
control group [424]. Comparing small resistance arteries from abdominal subcutaneous tissue, 
obese subjects had significant increased wall (media) thickness, smaller lumen diameter (not 
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significant) and significantly larger cross-sectional area compared to lean controls [425]. The 
authors suggested the growth in artery wall is secondary to vascular smooth muscle cell growth 
that is related to obesity-associated factors such as the release of norepinephrine, 
adipocytokines, tumour necrosis factor‐α, and leptin.   
4.4.8 High-Fat Diet Increased Fibrosis in Ageing Hearts 
Aged hearts had significantly increased fibrosis (interstitial and perivascular) with HFD 
compared to the ND group.  
As discussed previously in the collagen proteins section (page 190), HFD is associated with 
cardiac fibrosis. Increased inflammation and oxidative stress associated with HFD contributes 
to the fibrosis in the heart, alongside other factors such as metabolic dysregulation [426].  
However cardiac fibrosis has been reported in experimental models of HFD with the absence 
of metabolic dysregulation and hypertension [427].  
4.4.9 High-Fat Diet Reduced Capillary/Myocyte Ratio in Ageing 
Heart 
As mentioned previously, capillary/myocyte ratio is an important determinant for myocyte 
oxygen supply [342]. In our work, HFD reduced this ratio significantly in the ageing heart.  
Findings in the literature were contradictory. In a study in mice fed HFD, capillary/myocyte 
ratio was not affected in the skeletal muscle of the soleus [428]. Another study found that HFD 
lead to increased capillary density in the quadriceps femoris muscle in mice suggesting 
improved capillary angiogenesis with HFD [429]. However, in the heart, a study in mice fed 
HFD for 17 weeks showed no change in capillary/myocyte ratio compared to the control group 
[430]. Another study in mice showed that HFD decreased levels of hypoxia inducible factor 1α 
and 2α in the heart, through increased ROS production, which in turn was associated with a 
decreased capillary/myocyte ratio (as seen in our results) [208].. Additionally, reduced 
capillary density was also observed in human heart in association with obesity [431].  
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HIF signalling is important for angiogenesis and an impairment in this pathway results in a 
decrease in the angiogenesis capacity. From our proteomics data, HIF protein was significantly 
downregulated in the ageing heart after HFD, which might support the impairment in 
angiogenesis capacity of these hearts and justifies the lower capillary/myocyte ratio found in 
our results. 
4.4.10 High-Fat Diet did not Change Sarcomere Length in Ageing 
Hearts 
Sarcomere length did not change with HFD in the ageing heart compared to ND.  
Not many studies looked at the effects of HFD on sarcomere length, but in one study HFD was 
reported to be associated with a decrease in sarcomere length [432]. However, this study used 
adult mice and not aged ones, which could be the reason for the difference in findings. 
As described previously, sarcomere length is indicated in the contractility force of the heart. A 
decrease in sarcomere length is associated with lower calcium responsiveness and a weaker 
contraction force. This is not indicated in HFD hearts in this study.  
4.4.11 Mitochondria Became Larger in Size, More Rounded, and 
More Densely Distributed in Ageing Hearts after High-Fat Diet 
Ageing hearts from mice fed HFD had an increased total myocyte area covered by 
mitochondria. Though this increase was not significant overall, it was significantly increased 
for two of the three subpopulations of mitochondria (PN and SSL) but not for IF mitochondria. 
Additionally, mitochondria in ageing hearts after HFD became larger in size (significantly for 
all three subpopulations) and rounder (significant for SSL mitochondria). Fusion proteins 
(Opa1 and Mfn2) were downregulated after HFD, which supports the fact that the mitochondria 
became more rounded in shape rather than being elongated (fused). There are not many studies 
that examined the effects of HFD on cardiac mitochondrial morphometry, and none were done 
in the ageing heart. 
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One study in rats fed HFD showed a decrease in mitochondrial density and size compared to 
controls [221]. Another study in mice fed HFD reported the mitochondria becoming smaller in 
size and decreased in density, with fusion protein Opa1 decreasing (as seen in our results) but 
Mfn2 increased, and Mfn1 did not change [236]. A possible reason for the difference found in 
our results is the age, as none of the studies mentioned were done using aged animals.   
4.4.12 High-Fat Diet did not Increase Lipid Deposits in the Ageing 
Heart 
There was no change in lipid droplet count with HFD in the ageing heart. However, there was 
a large scatter in the data (count) of the lipid droplets/area2 of the ND hearts,  and when the 
outliers were excluded from the analysis HFD hearts showed a significant increase in lipid 
content compared to their ND controls. Using a larger sample size might be needed for further 
investigation.  
Additionally, HFD hearts also had significantly higher levels of perilipin proteins (Plin2 and 
Plin5) but lower levels of (Plin3) (this was taken from the proteomics data but was not used in 
the results section). Pirilipin is a protein involved in lipogenesis and lipolysis, and it protects 
the TAG in lipid droplets from lipolysis, which increases storage. This supports increased lipid 
storage (droplet count) in HFD hearts.  
4.5 Summary and Conclusion 
To summarise the findings in this chapter, ageing mice fed HFD had significant increases in 
body weight and body fat percentage (epididymal fat pads), but no change in heart weight. The 
obesity observed in these animals is a normal response to high-fat feeding. With the obesity, 
certain metabolic parameters also changed significantly in the HFD group including increased 
levels of plasma lipids (with LDL and VLDL increasing significantly). Unexpectedly, 
carbohydrate metabolites in the serum were decreased in the HFD group (glucose and lactate 
significantly). Even though this is not a normal response seen in HFD models in the literature, 
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it has been reported in a few studies (but was not significant) and could also be caused by the 
small sample number.  
Regarding the remodelling of the heart in the HFD group, alteration in cardiac energy 
metabolites, proteome and phospho-proteome profile, and structural and ultrastructural 
changes have been demonstrated. Ageing hearts with HFD had significantly lower levels of 
ADP, β-NAD, and inosine. ADP reduction might indicate a deficiency in mitochondrial energy 
production, as ATP levels were also lower than those seen in the ND ageing hearts (not 
significantly). However, the difference in the reduction between ATP and ADP in HFD hearts 
compared to ND hearts might also indicate improved phosphorylation, which has been reported 
in the literature with HFD. The reduction in β-NAD is normal as it is reduced with ageing due 
to a reduction in its precursor nicotinamide mononucleotide (NMN) in mice and humans, which 
contributes to energy metabolic disturbances, and also NAD+ is reduced with HFD due to a 
reduction in its synthesising enzyme nicotinamide phosphoribosyltransferase as mentioned 
earlier in the discussion section.  
The proteome profile showed a significant change in ageing heart after HFD with the majority 
of proteins being downregulated and 33 % were upregulated. Looking at proteins of the groups 
that we chose in relation to I/R, there was a downregulation in mitochondrial proteins which 
could indicate mitochondrial insufficiency. Some changes in ionic transport proteins were also 
observed, which could indicate a disturbance in ionic transport caused by HFD. Additionally, 
there was a change in antioxidant enzymes with some being upregulated such as catalase, and 
some being downregulated such as glutathione peroxidase 7. Apoptotic proteins were mainly 
upregulated which might support the increased apoptosis induced by HFD. Similarly, collagen 
proteins were also upregulated, and ageing hearts had significantly higher levels of fibrosis 
after HFD. Finally, carbohydrate metabolism proteins were downregulated while lipid 
metabolism proteins were mainly upregulated, which could be a response to the high-fat 
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feeding to increase metabolism of the excess fat provided. Because the data we have from the 
proteomics shows the expression of proteins rather than their activity, we cannot conclude what 
the changes reflect. Similarly, the phospho-proteome profile was altered with HFD in the 
ageing heart with the majority of proteins being downregulated. These proteins were 
categorised into ionic transport, cardiac signalling and apoptosis, carbohydrate metabolism, 
transport, structural proteins, and enzymes. Not many of the proteins had information available 
in the literature on the specific phosphorylation sites detected. Pyruvate dehydrogenase E1 
component subunit alpha, somatic form, mitochondrial, which links the glycolytic pathway to 
TCA cycle, was downregulated in phosphorylation in the ageing heart after HFD at S293, 
which inactivates the enzymes, indicating increased activity of the enzyme and utilisation of 
glucose for oxidation. Glycogen synthase; which is involved in glycogen biosynthesis, was 
downregulated in phosphorylation at S657 after HFD, and this phosphorylation is required for 
inhibitory phosphorylation at S641, S645, S649, and S653. Heat shock protein 90 beta is 
another protein downregulated in phosphorylation at  S226 and S255 with HFD in the ageing 
heart which inhibits AHR interaction. Finally, microtubule-associated protein tau which is 
responsible for the integrity and stability of microtubules, was downregulated in 
phosphorylation at S712 after HFD, which indicates more structural stability in these hearts as 
its phosphorylation at numerous serine and threonine sites leads to its detachment from 
microtubules and their disassembly. 
Structural changes in the ageing heart after HFD included a decrease in coronary artery sizes 
with increased arterial wall/total artery size and lumen size ratios (thicker walls). This has been 
reported in the literature in different muscles and various species. In addition, ageing hearts 
from the HFD group had significantly higher fibrosis (interstitial and perivascular), and a lower 
capillary/myocyte ratio; both of which could increase the vulnerability of the heart.  
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Finally, HFD also changed the ultrastructure of the ageing heart mainly in the mitochondria, 
which became larger in size, more rounded, and more densely distributed (specially PN and 
SSL mitochondria). Lipid droplet count did not show a difference after HFD but that could be 
due to the small sample size and the large scatter found in the data, which when removed we 
















5. Cardiac Vulnerability to 
Ischaemia/Reperfusion 
Injury with Ageing and 





Cardiac vulnerability to I/R injury with ageing and with HFD in ageing have been discussed in 
the introduction (chapter 1, pages 48 and 55). 
5.1.1 Cardiac Vulnerability to Ischaemia/Reperfusion Injury with 
Ageing 
Mostly, reports on I/R injury in the aged heart support increased vulnerability of the heart and 
decreased ischaemic tolerance. Several in vivo and ex vivo experiments in mice and rats 
reported similar findings and associated this increased vulnerability with ageing to various 
factors including a decrease in oxidative phosphorylation as well as a decrease in complexes 
III and IV activity of the mitochondria, increased apoptosis, accumulation of intracellular 
sodium at the end of ischaemia, disturbances in calcium homeostasis, decrease in coronary 
circulation and collateral flow, and changes in AMPK-SIRT1 signalling pathways [174, 176-
179, 186]. However, some studies showed contradictory findings and reported no change in 
cardiac vulnerability to I/R injury in both animal models (mice) and humans [183-185]. 
5.1.2 Cardiac Vulnerability to Ischaemia/Reperfusion Injury with 
High-Fat Diet 
Similar to ageing, HFD effects on cardiac vulnerability and tolerance to I/R injury are 
contradictory. Even though obesity (which is induced by HFD in most cases) is a risk factor 
for cardiac disease and failure, it has been associated with lower mortality risk as well (the 
obesity paradox) [224]. HFD has been shown to be protective of the heart against I/R injury 
when consumed acutely prior to ischaemia, and also for longer periods of time [225-230]. The 
cardioprotective effects of the HFD were associated with various reasons including an increase 
in autophagy and reduction in apoptosis, a decrease in transcriptional factor of activated 
mitochondria (Tfam), delaying the normalisation of pH during the start of reperfusion, and 
insulin resistance and elevated insulin levels which activate the RISK pathways [64].  
204 
 
In contrast to the previous studies, HFD (including acute feeding for 2 weeks) has been 
associated with increased vulnerability to I/R in rats, mice, and Guinea pigs [231-233, 235-
238]. Decreased tolerance to I/R was associated with a decrease in total and phosphorylated 
Akt, GSK‐3β, eNOS expression, overexpression of NOD-like receptor pyrin domain 
containing 3 (Nlrp3) inflammasome, reduction in hypoxia inducible factor 2α and components 
of the pro-survival signalling pathway (RISK), increased inflammatory markers (tumor 
necrosis factor-α (TNF-α) and interleukin-6 (IL-6)) after reperfusion, and increased levels of 
plasma triglycerides and lipotoxicity [234]. 
Few studies have explored the combined effects of HFD and ageing on the vulnerability of the 
heart and results still show conflicting findings. One study in female mice reported that ageing 
has a positive effect on ischaemic tolerance, but this was lost with 6 months of HF feeding 
[239]. Another study in Wistar rats reported that HFD induced obesity did not affect the hearts 














5.2 Materials & Methods 
Vulnerability of the hearts to I/R injury was measured using the Langendorff perfusion system 
(See Materials & Methods, page 82). Briefly, hearts were excised from freshly sacrificed mice, 
cannulated and perfused with Krebs-Henseleit buffer at 37° C for a stabilisation period of 20 
mins. Pressure was stabilised and flow rate was monitored throughout the experiment to 
determine functional recovery of the hearts. Global ischaemia was then started for 35 mins, 
followed by an hour of reperfusion. Heart effluent was collected at various time points during 
the experiment to measure the degree of injury through CK release, and the heart was stained 
at the end of reperfusion with TTC to measure infarction percent. Figure 5.1 shows a diagram 










5.3.1 Vulnerability to Ischaemia/Reperfusion in the Ageing Heart 
To determine the heart’s vulnerability to I/R, three measurements/parameters were considered: 
flow rate (to determine functional recovery), CK release from the heart, alongside infarcted 
tissue percentage of the heart (to determine degree of injury).   
5.3.1.1 Flow Rate and Functional Recovery 
Adult hearts had a starting pre-ischaemic average flow rate of 2.5 ± 0.2 ml/min, which then 
decreased to 1.5 ± 0.1 ml/min in the first min of reperfusion (40 % decrease) and this was 
significant (P = 0.005). Flow rate increased gradually until 10 mins of reperfusion, then started 
to drop again until it reached 1.6 ± 0.1 ml/min at the end (60 mins) of reperfusion (36 % 
decrease compared to the starting flow rate) and this was also significant (P < 0.001). Flow 
rate in the adult heart was significantly lower at all time points of reperfusion compared to the 
starting pre-ischaemic flow rate. Comparison of flow rates in adult and ageing hearts are shown 
in figure 5.2. 
Ageing hearts had a higher starting flow rate averaging at 3.6 ± 0.5 ml/min. Flow rate then 
dropped after ischaemia to an average of 2.9 ± 0.5 ml/min during the first min of reperfusion 
(19 % decrease). Following a similar pattern of flow rate change seen in adult hearts, flow rate 
in the ageing hearts also increased gradually but only until 5 mins of reperfusion before it 
started to decline again to reach an average of 2.5 ± 0.4 ml/min at 60 mins of reperfusion (31 
% decrease). Decrease in flow rate in ageing hearts was only significantly different from the 
pre-ischaemic starting point at 30 mins of reperfusion (P = 0.018) and 60 mins of reperfusion 







To compare the functional recovery between both groups, we compare the percentage of 
change in flow rate during reperfusion. Figure 5.3 shows the flow rate as a percentage of the 
starting pre-ischaemic rate in both adult and aged hearts.  The adult hearts seemed to have 
lower functional recovery as they had a larger decrease in flow rate during reperfusion than the 
ageing hearts compared to the pre-ischaemic flow rate within each group. Functional recovery 
was only significantly different at 1 min of reperfusion (P = 0.046), where ageing hearts had a 
recovery of 81 % compared to 61 % in adults, and at 5 mins of reperfusion (P = 0.048), where 
ageing hearts had 89 % recovery compared to 74 % in adults.  
Figure 5.2: Flow rate in adult and ageing hearts. Data are presented as mean ± 
SEM. Data were analysed using repeated measures ANOVA. * = P < 0.05 vs. pre-
ischaemia in the adult group, ** = P < 0.05 vs. pre-ischaemia in the ageing group. N 
























5.3.1.2 Creatine Kinase Release 
CK measured in heart effluent collected during different time points during the experiment was 
used as a marker of injury. Figure 5.4 shows CK release for adult and ageing hearts corrected 





































Total Creatine Kinase 
Release 
Figure 5.4: Creatine kinase release in adult and ageing hearts (corrected for heart 
weight and flow rate). Data are presented as mean ± SEM. Data were analysed using 
unpaired t-test. N = 6 for each age group. 
Figure 5.3: Flow rate % change from pre-ischaemic value in adult 
and ageing hearts. Data are presented as mean ± SEM. Data were 





































heart follows a similar pattern in both age groups where it increases until reaching a peak at 20 
mins of reperfusion and then starts to decrease. Increased CK release was not statistically 
significant at any time point during reperfusion compared to the pre-ischaemic point within 
each group, nor was it statistically different between the two groups. Additionally, comparing 
total CK release (by calculating area under the curve) was lower but not significantly in the 
ageing hearts compared to adults. 
 
5.3.1.3 Infarct Size 
Infarct size was measured and calculated as a percentage of total heart. When looking at the 
infarction, there were white areas (complete infarction), and pink areas (a mixture of viable 
and infarcted cells). Areas were compared separately and then together to compare injury 
between age groups (figure 5.5). The white and pink areas were both smaller in the ageing heart 
but not significantly. When added together, total infarcted area was significantly larger in the 
























Figure 5.5: Infarct size in adult and ageing hearts demonstrated by area and as a total. 
Data are presented as mean ± SEM. Data were analysed using unpaired t-test. * = P < 0.05. 
N = 6 for each age group. 
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5.3.2 Vulnerability to Ischaemia/Reperfusion in the Ageing Heart 
with High-Fat Diet 
5.3.2.1 Flow Rate and Functional Recovery 
Ageing ND hearts had a starting flow rate averaging at 3.6 ± 0.5 ml/min. Flow rate dropped 
after ischaemia to an average of 2.9 ± 0.5 ml/min during the first min of reperfusion (19 % 
decrease). After that, it increased gradually but only until 5 mins of reperfusion before it started 
to decline again to reach an average of 2.5 ± 0.4 ml/min at 60 mins of reperfusion (31 % 
decrease). Decrease in flow rate in ageing hearts was only significantly different from the pre-
ischaemic starting point at 30 mins of reperfusion (P = 0.018) and 60 mins of reperfusion (P = 
0.023) (figure 5.6).  
Ageing HFD hearts had a lower starting flow rate average at 2.9 ± 0.5 ml/min, which then 
decreased to 2.5 ± 0.3 ml/min in the first min of reperfusion (14 % decrease). Flow rate 
increased gradually between 1 and 5 mins of reperfusion then started to drop again until 20 
mins of reperfusion where it plateaued at an average of 2.6 ± 0.3 ml/min until the end (60 mins) 
of reperfusion (10 % decrease compared to the starting flow rate). There were no significant 






Even though ageing hearts had a lower flow rate after HFD, the decrease was not found to be 
significant at any time point during the experiment. When comparing the recovery of hearts 
after ischaemia, we found that HFD hearts had better recovery, but this was only significant at 















































Figure 5.6: Flow rate in ageing hearts with and without HFD. Data are 
presented as mean ± SEM. Data were analysed using repeated measures ANOVA. 
* = P < 0.5 vs. pre-ischaemic value within the group. N = 6 ND and 5 HFD. 
Figure 5.7: Flow rate % change from pre-ischaemic value in ageing hearts with 
and without HFD. Data are presented as mean ± SEM. Data were analysed using 






5.3.2.2 Creatine Kinase Release 
CK release from ageing hearts fed ND or HFD similarly increased during reperfusion until 20 
mins and 30 mins of reperfusion for ND and HFD respectively, before decreasing at the end of 
reperfusion.  As mentioned earlier, the ND hearts did not have a significant increase at any 
time point of reperfusion compared to the pre-ischaemic CK amount. However, HFD hearts 
had higher increase in CK release compared to pre-ischaemia, and this was found to be 
significant at 1 min of reperfusion (3.5 ± 0.3 u.min/L/mg, P = 0.025), 5 mins of reperfusion 
(7.8 ± 0.6 U.min/L/mg, P = 0.01), and at 20 mins of reperfusion (26.2 ± 4.6 U.min/L/mg, P = 
0.038) compared to the pre-ischaemic CK release (1.1 ± 0.1 U.min/L/mg) (Figure 5.8). 
Comparing CK release between hearts in both groups, there were no significant differences 
between them at any time point of reperfusion, nor was there a significant difference in total 
CK release (AUC). However, pre-ischaemic CK release was significantly lower in the HFD 
group (P = 0.032), which explains the significance reported in CK released from HFD hearts 
during reperfusion in comparison to the pre-ischaemic point that was absent in the ND group. 
A higher CK release in the ND group indicates injury before ischaemia which could possibly 






5.3.2.3 Infarct Size 
Infarct size measured in HFD hearts showed larger white infarct area, and larger total infarct 













































Total Creatine Kinase 
Release 
Figure 5.8: Creatine kinase release in ageing hearts with and without HFD (corrected 
for weight and flow rate). Data are presented as mean ± SEM. Data were analysed using 
unpaired t-test. * = P < 0.05 vs. pre-ischaemic value within the group, ** = P < 0.05 vs. 























Figure 5.9: Infarct size in adult and ageing hearts demonstrated by area and as a total. 
Data are presented as mean ± SEM. Data were analysed using unpaired t-test. N = 6 ND 





5.4.1 Key Findings 
Ageing does not alter vulnerability of the heart to I/R injury, nor does HFD in the ageing heart 
affect cardiac vulnerability to I/R. 
5.4.2 Ageing Does Not Alter Cardiac Vulnerability to 
Ischaemia/Reperfusion Injury 
In our work, ageing hearts seemed to have better tolerance to I/R injury compared to adult mice 
hearts, as seen by better functional recovery specially during the early stages of reperfusion (1 
and 5 mins), a lower CK release from the heart (though not significantly different), and a lower 
total infarct size. However, if we analyse each parameter closely, we see no actual change with 
ageing. 
Findings in the literature on vulnerability of the ageing heart to I/R injury have been 
contradictory (as mentioned in the introduction part of this chapter) where some studies showed 
an increased vulnerability of the heart to I/R injury with ageing and others showed no change 
[174, 176-179, 183-186]. 
If we rely on enzyme release and infarction size for measuring the tolerance to I/R and how it 
changed in the ageing heart, it might be concluded that the tolerance does not change. Total 
CK release was slightly (but not significantly) lower in the ageing heart and this is reported in 
another study (for LDH release) (figure 3.10) [2]. As seen in the figure, total LDH release from 
Figure 5.10: LDH release from the heart following ischaemia in different 




the heart during reperfusion peaked at middle aged mice (12 months) and started to decline 
afterwards in aged and senescent hearts to a point similar to that seen in young adults (2 
months). Mice used in our work fall between the two aged groups used in the study.  
Regarding infarct size of the heart, the significant difference found in our data is in total infarct 
size (this includes the white infarcted area and pink area which contains some viable tissue). If 
we use the white area only then we see no difference in the ageing hearts compared to adult 
hearts, and this is what most authors used in the studies mentioned in the introduction of this 
chapter when reporting infarct size. 
Finally, looking at functional recovery (flow rate) which reflects vascular dysfunction, we see 
an improvement in the ageing heart recovery compared to adult hearts at certain time points of 
reperfusion. This is considered a valuable measurement as vascular dysfunction has been linked 
to worsened cardiovascular outcomes and it correlates with contractile dysfunction [2]. 
However, if we compare end of reperfusion recovery with pre-ischaemic flow rate in each age 
group, we see that they both have a significant decrease in FR by the end of reperfusion 
indicating vascular dysfunction in both age groups.   
An important point to consider here is the age used (80 weeks) and where that falls in the 
C57Bl/6 mice frailty index. Figure 3.11 demonstrates the survival curves (Kaplan–Meier) for 
a colony of aged C57BL/6 mice at Dalhousie University, which shows mortality at different 
time points of aging [1]. This index shows that our ageing mice are not classified as aged but 
rather as older adults and have 100% survival. These mice start to show signs of frailty and a 




5.4.3 High-Fat Diet Does Not Alter Cardiac Vulnerability to 
Ischaemia/Reperfusion in the Ageing Heart 
In this work, ageing mice hearts seemed to have lower flow rate, higher CK release, and higher 
infarction rate after HFD. However, none of these changes were significant. The only 
significant difference between the two diet groups was the improved functional recovery (flow 
rate) at 30 mins of reperfusion in the HFD group.  
As mentioned earlier in the introduction part of this chapter, HFD has been associated with 
increased tolerance to I/R as well as increased vulnerability in other contradictive studies. In 
aged animals however, HFD either had no effect on cardiac tolerance to I/R or decreased it 
[239, 240]. Additionally, obesity (which has been observed in our HFD animals), has also been 
associated with improved cardiac outcomes after I/R [225, 226]. 
Whether or not we can conclude an improvement in tolerance to I/R from our findings based 
on an improvement in functional recovery in the HFD group at a single time point of 
reperfusion cannot be concluded. Also, comparing end of reperfusion flow rate to pre-
Figure 5.11: Kaplan–Meier curve showing survival and 
mortality in C57BL/6 mice [1] 
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ischaemic flow rate within each diet group shows a significant decrease (dysfunction) in the 
ageing heart, which was diminished after HFD. But the flow rate in the HFD group was lower 
to start with indicating a compromised heart.   
5.5 Summary and Conclusion 
Remodelling of the heart with ageing did not affect its vulnerability to I/R injury. Even though 
there was a significantly higher improvement seen in flow rate (functional recovery) in the 
ageing heart compared to the adult heart at 1 min and 5 mins of reperfusion, both age groups 
had a significantly lower flow rate at the end of reperfusion compared to their pre-ischaemic 
point. Similarly, HFD and its effects on remodelling the ageing heart did not change the hearts’ 
tolerance to I/R injury. Even though there was an improvement in functional recovery of the 
HFD heart compared to the ND heart at 30 mins of reperfusion, and the change from pre-
ischaemic flow rate to end of reperfusion flow rate was not significantly different in the HFD 
hearts (compared to the significant fall in flow rate from pre-ischaemia to end of reperfusion 











6. Summary and 
Conclusion, Limitations, 














6.1 Summary and Conclusion 
Ageing is associated with metabolic, cellular, and structural cardiac remodelling. Figure 6.1 
summarises the age-associated alterations in the heart from our findings. 
 
Ageing animals had an increase in body weight, body fat, hypertrophy of the heart, and 
significant decrease in blood glucose levels (figure 6.1).  
The remodelling of the heart was studied in terms of four different aspects: metabolic changes, 
cellular changes (protein expression), structural and ultrastructural changes. Ageing hearts had 
changes in cardiac energy metabolites including higher levels of inosine, lower levels of 
hypoxanthine, a decreased phosphorylation potential (seen in guanosine metabolites), and a 
significant decrease in total AAs pool as well as the non-protein AA taurine.  
Cellular (protein and phospho-protein expression) changes in the ageing heart mainly showed 
an upregulation in expression. Proteins including mitochondrial, ionic transport, apoptotic, 
antioxidants, structural (collagen), and lipid and carbohydrate metabolism were all upregulated 
in expression with ageing. Similarly, phospho-proteins showed an increased expression 
Figure 6.1: Remodelling of the ageing heart.  
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especially ionic transport, cardiac signalling and apoptosis, metabolism and energy production, 
and structural proteins.  
Lastly, structural remodelling of the ageing heart included larger coronary arteries with larger 
lumen sizes, a lower arterial wall/total artery size and lumen size ratios, and an increase in 
capillary/myocyte ratio, with no significant changes in fibrosis. Ultrastructural changes of the 
ageing heart included a change in mitochondrial morphometry, where mitochondria became 
smaller in size, and more elongated, increased lipid content (lipid droplets) of the heart, with 
no changes in sarcomere length or mitochondrial density (distribution).  
Regarding the effects of HFD on the remodelling of the ageing heart, mice fed HFD had 
significant increases in body weight and body fat percentage (epididymal fat pads), but no 
change in heart weight. With the obesity, certain metabolic parameters also changed 
significantly in the HFD group including increased levels of plasma lipids (LDL and VLDL), 
and decreased plasma glucose and lactate.  
The effects of HFD on cardiac remodelling included alteration in cardiac energy metabolites, 
with a decrease in total adenine metabolite pool.  Additionally, the proteome and phospho-
proteome profile changed with most proteins being downregulated even in phosphorylation 
after HFD. Downregulated proteins included mitochondrial and carbohydrate metabolism 
proteins. Other protein categories such as structural (collagen), apoptotic, and lipid metabolism 
were mostly upregulated after high fat feeding. Some protein groups showed changes in both 
directions (with some upregulating after HFD and others downregulating). These included 
antioxidant enzymes and ionic transport related proteins. Phospho-proteins were categorised 
into ionic transport, cardiac signalling and apoptosis, carbohydrate metabolism, transport, 




Structural changes in the ageing heart after HFD included a decrease in coronary artery sizes 
and lumen sizes, with increased arterial wall/total artery size and lumen size ratios (thicker 
walls). In addition, ageing hearts from the HFD group had significantly higher fibrosis 
(interstitial and perivascular), and a lower capillary/myocyte ratio. Changes in the ultrastructure 
of the ageing heart after HFD were mainly in the mitochondria, which became larger in size, 
more rounded, and more densely distributed (specially PN and SSL mitochondria). Lipid 
content (lipid droplets) did not change nor did the sarcomere length in the myocytes. Figure 
6.2 summarises all these changes.  
 
 
Despite the effects of ageing and HFD on cardiac remodelling, neither seemed to affect the 
heart’s vulnerability to I/R injury. Ageing hearts seemed to have better functional recovery 
compared to their adult controls (seen by improved flow rate during reperfusion), but as 
explained earlier in chapter 5 discussion, both age groups had a significantly lower flow rate at 
the end of reperfusion compared to their pre-ischaemic points. This indicates similar vascular 
Figure 6.2: Remodelling of the ageing heart after HFD. 
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dysfunction in both age groups after ischaemia. Similarly, hearts from ageing animals fed HFD 
seemed to have improved flow rate (functional recovery) during reperfusion, and no significant 
fall in their FR at the end of reperfusion compared to pre-ischaemic flow. However, these hearts 




Using ageing mice in this work created a challenge in the sense that mice were hard to obtain 
at 80 weeks old from the suppliers, so often we had to purchase them at a much younger age 
and keep them in the university facility until they reached the age required, which caused a lot 
of delays in the work schedule plus additional expenses. Additionally, it was not feasible to get 
more mice when needed (extra sample numbers or a fault in an experiment) leading to having 
limited numbers for comparisons which may affects results due to a scatter in the analysis.  
6.2.2 HPLC 
For the HPLC samples, the first samples (adult vs. ageing) were run together for cardiac energy 
metabolites and then for AAs. For the HFD ageing samples, they were done separately (when 
the animals were ready for use) and by that period the SAVANT (AS160 Automatic Speed 
Vac) used for drying the samples in preparation for AA measurements, was not working. There 
was no alternative equipment to use so the HFD hearts were not measured for AA content.  
6.2.3 NMR 
Some of the issues encountered in NMR sample analysis included the collection of blood 
samples. As the blood was collected from the thoracic cavity after harvesting the heart, this led 
to a small amount of blood collected and inability to obtain it from all mice.  
When analysing the data, references were used to determine the peaks of each metabolite 
measured. However, because peaks were slightly different in shape and shifted in the samples, 
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this made specifying where each metabolite occurred difficult at times, and possibly 
measurements were not completely accurate.  
6.2.4 Light Microscopy 
One major issue when using histological samples for analysis was the quality of the samples, 
which depends on processing, cutting, staining, and mounting the slides. Additionally, the 
method used in image analysis, which relies on choosing 3-4 areas from the section randomly 
to analyse them, may not be a true representation of what is being measured.  
Using EVG staining to measure the morphometry of coronary arteries, certain samples had 
major arteries that could not be measured (due to the cutting of the tissue, arteries did not appear 
cross-sectional and were elongated), so they had to be excluded from the analysis.  
For measuring fibrosis in the heart using Masson’s Trichrome staining, the threshold of the 
image was altered using the software ImageJ to detect fibrous tissue (represented by blue 
colour), in certain images if the blue shade was extremely lighter or darker it could have been 
excluded from the analysis.  
6.2.5 Electron Microscopy 
One of the main limitations found during analysis of electron micrographs was the quality of 
sections and how they are oriented (during cutting). A lot of the samples used had been cut 
cross-sectionally, so finding areas that can be used for the required analysis was difficult. This 
made distinguishing mitochondrial subtype (for calculating distribution) and measuring 
mitochondrial morphometry difficult at times and possibly not very accurate.  
6.2.6 Langendorff Perfusion 
The major issue found in Langendorff experiments was measuring the infarct size of the hearts. 
Sections of the heart had clearly distinguished white areas (which many authors use for 
calculating infarction of the heart), and the viable part of the heart (stained in red) had a mix of 
shades of pink and brick-red areas. So, when measuring infarction, the brick-red area was 
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determined to be the absolute viable tissue, the white area was the infarcted tissue, and the pink 
area was measured separately as it represents a mix of dead and viable tissue. All three areas 
were presented in the data individually, and the white area was mostly used to determine the 
differences in infarct size between groups. However, this means that the actual percentage of 
infarction is not determined precisely as some infarcted tissue was not included. 
 
6.3 Future Directions 
Investigating cardiac remodelling in the C57BL/6J mouse model at 80 weeks old showed some 
changes that are associated with ageing (e.g. cardiac hypertrophy) while other expected 
changes (e.g. cardiac fibrosis) were not found. This indicates that the age used is possibly not 
the right one to use in age related studies. As seen earlier in the frailty index for C57BL/6 mice, 
the age we used in this study (and used in many studies related to ageing) is considered to be 
older adults. Mice are considered to be aged around 122 weeks old. Comparing the frailty index 
of mice to that of humans (after normalising age), they were found to be similar (figure 6.3) 
[1].  
Figure 6.3: Clinical frailty index in human and mouse normalised for age.  
225 
 
For this reason, it would be interesting to study the remodelling and vulnerability of the heart 
to I/R injury using older animals. The downside to that is these older animals can be very costly 
and their survival decreases. Additionally, females of the same strain can be used for the 
purpose of investigating gender-related differences in cardiac remodelling and tolerance to I/R 
injury.  
Regarding using HFD and studying its effects in the heart, work from a previous colleague 
used the same diet that was used in this work in a different age group (adult mice) [236]. Unlike 
ageing hearts used here, adult hearts with HFD became more vulnerable and had increased 
injury after I/R. Proteomics data from both age group were compared to look at changes in 
protein expression patterns (increase or decrease) with HFD, with some proteins showing 
change in opposite directions between the two age groups. It would perhaps be interesting to 
investigate the causes behind the change in cardiac tolerance to I/R after HFD in the ageing 






































7.1 Normal Chow Diet and High-Fat Diet Detailed 
Constituents  
7.1.1 Normal Chow Diet 
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7.1.2  High-Fat Diet 
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7.2 Protein Description List (Adult Vs. Ageing) 
Gene Protein Name 
Lipid metabolism and transport proteins 
Hacd2 Very-long-chain (3R)-3-hydroxyacyl-CoA dehydratase 2  
Plpp1 Lipid phosphate phosphohydrolase 1  
Gltp Glycolipid transfer protein  
Slc25a20 Solute carrier family 25 (Mitochondrial carnitine/acylcarnitine translocase), 
member 20  
Echdc2 Enoyl-CoA hydratase domain-containing protein 2, mitochondrial  
Acox1 Peroxisomal acyl-coenzyme A oxidase 1  
Acad11 Acyl-CoA dehydrogenase family member 11  
Acox3 Peroxisomal acyl-coenzyme A oxidase 3  
Acsl6 Long-chain acyl-CoA synthetase 
Acsm5 Acyl-coenzyme A synthetase ACSM5, mitochondrial  
Carbohydrate metabolism and transport proteins 
Eno2 Gamma-enolase  
Slc2a1 Solute carrier family 2, facilitated glucose transporter member 1  
Gyg1 Glycogenin-1  
Naglt1c Sodium-dependent glucose transporter 1C  
Gys1 Glycogen [starch] synthase, muscle 
Ugdh UDP-glucose 6-dehydrogenase 
Ugp2 UTP--glucose-1-phosphate uridylyltransferase 
Ionic transport-related proteins 
Camk2b Calcium/calmodulin-dependent protein kinase II, beta, isoform CRA_b  
Slc8a1 Sodium/calcium exchanger 1  
Scn2b Sodium channel subunit beta-2 
Scn4b Sodium channel subunit beta-4  
Naglt1c Sodium-dependent glucose transporter 1C  
Slc4a4 Electrogenic sodium bicarbonate cotransporter NBCe1 variant D  
Kcna7 Voltage-gated potassium channel Kv1.7 (Fragment)  
Kcnj13 Inward rectifier potassium channel 13  
Mitochondrial proteins: Lipid metabolism 
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Acsm5 Acyl-coenzyme A synthetase ACSM5, mitochondrial  
Bdh1 D-beta-hydroxybutyrate dehydrogenase, mitochondrial  
Echdc2 Enoyl-CoA hydratase domain-containing protein 2, mitochondrial  
Hmgcs2 Hydroxymethylglutaryl-CoA synthase, mitochondrial  
Slc25a20 Solute carrier family 25 (Mitochondrial carnitine/acylcarnitine translocase), 
member 20  
Cyp27a1 Sterol 26-hydroxylase, mitochondrial  
Mitochondrial proteins: Energy production 
Atp5i ATP synthase subunit e, mitochondrial  
Ckmt1 Creatine kinase U-type, mitochondrial  
Uqcrh Cytochrome b-c1 complex subunit 6, mitochondrial  
Idh2 Isocitrate dehydrogenase [NADP], mitochondrial  
L2hgdh L-2-hydroxyglutarate dehydrogenase, mitochondrial  
Suclg2 Succinyl-CoA ligase [GDP-forming] subunit beta, mitochondrial  
Mitochondrial proteins: Amino acids metabolism 
Abat 4-aminobutyrate aminotransferase, mitochondrial  
Lactb Serine beta-lactamase-like protein LACTB, mitochondrial  
Tmlhe Trimethyllysine dioxygenase, mitochondrial  
Mitochondrial proteins: Mitochondrial transport 
Grpel2 GrpE protein homolog 2, mitochondrial  
Slc25a10 Mitochondrial dicarboxylate carrier  
Timm17a Mitochondrial import inner membrane translocase subunit Tim17-A (Fragment)  










7.3 Protein Description List (Ageing Normal Diet Vs. Ageing 
High-Fat Diet) 
7.3.1 Mitochondrial Proteins 
Gene Protein Name 
Mitochondrial Lipid Metabolism Proteins 
Sirt4 NAD-dependent protein lipoamidase sirtuin-4, mitochondrial  
Gpd2 Glycerol-3-phosphate dehydrogenase, mitochondrial  
Bdh1 D-beta-hydroxybutyrate dehydrogenase, mitochondrial  
Ech1 Delta(3,5)-Delta(2,4)-dienoyl-CoA isomerase, mitochondrial  
Oxct1 Succinyl-CoA:3-ketoacid coenzyme A transferase 1, mitochondrial  
Mitochondrial Energy Metabolism Proteins 
Pdha2 Pyruvate dehydrogenase E1 component subunit alpha, testis-specific form, 
mitochondrial  
Tmem70 Transmembrane protein 70, mitochondrial  
Cox7a2l Cytochrome c oxidase subunit 7A-related protein, mitochondrial  
Pdk4 [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 4, 
mitochondrial  
Pdhx Pyruvate dehydrogenase protein X component, mitochondrial  
Mitochondrial Structural Proteins 
Tmem126b Complex I assembly factor TMEM126B, mitochondrial  
Higd1a HIG1 domain family member 1A, mitochondrial  
Coq10b Coenzyme Q-binding protein COQ10 homolog B, mitochondrial  
Cox16 Cytochrome c oxidase assembly protein COX16 homolog, mitochondrial  
Coa3 Cytochrome c oxidase assembly factor 3 homolog, mitochondrial  
Ndufaf7 Protein arginine methyltransferase NDUFAF7, mitochondrial  
Bcs1l Mitochondrial chaperone BCS1  
Mitochondrial Ionic-Related Proteins 
Stoml2 Stomatin-like protein 2, mitochondrial  
Slc25a13 Calcium-binding mitochondrial carrier protein Aralar2  
Mitochondrial Transport Proteins 
Tomm22 Mitochondrial import receptor subunit TOM22 homolog  
Timm10b Mitochondrial import inner membrane translocase subunit Tim10 B  
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Timm17b Mitochondrial import inner membrane translocase subunit TIM17  
Timm23 Mitochondrial import inner membrane translocase subunit TIM23  
Ucp3 Uncoupling protein 3 (Mitochondrial, proton carrier)  
Slc25a31 Solute carrier family 25 (Mitochondrial carrier adenine nucleotide 
translocator), member 31  
Tomm5 Mitochondrial import receptor subunit TOM5 homolog  
Abcb10 ATP-binding cassette sub-family B member 10, mitochondrial  
Tomm40 Mitochondrial import receptor subunit TOM40 homolog  
Grpel1 GrpE protein homolog 1, mitochondrial  
Mitochondrial AA Metabolism and Transport Proteins 
Slc25a29 Mitochondrial basic amino acids transporter  
Slc25a19 Solute carrier family 25 (Mitochondrial thiamine pyrophosphate carrier), 
member 19  
Prodh Proline dehydrogenase 1, mitochondrial  
Gcat 2-amino-3-ketobutyrate coenzyme A ligase, mitochondrial  
 




Atp1a3 Sodium/potassium-transporting ATPase subunit alpha  
Slc25a13 Calcium-binding mitochondrial carrier protein Aralar2  
Tmco1 Calcium load-activated calcium channel (Fragment)  
Kcnq1 Potassium voltage-gated channel subfamily KQT member 1  
Camk2a Calcium/calmodulin-dependent protein kinase type II subunit alpha 
Scn4b Sodium channel subunit beta-4  
Cacna1d Voltage-dependent L-type calcium channel subunit alpha-1D  
Tmem66; 
Saraf Store-operated calcium entry-associated regulatory factor  
Slc38a3 Sodium-coupled neutral amino acid transporter 3 
Clic5 
Chloride intracellular channel protein 5 OS=Mus musculus GN=Clic5 PE=1 
SV=1 




7.3.3 Antioxidant Proteins 
 
7.3.4 Collagen (Structural) Proteins 
 





Slc27a1 Long-chain fatty acid transport protein 1  
Mboat7 Lysophospholipid acyltransferase 7 
Acot11 Acyl-coenzyme A thioesterase 11  
Acox1 Peroxisomal acyl-coenzyme A oxidase 1  
Gnpat Dihydroxyacetone phosphate acyltransferase  
Mboat7 Lysophospholipid acyltransferase 7  
Abhd5 1-acylglycerol-3-phosphate O-acyltransferase ABHD5  
Lpcat1 Lysophosphatidylcholine acyltransferase 1  
Acbd3 Acyl-Coenzyme A binding domain containing 3, isoform CRA_b 




Gpx7 Glutathione peroxidase 7  
Gsto1 Glutathione S-transferase omega-1  
Cat Catalase  




Col4a2 Collagen alpha-2(IV) chain  
Col18a1 Collagen alpha-1(XVIII) chain  
Col6a2 Collagen alpha-2(VI) chain  
Col4a1 Collagen alpha-1(IV) chain  
Col6a1 Collagen alpha-1(VI) chain  




Hk1 Hexokinase-1  
Slc2a1 Solute carrier family 2, facilitated glucose transporter member 1  
Ugdh UDP-glucose 6-dehydrogenase  
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